Gene therapy vector based on microalgal extracellular vesicles (MEV-GTV), its preparation and applications
By using microalgal extracellular vesicles (MEVs) as gene therapy vectors, the problems of low transduction efficiency and immune response of existing vectors have been solved, providing an efficient and safe gene therapy solution that enables effective delivery and long-term expression of plasmids in the cell nucleus.
Patent Information
- Application Number
- CN202580029297.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-21
- Filing Date
- 2025-02-21
- Publication Date
- 2026-11-17
AI Technical Summary
Existing gene therapy vectors, such as lipid nanoparticles and viral vectors, suffer from low transduction efficiency, lack of targeting, toxicity, and biological barrier issues. Furthermore, the immune response induced by viral vectors can lead to serious complications, and there is a lack of safe and universal vector solutions.
Microalgal extracellular vesicles (MEVs) were used as nanoparticles containing ITR plasmids and encoding gene products. The plasmids were loaded into MEVs through purification and explantation techniques to form the MEV-GTV vector, avoiding viral capsids and integration plasmids, and achieving efficient delivery into the cell nucleus.
It provides a highly efficient and safe gene therapy vector. The plasmid does not integrate into the genome, avoiding the side effects of viral vectors, and enables long-term transcription and translation of bioactive products. It is suitable for various administration routes and target cell types.
Smart Images

Figure CN123125337A_ABST
Abstract
Description
Related applications
[0001] Inventors Lila Dritanti and Manuel Vega, along with applicant AGS Therapeutics SAS, claim priority to U.S. Provisional Application Serial No. 63 / 663,030, entitled “Gene therapy vector based on microalgal extracellular vesicles (MEV-GTVS), its preparation and use thereof,” filed June 21, 2024.
[0002] Inventors Lila Dritanti and Manuel Vega and applicant AGS Therapeutics SAS claim priority to U.S. Provisional Application Serial No. 63 / 556,325 entitled “Ocular Delivery of Active Agent via Microalgal Extracellular Vesicles”, filed February 21, 2024.
[0003] Inventors Lila Dritanti and Manuel Vega, along with applicant AGS Therapeutics SAS, claim priority to U.S. Provisional Application Serial No. 63 / 562,941, entitled “Ocular Delivery of Active Agent via Microalgal Extracellular Vesicles,” filed March 8, 2024.
[0004] By incorporating into the sequence list provided electronically. The electronic version of the sequence listing is submitted here, the contents of which are incorporated herein by reference in their entirety. The electronic file was created on 18 February 2025, is 256,557 bytes in size, and is titled 5510 SEQPC01.xml. Technical Field
[0005] A gene therapy vector named MEV-GTV is provided, which is an MEV containing an ITR-containing plasmid (also known as a small gene plasmid). This plasmid contains an inverted terminal repeat (ITR), such as a viral ITR, and nucleic acid encoding the target product, and optional regulatory sequences. The ITR is used to circularize the ITR plasmid. The plasmid does not contain any additional viral components (except for the regulatory sequences as part of the transgene), ensuring that the resulting DNA is not encapsulated in a viral capsid or envelope and is not replicated by the viral gene. The plasmid can be inserted into bacterial plasmids for propagation. Background Technology
[0006] Gene therapy, developed since the 1980s, aims to replace, substitute, or correct defective genes responsible for disease development and / or to treat diseases by delivering gene products. Diseases originating from mutations in the DNA sequence, such as severe combined immunodeficiency, cystic fibrosis, and hemophilia A, can be targeted by introducing functional genes. Gene therapy requires appropriate vectors to deliver genetic material into cells. The selection of suitable vectors is crucial for the safety and efficacy of gene therapy, as they serve as the means to transport therapeutic genes (or gene-editing tools) to specific cellular locations. The selection and further development of these vectors involve optimizing their toxicity, immunogenicity, precision, and reliability in delivering genetic interventions.
[0007] Several vector types have been developed to address the challenges and requirements of gene therapy. Non-viral vectors, such as lipid nanoparticles and polymer-based vectors, are considered safe. Lipid nanoparticles, composed of lipids or lipid-like materials, encapsulate genetic material and facilitate its delivery into cells. On the other hand, polymer-based vectors use synthetic polymers to form complexes with the genetic load used for gene delivery. These have failed to deliver satisfactory solutions and continue to present challenges associated with low transduction efficiency and lack of targeting, as well as issues related to toxicity and biological barriers to delivery.
[0008] Viral vectors, such as adeno-associated virus (AAV), adenovirus, traditional (Moloney murine leukemia virus-derived) retroviruses, and lentiviruses, stand out due to their natural ability to efficiently enter host cells and transfer their genetic load. Although associated with immune responses, adenoviruses have attracted attention due to their high transduction efficiency across various cell types. Lentivirals derived from human immunodeficiency virus (HIV) can infect both dividing and non-dividing cells and are known to integrate genetic material into the host genome, thereby providing stable and long-term gene expression.
[0009] The immune response to viruses poses a significant obstacle, hindering the efficient delivery of genes to target cells and potentially leading to serious complications, as demonstrated by the treatment-related patient deaths during a clinical trial of adenovirus vectors in 1999. The choice of viral vector introduces complexity. Some vectors, such as retroviruses, appear to randomly integrate their genomes into the host chromosome, potentially disrupting cellular gene function and promoting cancer development. In some trial participants, severe combined immunodeficiency in a 2002 trial using retroviral gene therapy led to the development of leukemia.
[0010] Therefore, there remains a need for more versatile, convenient, and safe vectors for gene therapy and related applications. The purpose of this article is to provide such vectors. Summary of the Invention
[0011] Gene therapy vectors (GTVs) are provided that contain ITR plasmids, such as extracellular vesicles (EVs), particularly microalgal EVs (MEVs), within nanoparticles. The ITR plasmids contain one or more ITRs of viral origin, along with transgenes encoding gene products and any desired regulatory sequences. No viral capsid or other genes are generated; the nanoparticles, such as EVs, encapsulate the ITR plasmids. An example of a vector is the MEV-GTV detailed herein.
[0012] MEV-GTV contains two differentiated parts: the MEV part and the cargo or payload part, which is an ITR plasmid. The plasmid carries the following three genetic elements in a suitable functional array combination: (1) A viral-derived ITR, such as an AAV-derived ITR. The ITR ensures the survival of the plasmid within the recipient cell, which is a replicative and non-integrative episome. The plasmid may carry one or two ITRs. (2) Genetic elements for the appropriate expression, processing, and ultimately other events of the transgenic component. These elements are promoters, enhancers, Kozak concordant sequences, IRES, polyA, and any other regulatory sequences for transcription and translation that encode products. (3) The transgene encodes a biologically active product, such as a therapeutic product. The transgene encodes or contains one of such products, including but not limited to mRNA, genes, exons, proteins, peptides, siRNA, miRNA, RNA components of the gene editing complex, and a large number of genetic and / or biologically active elements.
[0013] As is evident from the disclosure herein, MEV-based nanoparticles are provided for delivering their payloads to the cell nucleus. This contrasts with other available delivery systems, such as lipid nanoparticles (LNPs), mammalian EVs, and AAV-based vectors. MEVs deliver their plasmids into the cell nucleus. As detailed herein, the plasmids do not integrate into the genome, nor do they possess the undesirable side effects associated with AAV or other viral vectors. Once in the nucleus, the expression cassette within the plasmid is transcribed into mRNA, and the resulting mRNA is translated into a bioactive protein. ITR-plasmids provide long-term expression of transgenes, which include the expression cassette. Therefore, MEVs loaded with ITR-plasmids constitute an efficient and non-viral alternative to viral vectors (such as AAV and other vectors) for gene therapy.
[0014] MEV-GTV is produced as follows. The MEV portion, as detailed herein, is produced by growing microalgae in a photobioreactor and then purifying the MEV from the supernatant of these cultures. The product of this production, clarification, and purification process provides purified MEV, which is easy to use, characterize, store, and ultimately load with a customized cargo or payload. The plasmid (payload) portion is produced using standard and well-established plasmid production methods, as described herein, including transfecting plasmid constructs (carrying the three genetic elements described above) into suitable bacteria, cloning or amplifying the plasmid by growing the transformed bacteria, and purifying the plasmid from bacterial cultures according to standard, well-known, and well-established plasmid production and purification methods. After obtaining both portions (purified MEV and purified plasmid payload), the plasmid is loaded into the MEV using the exo-loading protocol described previously and herein.
[0015] Therefore, the production or manufacturing of MEV GTV is simple and straightforward, with high yields, safety, and low cost, especially compared to other gene therapy vectors such as AAV vectors. AAV vector production and manufacturing are complex, have low yields, are not necessarily safe, and are expensive. The manufacturing of MEV-GTV is highly advantageous compared to the manufacturing of AAV vectors. This advantage or superiority of MEV-GTV in terms of manufacturing adds to the many advantages of MEV-GTV compared to AAV, which is detailed in this paper.
[0016] The product detailed in this article is a gene therapy vector with two components: (1) an outer membrane, which is an extracellular vesicle derived from EVs, such as microalgal EVs (MEVs), which is a nanoscale lipid nanoparticle, and (2) an inner payload, which is an expression plasmid carrying at least three genetic elements: (i) an AAV-ITR sequence to confer plasmid stability, persistent survival and episome behavior, (ii) control genetic elements, such as promoters, enhancers, introns, IREs, Kozak sequences, etc., and (iii) a transgene, which is made of simple or multiple coding sequences encoding mRNA, siRNA, miRNA or any other kind of genetically active molecule, whether or not.
[0017] ITR sequences include viral ITRs, such as the ITRs of any known strain of adeno-associated virus (AAV), such as strains AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, and other viruses, such as poxviruses and adenoviruses.
[0018] As detailed herein and in co-owned publications, MEVs, and therefore MEV-GTVs, can be formulated for and administered via various routes of administration: local (on the eye), topical, oral, intranasal, intravenous, intramuscular, respiratory, and other such routes. Depending on the route of administration, different organs and tissues are targeted. Targeted organs include, for example, the choroid and retina of the eye, endothelial cells, intestinal cells, GALT cells, spleen cells, neurons, brain cells other than neurons, lung cells, skin cells, immune cells, blood cells, and mucosal cells via local administration. They also target intracellular endosome Toll-like receptors (TLRs) embedded in various cell types. Any gene product of interest can be encoded in an ITR plasmid. MEVGTVs can be used to treat, prevent (reduce their risk), and / or modulate diseases, conditions, and states such as metabolic diseases, genetic diseases, lung diseases, intestinal diseases, eye diseases, brain diseases, and immune-modulating diseases.
[0019] An ITR plasmid containing an ITR and a transgene is provided. The ITR is a eukaryotic viral ITR, such as that from adeno-associated virus (AAV), and is the only eukaryotic element of the plasmid, apart from the promoter and regulatory sequences that are part of the transgene. The transgene contains nucleic acid encoding a gene product operatively linked to a promoter recognized in eukaryotic cells, and may optionally contain additional eukaryotic transcriptional and / or translational regulatory sequences. Exemplary plasmids can typically contain transgenes up to about 20 kB in size; this varies depending on the ITR and / or transgene.
[0020] In some embodiments, a bacterial plasmid is provided for disseminating the ITR plasmid in a bacterial host. The bacterial plasmid contains the ITR and the transgene, as well as a bacterial cloning vector for propagation in the bacteria. The cloning vector used to amplify the ITR plasmid is selected from plasmids, bacteriophages, granules, and bacterial artificial chromosomes (BACs), or alternatively, the cloning vector may be a bacterial plasmid with a pUC or pBR322 backbone.
[0021] ITRs include eukaryotic ITRs, such as those from poxviruses, adenoviruses, or adeno-associated viruses (AAVs), or ITRs can be synthetic ITRs. Examples of ITRs are those listed in the table below:
[0022] Delivery vectors containing ITR plasmids and / or vectors, wherein the vectors contain ITR and transgenes, are provided. Specifically, an ITR vector is provided within the delivery vector. Delivery vectors include, but are not limited to, extracellular vesicles, exosomes, or nanoparticles. Extracellular vesicles include microalgal extracellular vesicles (MEVs). MEVs containing ITR vectors can be used as microalgal extracellular vesicle gene therapy vectors (MEV-GTVs). MEV-GTVs can include MEVs and ITR plasmids containing transgenes operatively linked to ITRs. MEV-GTVs can be used in any application using gene therapy vectors (e.g., AAV gene therapy vectors). MEV-GTVs have many advantages not present in existing gene therapy vectors (such as AAV vectors). These advantages are apparent from the description herein.
[0023] Transgenic organisms can encode one or more therapeutic products, as well as regulatory elements for controlling / directing the expression of the encoded products in eukaryotic cells. The encoded one or more therapeutic products include, but are not limited to, nucleic acid molecules, peptides, proteins, plasmids, aptamers, or antisense oligonucleotide (ASO) peptides, and can be used to treat or prevent or regulate diseases, symptoms, or conditions. Multiple sequences can be encoded under separate regulatory sequences and / or can be encoded as polycistronic information, which is processed into individual products, such as polycistronic information, where the nucleic acids encoding the product are separated, for example, by the nucleic acid encoding a 2A peptide to produce polycistronic information, where the individual product is translated. Therefore, multiple nucleic acids encoding individual products can contain individual promoters, single promoters, or combinations of promoters and / or such structures.
[0024] ITR plasmids may contain regulatory sequences or elements to control the expression of one or more encoded products. Such regulatory sequences or elements include promoter sequences, transcription and translation sequences, enhancers, introns, IRES, 2A peptides, and Kozak sequences. Promoters include, but are not limited to, promoters recognized by eukaryotic polymerases (including RNA polymerase II or RNA polymerase III). Promoters may be selected from eukaryotic promoters, such as plant or animal promoters, and / or eukaryotic viral promoters, as well as synthetic promoters. Promoters include, but are not limited to, for example, cytomegalovirus promoters, simian virus 40 promoters, herpes simplex virus promoters, Epstein-Barr virus promoters, adenovirus promoters, synthetic promoters, actin promoters, and synthetic chimeric promoters.
[0025] The encoded therapeutic products include, but are not limited to, RNAi and mRNA, such as silent RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), short activating RNA (saRNA) or long non-coding RNA (lncRNA), ASO, oligonucleotides, dsRNA or ribozymes; and / or may be polypeptides or peptides; and / or complex or biochemical pathways or systems, such as gene editing systems, such as CRISPR-related or CRISPR-like systems.
[0026] The coded therapeutic products include, but are not limited to, immunomodulators or immunomodulatory products, such as immunomodulators that increase or decrease the production of one or more cytokines; upregulators or downregulators of self-antigen presentation; masking of MHC antigens; and / or promotion of the proliferation, differentiation, migration, or activation of one or more types of immune cells; and / or antibodies or their antigen-binding fragments, such as scFv, bispecific antibodies, their antigen-binding fragments, checkpoint inhibitor antibodies or their antigen-binding fragments, or tumor antigen-specific antibodies or their antigen-binding fragments, or anticancer gene-specific antibodies or their antigen-binding fragments, or tumor-specific receptors, or signaling molecule antibodies or their antigen-binding fragments; and the antibodies or antigen-binding fragments can specifically bind to and inhibit CTLA-4, PD-1, PD-L1, PD-L2, PD-1 / PDL1 pathway, PD-1 / PDL2 pathway, HER2, EGFR, VEGFR, TIM-3, LAG-3, BTLA-4, HHLA-2, CD4+, etc. 28 and one or more of the following: checkpoints or immunosuppressants, or tumor antigens; and / or vaccines used to treat or prevent or reduce the risk of a disease, condition or illness, which may be DNA, RNA or protein vaccines.
[0027] Hormones, cytokines, and chemokines belong to the category of encoded therapeutic products. Exemplary molecules include, for example, human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; relaxin; glycoprotein hormones such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); liver growth factor; fibroblast growth factor; prolactin; placental prolactin; tumor necrosis factor-α and-β; Müllerian inhibitory substance; mouse gonadotropin-related peptide; inhibin; activin. Vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factor, transforming growth factor (TGF); insulin-like growth factor-I and-II; erythropoietin (EPO); bone-inducing factor; interferons, such as interferon-α,-β, and-γ; colony-stimulating factors (CSFs), such as macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), and granulocyte-CSF (G-CSF); or interleukin (IL); and / or Encoded therapeutic agents include agents used to treat infections, such as antifungal agents, antibacterial agents, antiviral agents, or antiparasitic agents.
[0028] Encoded therapeutic products include prodrugs and enzymes that convert the prodrugs into drugs for the treatment, prevention, or regulation of diseases, conditions, or illnesses such as or involving the brain. The encoded products may be used to treat cancers or tumors in the brain, or to treat infectious diseases in the brain, or to treat neurodegenerative diseases or other central nervous system (CNS) conditions, or to treat dementia. Genetically modified organisms may additionally or alternatively encode products that are psychoactive or treat mental disorders, or immunomodulatory products, or detectable products, or treatments for brain injury or trauma, or treatments for cancer, or treatments for neurocranial disorders, or treatments for CNS disorders, or treatments for genetic brain disorders, or treatments for brain cancer, or have anti-aging activity, or have brain regeneration activity.
[0029] MEV-GTV can be used for any purpose using viral vectors or other delivery systems, such as treatment, prevention (reducing their risk), and / or modulation of diseases, conditions, and illnesses, such as metabolic diseases, genetic diseases, lung diseases, intestinal diseases, eye diseases, brain diseases, and immune modulation diseases.
[0030] MEV GTV can be used to treat diseases, conditions, and illnesses involving or affecting the eye, including the posterior eye or the posterior segment of the eye, such as the choroid-retinal region, retinal pigment epithelium (RPE) cells, and / or photoreceptor cells. Exemplary diseases, conditions, and illnesses include, but are not limited to, age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion (RVO), macular edema, diabetic macular edema (DME), optic neuropathy, glaucoma, geographic atrophy, retinitis pigmentosa, ocular hypertension, or one or more of these conditions. Diseases, conditions, and illnesses include, but are not limited to, age-related macular degeneration (AMD), retinal degenerative diseases, conditions, or illnesses, or diseases, conditions, or illnesses involving choroidal neovascularization, genetic diseases, conditions, or illnesses involving the retina, and ocular hypertension, or one or more of these conditions. For example, a disease, condition, or ailment is selected from one or more of the following: age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, diabetic macular edema (DME), retinal vein occlusion (RVO), and optic neuropathy. Glaucoma diseases include, for example, wet AMD, geographic atrophy, diabetic retinopathy, macular edema, retinitis pigmentosa, glaucoma, and / or ocular hypertension. Diseases, conditions, and ailments include retinal diseases that lead to blindness, including genetic diseases that can be treated with gene therapy or gene editing or peptide therapy.
[0031] Diseases, conditions, and illnesses that can be treated by administration of the plasmids, delivery vectors, or MEV-GTV compositions provided herein include, but are not limited to, neurodegenerative diseases, conditions, and illnesses (such as Parkinson's disease, or Alzheimer's disease, Huntington's disease, Creutzfeldt-Jakob disease, or other neurodegenerative diseases); or cognitive impairments (such as dementia, or amnesia, or delirium, or other cognitive impairments); or brain disorders (such as encephalitis, or seizures, or tumors, or other brain disorders); or neurological disorders (such as pain, or seizures, or infections, or Other neurological disorders; or genetic diseases (such as cystic fibrosis, thalassemia, sickle cell anemia, Huntington's disease, Duchenne muscular dystrophy, Ty-Sachs disease, Rett syndrome, or other genetic diseases); or brain tumors; or Niemann-Pick disease; or prions; or Parkinson's disease; or autoimmune diseases; or multiple sclerosis; or amyotrophic lateral sclerosis (ALS); or muscular dystrophy; or other diseases of the brain or cancers involving the brain, such as those treated with peptides (including antibodies), such as checkpoint inhibitors.
[0032] Plasmids, delivery vectors, or MEV-GTVs can be formulated for administration via specific routes, such as inhalation, oral, or intranasal administration. They can be applied topically or locally or systemically. For example, MEV-GTVs can be formulated for intranasal administration to deliver the encoded product to one or more of neurons, astrocytes, oligodendrocytes, microglia, ependymal cells, and / or neural stem cells in the brain, and can be used for mood, behavioral, psychiatric, neurological, degenerative, genetic, malignant (cancer), and / or traumatic brain diseases, conditions, or illnesses.
[0033] Transgenic genes can encode products for the treatment, prevention, or regulation of diseases, conditions, or illnesses caused by or involving pathogens, or inflammatory diseases, or diseases involving signaling pathways activated by TLRs or intracellular or endosome receptors, or autoimmune diseases, or any disease, condition, or illness treated through immunomodulation. Such transgenic genes may include those encoding products that elicit or contribute to a protective humoral response, such products comprising serum IgG and IgA and / or mucosal IgG and IgA, such as vaccines, or antigens or their immunogenic moieties, or epitopes, or... Immunomodulatory agents used to reduce or eliminate immune tolerance to previous immunotherapies or vaccines. Exemplary products that may be encoded by genetically modified organisms (GMOs) are TLR antagonists or agonists. TLRs and their agonists can be one or more of the following:
[0034] TLR and antagonist can be one or more of the following:
[0035] MEV-GTV can be used to treat diseases, conditions, or illnesses that are cancerous, or inflammatory or autoimmune, or where inflammation plays a role in the etiology of the disease, condition, or illness. Examples of such conditions include septic shock, autoimmune diseases, atherosclerosis, metabolic syndrome and gastric cancer, inflammatory bowel disease, rheumatoid arthritis, sepsis, allergies, Alzheimer's disease, Parkinson's disease, ulcerative colitis and Crohn's disease.
[0036] MEVs are a classification of microalgae from the phylum Euglena, Chrysophyta (golden brown algae and diatoms), Dinophyta (fire algae), Chlorophyta (green algae), Rhodophyta (red algae), Phaeophyta (brown algae), and Xanthophyta (yellow-green algae). Unicellular green algae include those belonging to the order Chlorella, particularly those in the family Chlorellaceae, and especially those belonging to the genera *Chlorella* or *Pseudo-Chlorella*, such as *Chlorella ellipsoides*. Chlorella ellipsoidea Chlorella proteoglycans () Chlorella pyrenoidosa ), Sorokin Chlorella ( Chlorella sorokiniana), common Chlorella ( Chlorella vulgaris ) and variant Chlorella ( Chlorella variabilis ), or Chlorella vulgaris ( Parachlorella kessleri ), Bejelin's Chlorella Parachlorella beijerinckii ) and *Pseudochophyton floccosum* ( Parachlorella hussii ).
[0037] Compositions containing MEV-GTV can be formulated for administration via any route of administration. The route of administration of MEV is the function of the target organ or tissue. Routes of administration include, but are not limited to, local, systemic, parenteral, enteric, mucosal, subcutaneous, intramuscular, oral or nasal inhalation (lung, nasal, vaginal, rectal, auditory), oral, and other routes of administration. Exemplary routes of administration and targets:
[0038] MEVs can be formulated in any form, including as tablets; as liquids, such as emulsions, including microemulsions and nanoemulsions; as powders; as pills; as liquid solutions or suspensions (e.g., including injectable; ingestible and topical formulations, such as eye drops, gels, pastes, creams, or ointments); aerosols (e.g., nasal sprays and inhalers); suppositories; vaginal suppositories; injectable and infusionable solutions; and sustained-release forms; said forms and formulations correspond to routes of administration, including for oral administration, for nebulization, or for inhalation. For vaccination, routes include oral and intramural. For ocular administration, MEV-GTV compositions can be formulated for instillation onto the surface of the eye, or for intraocular, intravitreal, choroidal, or subretinal injection. Compositions can be formulated for oral administration to treat diseases, conditions, or illnesses involving the gastrointestinal tract or immune system or white spleen. Compositions can also be formulated for intranasal administration to treat diseases, conditions, or illnesses involving the brain. Attached Figure Description
[0039] Figure 1 This is a schematic diagram of the AAV genome with the ITR-coding Cap and Rep AAV genes on both sides [from: Asaad et al. (2023). AAV genome modification for efficient AAV production. Heliyon, 9(4), e15071].
[0040] Figure 2The secondary structure of the ITR of AAV serotype 2 is shown. The characteristic T-shape of the ITR is formed by two adjacent inverted repeats (BB' and CC') separated by a single unpaired nucleotide. The third inverted repeat is the central AA', forming a three-way connection. The D sequence does not participate in the T secondary structure. The replicase-binding element (RBE) is formed by a specific tetranucleotide repeat. The inverted terminal repeats (ITRs) at both ends of the adeno-associated virus (AAV) genome exist in both flip and flop configurations in equal proportions. [From Wilmott et al. (2019). A User's Guide to the Inverted Terminal Repeats of Adeno-Associated Virus. Human Gene Therapy Methods, 30(6), 206-213].
[0041] Figure 3 The sequences and structures of ITRs derived from AAV serotypes 1, 2, 3, 4, 6, and 7 are shown. Lowercase letters indicate non-conserved nucleotides in the ITR sequence [from Earley et al. (2020) Adeno-Associated Virus serotype-specific Inverted Terminal Repeat sequence role in vector transgene expression. Human gene therapy, 31(3-4), 151-162].
[0042] Figure 4 This section shows a comparison of the composition of MRV-GTV with that of other (ITR)AAV-based delivery or gene therapy systems. (A) AAV genome: a linear ssDNA molecule flanked by ITRs. (B) AAV- or AAV-based vector carrying a native or engineered linear ssDNA molecule flanked by ITRs within its capsid. Engineered genomes can be up to 5 kb in size. (c) AAV or AAV- vector (approximately 20 nm in diameter) loaded into an extracellular body measuring 200–250 nm (chimeric vectors from evoxatheatics.com). (D) MEV-GTV loaded into a MEV containing a dsDNA expression plasmid flanked by AAV-ITRs (up to 10 kb).
[0043] Figure 5Exemplary elution profiles for higher purity MEV formulations were plotted, in which MEV previously concentrated by TFF, purified by ultracentrifugation, and formulated in PBS at concentrations of 10¹¹ to 10¹³ / mL was inoculated into a pre-packed column qEV1 from IZON. MEV was eluted with PBS solution. 0.5 mL of the elution fraction was collected. MEV was recovered from the first fraction, as shown in the figure. The most concentrated fractions (4-5) were combined and stored at 4°C before use.
[0044] Figure 6 An exemplary image of a MEV obtained using transmission electron microscopy (TEM) is shown. See Example 2.
[0045] Figures 7A to 7B An exemplary image is shown obtained by confocal microscopy using MEVs labeled with lipophilic dyes. Figure 7A The MEV labeled pKH26 is shown. Figure 7B The MEV marked with DiD is shown. See Example 2.
[0046] Figures 8A-8C The image shows the MEV uptake analysis using confocal microscopy. After 16 hs incubation, pKH26-labeled MEVs were taken up into the cells. Figure 8A Cell arrangement (2D image). Figure 8B Single cell (2D image). Figure 8C Single cell (3D image). See Example 2.
[0047] Figure 9 The distribution of MEVs labeled with a lipophilic dye by cell counting is shown. See Example 2.
[0048] Figures 10A-10B The analysis shows MEV uptake by cell counting. MEV (labeled with a lipophilic dye) uptake in different cell types is shown as the percentage of fluorescent cells. Figure 10A Epithelial cells are visible. Figure 10B Mononuclear cells are shown. See Example 2.
[0049] Figure 11 The diagram shows MEVs loaded with fluorescent payloads quantified by cell counting. The percentage of loaded MEVs was determined. See Example 4.
[0050] Figure 12 Representative patterns of biodistribution according to the route of administration are shown for intravenous (IV), intratracheal (IT), and per os (PO) routes. See Example 5A. Figure 13 The kinetics of accumulation in the liver, lungs, and spleen (average 6 animals) following intravenous administration were depicted. See Example 5A.
[0051] Figure 14 The kinetics of Per os administration in the lungs, spleen, and intestines (average 6 animals) were depicted. See Example 5A.
[0052] Figure 15 The kinetics of lung and kidney accumulation (average 4 animals) following intranasal administration were depicted. See Example 5A.
[0053] Figure 16 The kinetics of accumulation in the lungs, spleen, and intestines (average of 3 animals) after intratracheal administration were described. See Example 5A.
[0054] Figure 17 Representative patterns of biodistribution of intravenous (IV) administration at different time points (0h–72h) are shown. See Example 5A. Figure 18 Representative patterns of biodistribution of Per os (PO) at different time points (0h–72h) are shown. See Example 5A.
[0055] Figure 19 Representative patterns of biodistribution of intranasal (IN) at different time points (0h–72h) are shown. See Example 5A.
[0056] Figure 20 Representative patterns of biodistribution of intratracheal administration (IT) at different time points (0h–72h) are shown. See Example 5A.
[0057] Figure 21A Accumulation in liver tissue following intravenous (IV), intranasal (IN), intratracheal (IT), and per os (PO) administration (average 6 animals) was depicted as described in Example 5A.
[0058] Figure 21B Accumulation in spleen tissue was depicted by intravenous (IV), intranasal (IN), intratracheal (IT), and peros (PO) administration (average 6 animals) as described in Example 5A.
[0059] Figure 21C Accumulation in lung tissue following intravenous (IV), intranasal (IN), intratracheal (IT), and per os (PO) administration (average 6 animals) was depicted as described in Example 5A.
[0060] Figure 21D Accumulation in brain tissue following intravenous (IV), intranasal (IN), intratracheal (IT), and per os (PO) administration (average 6 animals) was depicted as described in Example 5A.
[0061] Figure 22 Microscopic images of mouse intestinal epithelium 8 hours after administration of PKH26-labeled MEV via the Peros route are shown. See Example 5B.
[0062] Figure 23A -B shows a microscopic image of mouse GALT tissue 8 hours after administration of PKH26-labeled MEV via the Per os pathway. Figure 23A The intestine was depicted with hematoxylin and eosin staining (G=GALT tissue). Figure 23B DAPI (nuclear) staining and MEV-PKH26 fluorescence (e.g., the portion marked "ro") were depicted. See Example 5B.
[0063] Figure 24 Microscopic images of mouse spleen via the Per Os pathway are shown 24 h after PKH26-labeled MEV administration. The image depicts spleen pulp stained with DAPI (nucleus), and MEV-PKH26 is indicated by fluorescence (light gray staining / spots). See Example 5B.
[0064] Figure 25 This is a diagram showing the migration of MEVs from the GALT to the spleen. See Example 5B.
[0065] Figure 26A Whole-body bioluminescence imaging of a representative animal treated with MEV loaded with luciferase mRNA is shown. See Example 5C.
[0066] Figure 26B Whole-body bioluminescence imaging of representative animals treated with MEV loaded with luciferase protease was depicted. See Example 5C.
[0067] Figure 27A-27I The study demonstrated non-hematologic toxicity in mice following oral or intratracheal administration of MEV. Figures 27A-27D The assessment of MEV toxicity using chemical parameters—ALAT, ASAT, urea, and creatine—is depicted. Figure 27 E-27I depicts the assessment of MEV toxicity using hematological parameters—RBC, hemoglobin, hematocrit, MCV, and eosinophils. Group 1: Mice received 100 μl of PBS (white column) via PO delivery. Group 2: Mice received 100 μl of 4*10 PBS via PO delivery. 11 MEV / mouse (column with black and white patches). Group 3: Mice received 100 μl of 4*10 via PO delivery. 12 MEV / mouse (columns with vertical lines). Group 4: 100 μl of 4*10 [unclear] was administered to mice via IT delivery (square column). 11MEV / mouse. Data were obtained from 6 mice per group for each parameter. ALAT: alanine aminotransferase. ASAT: aspartate aminotransferase. MCV: mean corpuscular volume. PO: per os (oral delivery). IT: intratracheal. See Example 6.
[0068] Figures 28A-28C The response to the antigen (orally or intramuscularly administered ovalbumin (OVA) with adjuvant) is shown compared to the response following administration of MEV loaded with OVA via the same route. Example 7. Figure 29 The increased expression of GFP mRNA in cultured cells following MEV-GTV-mediated delivery of an ITR-carrying plasmid is shown compared to MEV-mediated delivery of GFP mRNA and MEV-mediated delivery of a control plasmid without ITR. See Example 8.
[0069] Figure 30A and 30B The MEV loaded with aflibercept (SEQ ID NO: 73) encoded by mRNA was shown to have anti-angiogenic activity; the MEV entered the cell and the mRNA was translated. Figure 30A The bioactivity of aflibercept (SEQ ID NO: 94) (inhibition of VEGF angiogenic activity) was demonstrated, wherein the aflibercept was expressed by a plasmid carrying an ITR-, which was delivered by MEV-GTV in an alternative in vitro model of angiogenesis. Images from the Matrigel® tube formation assay show the extent of tube formation (VEGF-induced) in HUVECs (primary human umbilical cord endothelial cells). Figure 1 Negative control: No VEFG, no MEV-GTV. Figure 2 Positive control: 1 ng / ml VEGF, no MEV-GTV. Figure 3 1 ng / ml VEGF, loaded with an ITR-plasmid encoding aflibercept in MEV-GTV. Figure 4 1 ng / ml VEGF loaded with MEV-GTV containing ITR-plasmids encoding different aflibercept sequences. See Example 9. Figure 30B Images of nodes and networks obtained in the tube formation assay are shown; analysis results using the ImageJ angiogenesis plugin are shown: 5-6 from cells pretreated with VEGF; 7-8 from cells not pretreated with VEGF; 9-10 from cells pretreated with VEGF and with unloaded MEV; and 11-12 from cells pretreated with VEGF and with MEV loaded with mRNA encoding aflibercept.
[0070] Figure 31This is a bar graph showing the quantitative biological activity (inhibition of VEGF angiogenesis activity) of aflibercept expressed by a plasmid carrying ITR- encoded aflibercept delivered by MEV-GTV in an in vitro model of angiogenesis. The grid area size is calculated from tube formation assays on HUVECs (primary human umbilical cord endothelial cells). (A) Negative control: No VEFG, no MEV-GTV. (B) Positive control: 1 ng / ml VEGF, no MEV-GTV. (C) 1 ng / ml VEGF, MEV-GTV loaded with an ITR- encoded plasmid of aflibercept. (D) 1 ng / ml VEGF, MEV-GTV loaded with an ITR- encoded plasmid of a different aflibercept sequence. See Example 9.
[0071] Figure 32 The locations of five brain slices studied in the delivery experiment are shown, as well as gene expression of MEV-GTV and its payload.
[0072] Figure 33 This study demonstrates the penetration of MEVs into ARPE-19 cells. Time-response studies (data not shown) indicate that penetration peaked at 48 hours of treatment. Figure 1 -T=0h, ARPE-19 cells treated with PKH26-labeled MEV (combined DAPI / actin (Alexa 488) / PKH26-labeled MEV (Alexa 546)); small Figure 2 ARPE-19 cells treated with PKH26-labeled MEVs at -T=24h (combined DAPI / actin (Alexa 488) / PKH26-labeled MEVs (Alexa 546)). GFP expression from the mRNA delivered by MEVs to ARPE-19 cells was maximized at 72h (data not shown). The results demonstrate the ability of MEVs to deliver their payload to retinal pigment epithelial (RPE) cells and the release of the encoded payload (mRNA) from endosome vesicles, which is then translated into protein.
[0073] Figure 34 This shows persistent expression of GFP protein in ARPE-19 cells treated with MEVs one week after treatment, containing a plasmid carrying an ITR plasmid and encoding the GFP protein: small Figure 1 -T=0h, ARPE-19 cells (combined with DAPI / GFP (Alexa 488)) were treated with MEVs carrying a plasmid containing AAV'ITR and encoding GFP; small Figure 2 -T=72h, ARPE-19 cells (combined with DAPI / GFP (Alexa 488)) were treated with MEVs carrying a plasmid containing AAV'ITR and encoding GFP; small Figure 3-T=96h, ARPE-19 cells (combined with DAPI / GFP (Alexa 488)) were treated with MEVs carrying a plasmid containing AAV'ITR and encoding GFP; Figure 4 -T=144h, ARPE-19 cells (combined DAPI / GFP (Alexa 488)) were treated with MEVs carrying a plasmid containing AAV'ITR and encoding GFP. The figure shows that GFP protein expression increased from 72h to 144h, which is the longest time point studied. The results demonstrate the ability of MEVs to deliver their payload into RPE cells and the endosome escape of the payload (plasmid) to the nucleus, where it is transcribed into mRNA and then translated into protein.
[0074] Figure 35 Images of nodes and networks obtained from a tube formation assay are shown, illustrating the anti-angiogenic effect of MEVs loaded with the anti-angiogenic product aflibercept protein or mRNA encoding aflibercept. This figure illustrates the anti-angiogenic activity of HUVEC cells after exposure to MEVs loaded with aflibercept protein or mRNA encoding aflibercept. It presents images from the tube formation assay: A-cells (negative control (w / o VEGFa)); B-cells (positive control (1 ng / mL VEGFa)); C-cells (positive control (2 ng / mL VEGFa)); D-cells treated with 0.5 ng / mL aflibercept protein + 1 ng / mL VEGFa; E-cells treated with MEVs loaded with mRNA (encoding aflibercept) + 1 ng / mL VEGFa; F-cells treated with MEVs loaded with aflibercept protein + 1 ng / mL VEGFa.
[0075] Figures 36A-36B show the efficacy of treatment against angiogenesis using primary HUVEC cells and the tube formation assay using MEVs loaded with an ITR-plasmid encoding aflibercept (pITR). Figure 36A Images obtained 4 hours after scraping are shown to demonstrate the anti-angiogenic activity (cell migration inhibition) of HUVEC cells after exposure to MEVs loaded with aflibercept protein, aflibercept mRNA, or an ITR plasmid encoding aflibercept (also known as VEGF Trap-Eye). Figure 36B This is a bar chart showing the quantitative results of wound healing measurements. Invention Details A. Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Unless otherwise stated, all patents, patent applications, publications, GenBank sequences, databases, websites, and other public materials mentioned throughout this disclosure are incorporated herein by reference in their entirety. In cases where multiple definitions exist for a term herein, the definition in this section shall prevail. In the case of references to URLs or other such identifiers or addresses, it should be understood that such identifiers can change, and specific information on the Internet can come and go, but equivalent information can be found by searching the Internet. References to such URLs demonstrate the availability and public dissemination of this information.
[0077] As used in this article, inverted terminal repeat (ITR) sequences are terminal hairpin structures that appear in viruses.
[0078] As used herein, an ITR plasmid (also known as a small gene plasmid) is a circular plasmid containing one or more ITRs, typically two complementary ITRs, such as ITRs from the same source, flanking the transgene, and optional regulatory sequences. The term "small gene" does not refer to size, but rather to the construct containing the gene or polycistronic gene and any desired regulatory sequences. The gene may include introns or may not have any introns, such as cDNA. As described herein, the amount of genetic material in a small gene ITR plasmid (including the ITR) can be as high as any amount that can be loaded into a MEV. Based on data (see discussion below), this amount is approximately 20 kB, but may be more depending on the sequence. An ITR plasmid is a plasmid containing one or more viral ITRs and a transgene, thereby circularizing the plasmid containing only the ITR and the transgene to form a microcircle. Typically, the plasmid contains two ITRs flanking the transgene. The resulting ITR plasmid microcircle may contain one or more copies of the ITR and the transgene. ITR plasmids can be segregated by size, particularly those containing one copy of the ITR and the transgene. ITR plasmids do not contain genes for replication or for the capsid; they may contain viral promoters as well as transcriptional and translational regulatory sequences for expressing the coding product.
[0079] As used herein, a bacterial ITR plasmid is a plasmid containing an ITR plasmid that can replicate or proliferate within bacterial cells. Bacterial ITR plasmids may contain sequences flanked by the ITR plasmid sequence for excision of the ITR plasmid, for example, through recombination. A bacterial plasmid is a bacterial clone plasmid containing an ITR plasmid, typically flanked by sequences for recombination or other sequences to facilitate excision of the ITR plasmid.
[0080] As used herein, a transgenic refers to a nucleic acid that encodes one or more products and optional transcriptional and translational regulatory sequences. Transgenics typically include a promoter operatively linked to the nucleic acid encoding the product and any other desired regulatory sequences to produce the product in eukaryotic cells.
[0081] As used herein, a bacterial plasmid refers to a plasmid that can reproduce in bacteria. For the purposes of this document, a bacterial plasmid contains a small gene ITR plasmid, which can then be excised or removed from the bacterial plasmid by including sequences that allow and / or induce internal recombination. Bacterial plasmids can include any suitable plasmid that replicates in bacteria, and may include selected ITRs, transgenes, and any regulatory sequences, as well as optional sequences for recombination to extract the small gene plasmid.
[0082] As used in this article, bacterial cloning vectors (often also referred to as bacterial plasmids) include plasmids, bacteriophages, phages, and bacterial artificial chromosomes (BACs), as well as any such construct in which the ITR plasmid can be fully inserted and replicated in bacteria and remain free.
[0083] As used herein, gene therapy is the delivery of genetic material into cells. For the purposes of this article, genetic material includes DNA to repair or replace disease-related mutations or genes, and RNA, including complexes of mRNA, miRNA, siRNA, hybrids, and molecules of different properties, including gene editing complexes and portions, such as editing complexes composed of RNA and DNA fragments, and is considered a gene therapy method aimed at correcting mutations on disease genes (thereby repairing disease genes).
[0084] As used herein, cargo refers to exogenous molecules, such as bioactive molecules, including biomolecules and small molecules, as well as ITR plasmids and bacterial ITR plasmids provided herein, which are loaded into microalgal extracellular vesicles (MEVs) provided herein after isolation of MEVs. This includes cargo heterologous to MEVs. In particular, for the purposes of this document, cargo contains plasmids that are introduced into MEVs to produce MEV gene therapy vectors (MEV-GTVs) as detailed and illustrated herein.
[0085] As used herein, generally, "heterogeneous" relative to cargo in a MEV means that the cargo in the MEV is not naturally present in the MEV but is exogenously loaded, as stated above. It also refers to cargo in an MEV that has been endogenously loaded into the MEV through genetic modification of the microalgae. MEVs with heterogeneous cargo include cargo that is not naturally present in the MEV. Cargo heterogeneous with microalgae and / or MEV is cargo that is not inherently present in the microalgae nor naturally packaged in the MEV, and / or cargo that is not present in the MEV unless the microalgae is modified to produce it or the cargo is exogenously loaded.
[0086] As used herein, a bioactive molecule or bioactive agent means any molecule or reagent that may have biological activity (such as therapeutic activity) or act as a detectable marker or have an effect on a subject in vivo. Bioactive agents and molecules include biomolecules (such as DNA, RNA, proteins, other biopolymers) and small molecules (such as small molecule drugs and pharmaceuticals), immunogens, and any molecule that will be delivered to a subject (such as a human or other animal or plant or microorganism (bacteria or others)) in conjunction with therapeutic, diagnostic, or other such uses (such as cosmetics). Bioactive agents or molecules may act as or have the activity of, for example, a therapeutic agent, immunogen, diagnostic agent, detectable marker, or cosmetic. The bioactive molecule used herein is any bioactive molecule that can be loaded into microalgal extracellular vesicles (MEVs). Bioactive molecules include therapeutic agents and diagnostic agents, such as reporter molecules and detectable molecules, thereby enabling the monitoring or diagnosis of diseases, symptoms, or conditions.
[0087] As used herein, a biomolecule means any biologically active biopolymer or molecule that is present or can be present in a living organism or virus, or a modified form of such a biopolymer or molecule. Therefore, a biomolecule includes modified, naturally occurring biomolecules, such as proteins comprising modified primary sequences, for example by altering the primary sequence through deletion, insertion, and / or substitution of amino acids, and / or by modifications, such as post-translational modifications of proteins.
[0088] As used herein, the term "therapeutic agent" refers to any molecule that, in vivo, improves or affects the progression of a disease, condition, or illness, or prevents or reduces the risk of a disease, condition, or illness, or has a side effect of treatment. Therapeutic agents include, but are not limited to, nucleic acids encoding mRNA or proteins (where the mRNA or protein is a therapeutic product), DNA, aptamers, proteins, small molecules, and any such products as understood by those skilled in the art.
[0089] As used herein, when it is stated that MEVs have the same or substantially the same amount of cargo or cargo, it should be understood that this refers to the average value of the group of MEVs in the composition. It should be understood that when MEVs are exogenously loaded, the cargo / MEV ratio can be selected such that each MEV has a predetermined amount of cargo on average. As a simple example, to load an average of one molecule of cargo / MEV, a person skilled in the art can calculate the amount of cargo loaded into the composition of MEVs and understand that in the composition of MEVs, some will have more than one molecule of cargo / MEV, while others will have no cargo / MEV. On average, an MEV will have one cargo / MEV molecule. Those skilled in the art will understand that, typically, the amount of cargo / MEV will be more than one molecule / MEV, and the amount of cargo depends on various parameters, including cargo, target tissue and / or cells, the disease, condition or illness being treated, and the subject being treated. Typically, each MEV loads more than one cargo molecule, for example, at least 10 or about 10 molecules / MEV. It is also possible to load substantially more cargo, 100, 500, 1000, 10 4 Molecular weight / MEV and more. The payload amount depends on the target, disease, symptom or condition, subject, cargo, and MEV capacity. The selection of this amount is within the skill level of a person skilled in the art.
[0090] As used herein, a subject is any organism, typically an animal or plant, in which or on which a composition containing MEV is introduced. Subjects include, but are not limited to, humans, plants, particularly crop plants, and animals, including farm animals and pets such as dogs and cats, as well as zoo animals.
[0091] As used herein, disease or symptom or condition means a pathological or undesirable condition in an organism caused by, but not limited to, infections, acquired conditions and genetic conditions, and those characterized by identifiable symptoms.
[0092] As used in this article, treating a subject with a disease, symptom, or condition means that the subject’s symptoms or manifestations of the disease or condition are partially or completely relieved or remain static after treatment.
[0093] As used in this article, "patient" refers to a human subject.
[0094] As used herein, subjects include animals; animals include any animal, such as, but not limited to, primates, including humans, gorillas, and monkeys; rodents, such as mice and rats; poultry, such as chickens; ruminants, such as goats, cattle, deer, and sheep; and pigs and other animals. Non-human animals exclude humans as the intended animals.
[0095] As used herein, treatment means any action that improves the symptoms of a disease or condition. Treatment includes prevention, treatment, and / or cure. Treatment also includes any pharmaceutical use of any MEV or composition provided herein.
[0096] As used herein, prevention means preventing potential disease and / or preventing the worsening of symptoms or progression of disease. Prevention or avoidance, and their grammatically equivalent forms, refer to methods that reduce or eliminate the risk or probability of a disease or condition occurring, as well as products that reduce or eliminate the risk or probability of a disease or condition occurring.
[0097] As used herein, an eye disease, condition or symptom or condition involving the eye is such a disease, condition or symptom as the cause of which involves the eye, such that delivery of a therapeutic agent to the eye can achieve treatment, including improving or relieving symptoms, and / or treating the cause or manifestation of the disease, condition or symptom, or delivering diagnostic molecules, such as marker molecules, reporter molecules or enzymes, which can be used to aid or achieve diagnosis, or can be used to monitor the progress or effectiveness of treatment.
[0098] As used herein, modification of the amino acid sequence of a polypeptide or the nucleotide sequence of a nucleic acid molecule refers to and includes the deletion, insertion, and substitution of amino acids or nucleotides. These include modifications to the primary sequence of the polypeptide or protein. Methods for modifying polypeptides and nucleic acid molecules are routine to those skilled in the art, for example, by using recombinant DNA methods. When referring to a polypeptide or protein rather than its sequence, modification refers to post-translational or post-purification changes, such as conjugations or linkages that alter the properties of the polypeptide or protein, such as half-life extensions, glycosylation, purification tags, detectable reporters, and other such modifications.
[0099] As used herein, modifications to a genome, plasmid, or gene include the deletion, substitution, insertion, and translocation of nucleic acids. These include any alteration to the natural or naturally occurring nucleic acid sequence.
[0100] As used in this article, RNA interference (RNAi) is a biological process in which RNA molecules suppress gene expression or translation by neutralizing targeted mRNA molecules to inhibit translation and thereby suppress the expression of the target gene.
[0101] As used in this article, RNA molecules that function via RNAi are described as repressive because they silence the expression of their target genes. Silencing expression refers to the reduction, repression, or inhibition of the expression of the target gene.
[0102] As used herein, gene silencing via RNAi is said to suppress, repress, disrupt, or silence the expression of a target gene. The target gene contains a nucleotide sequence that corresponds to a sequence in the repressive RNA, thereby silencing the expression of the mRNA. Small interfering RNA (siRNA) is a short, double-stranded (ds) RNA fragment, typically about 21 nucleotides long, with a 3' overhang (2 nucleotides) at each end, which can be used to interfere with protein translation by binding at a specific sequence and promoting the degradation of messenger RNA (mRNA). In doing so, siRNA prevents the production of a specific protein based on the nucleotide sequence of its corresponding mRNA. This process is called RNA interference (RNAi) and is also known as siRNA silencing or siRNA knockdown. Short hairpin RNA or small hairpin RNA (shRNA) is an artificial RNA molecule with a tight hairpin bend that can be used to silence the expression of a target gene via RNA interference (RNAi). shRNA expression in cells is typically accomplished by delivery of plasmids or via viral or bacterial vectors.
[0103] As used herein, non-coding RNA is RNA that does not encode proteins. Categories of non-coding RNA include, but are not limited to, small interfering RNA (siRNA) and microRNA (miRNA). As used herein, inhibiting, suppressing, disrupting, or silencing a target gene refers to the process of altering the expression (e.g., translation) of a target gene, thereby reducing the activity or expression of the product encoded by the target gene. Reduction includes complete or partial knockout, thereby achieving therapeutic effects by referring to the MEVs provided herein and the administration described herein.
[0104] As used herein, the tumor microenvironment (TME) is the cellular environment in which a tumor exists, including peripheral blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules, and the extracellular matrix (ECM). Presence of these conditions includes, but is not limited to, increased angiogenesis, hypoxia, low pH, increased lactate concentration, increased pyruvate concentration, increased interstitial fluid pressure, and altered metabolites or metabolism, such as higher levels of adenosine, which indicates a tumor.
[0105] As used herein, the description of a nucleic acid or its encoded RNA targeting a gene means that it inhibits, represses, or silences gene expression through any mechanism. Typically, such a nucleic acid includes at least a portion complementary to the target gene, wherein that portion is sufficient to form a hybrid with the complementary portion.
[0106] As used herein, when referring to a nucleic acid or polypeptide sequence, a deletion refers to the absence of one or more nucleotides or amino acids compared to the sequence (e.g., target polynucleotide or polypeptide or natural or wild-type sequence).
[0107] As used herein, when referring to nucleic acid or amino acid sequences, an insertion describes the inclusion of one or more additional nucleotides or amino acids within the target, native, wild-type, or other relevant sequence. Therefore, a nucleic acid molecule containing one or more insertions contains one or more additional nucleotides within the linear length of the sequence compared to a wild-type sequence.
[0108] As used in this article, the addition of nucleic acid and amino acid sequences describes the addition of a nucleotide or amino acid to either end compared to another sequence.
[0109] As used herein, substitution refers to replacing one or more nucleotides or amino acids in a natural, target, wild-type, or other nucleic acid or polypeptide sequence with a substitute nucleotide or amino acid, without altering the length of the molecule (as described in the residue number description). Therefore, one or more substitutions in a molecule do not change the number of amino acid residues or nucleotides in the molecule. Amino acid substitutions, compared to a specific polypeptide, can be expressed based on the number of amino acid residues along the length of the polypeptide sequence.
[0110] As used herein, the location corresponding to or describing a nucleotide or amino acid position that corresponds to a nucleotide or amino acid position in the disclosed sequence, such as as shown in the sequence listing, refers to the nucleotide or amino acid position identified during alignment with the disclosed sequence to maximize similarity using standard alignment algorithms (such as the GAP algorithm). By aligning the sequences, those skilled in the art can identify the corresponding residues, for example, using conserved and identical amino acid residues as guidance. Typically, to identify the corresponding position, amino acid sequences are aligned to obtain the highest-order match (see, for example, Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carrillo et al. (1988) SIAM J Applied Math 48:1073).
[0111] As used herein, sequence alignment refers to the alignment of two or more sequences of nucleotides or amino acids using homology. Typically, two or more sequences related by 50% or more identity are aligned. A set of aligned sequences refers to two or more sequences aligned at corresponding positions and may include RNA-derived alignment sequences, such as ESTs and other cDNAs, aligned to genomic DNA sequences. Related or variant polypeptide or nucleic acid molecules can be aligned using any method known to those skilled in the art. Such methods generally maximize matching and include methods such as manual alignment and the use of numerous available alignment programs (e.g., BLASTP) and other alignment programs known to those skilled in the art. By aligning polypeptide or nucleic acid sequences, those skilled in the art can use conserved and identical amino acid residues as guidance to identify similar portions or positions. Furthermore, those skilled in the art can use conserved amino acid or nucleotide residues as guidance to find corresponding amino acid or nucleotide residues between and within human and non-human sequences. Corresponding positions can also be based on structural alignment, for example, by using computer-simulated protein structure alignment. In other cases, corresponding regions can be identified. Those skilled in the art can also use conserved amino acid residues as a guide to find corresponding amino acid residues between and within human and non-human sequences.
[0112] As used herein, the properties of a polypeptide (e.g., an antibody) refer to any property exhibited by the polypeptide, including but not limited to binding specificity, structural configuration or conformation, protein stability, resistance to proteolysis, conformational stability, heat resistance, and tolerance to pH conditions. Changes in properties can alter the activity of a polypeptide. For example, changes in the binding specificity of an antibody polypeptide can alter its ability to bind to an antigen, and / or alter various binding activities of the polypeptide, such as affinity or affinity, or in vivo activity.
[0113] As used herein, the activity or functional activity of a polypeptide (e.g., an antibody) refers to any activity exhibited by the polypeptide. Such activity can be determined empirically. Exemplary activities include, but are not limited to, the ability to interact with biomolecules, such as through antigen binding, DNA binding, ligand binding, or dimerization, or enzyme activity, such as kinase activity or proteolytic activity. For antibodies (including antibody fragments), activity includes, but is not limited to, the ability to specifically bind to a particular antigen, the affinity of antigen binding (e.g., high affinity or low affinity), the on-rate, off-rate, effector function, such as the ability to promote antigen neutralization or clearance, the ability to neutralize viruses, and in vivo activity, such as the ability to prevent pathogen infection or invasion, or to promote clearance, or to penetrate specific tissues or fluids or cells in the body. Activity can be assessed in vitro or in vivo using recognized assays such as ELISA, flow cytometry, surface plasmon resonance or equivalent assays measuring the on or off rate, immunohistochemistry and immunofluorescence histology and microscopy, cell-based assays, flow cytometry, and binding assays (e.g., panning assays)
[0114] As used herein, the terms "binding," "association," and "syntactic variants" refer to any interaction between a molecule and another molecule or between molecules that results in a stable association in which the molecules are in close proximity to each other. Binding includes, but is not limited to, non-covalent bonds, covalent bonds (such as reversible and irreversible covalent bonds), and includes interactions between molecules (such as, but not limited to, proteins, nucleic acids, carbohydrates, and lipids) and small molecules (such as compounds including drugs).
[0115] As used herein, an antibody refers to immunoglobulins and immunoglobulin fragments, whether natural or partially or wholly synthetic, such as recombinant, including any fragment containing at least a portion of the variable heavy chain and light chain regions of an immunoglobulin molecule, sufficient to form an antigen-binding site and, when assembled, sufficient to specifically bind an antigen. Therefore, an antibody includes any protein having a binding domain homologous or substantially homologous to an immunoglobulin antigen-binding domain (antibody binding site). For example, an antibody is defined as an antibody containing two heavy chains (which may be denoted as H and H') and two light chains (which may be denoted as L and L'), wherein each heavy chain may be a full-length immunoglobulin heavy chain or a portion thereof sufficient to form an antigen-binding site (e.g., heavy chains include, but are not limited to, the VH chain, the VH-CH1 chain, and the VH-CH1-CH2-CH3 chain), and each light chain may be a full-length light chain or a portion thereof sufficient to form an antigen-binding site (e.g., light chains include, but are not limited to, the VL chain and the VL-CL chain). Each heavy chain (H and H') pairs with one light chain (L and L', respectively). Typically, antibodies include at least all or a portion of the variable heavy (VH) chain and / or variable light (VL) chain. Antibodies may also include all or a portion of the constant region.
[0116] For the purposes of this document, the term antibody includes full-length antibodies and portions thereof, including antibody fragments such as antitumor antibodies or antipathogen or gene-silencing fragments. Antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, disulfide-linked Fv (dsFv), Fd fragments, Fd' fragments, single-chain Fv (scFv), single-chain Fab (scFab), biantibodies, anti-idiotypic (anti-Id) antibodies, or antigen-binding fragments of any of the above antibodies. Antibodies also include synthetic antibodies, recombinant antibodies, multispecific antibodies (e.g., bispecific antibodies), human antibodies, non-human antibodies, humanized antibodies, chimeric antibodies, and in vivo antibodies. The antibodies described herein include members of any immunoglobulin class (e.g., IgG, IgM, IgD, IgE, IgA, and IgY), any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass (e.g., IgG2a and IgG2b).
[0117] As used herein, nucleic acid refers to at least two linked nucleotides or nucleotide derivatives typically linked together by phosphodiester bonds, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The term nucleic acid also includes analogs of nucleic acids, such as peptide nucleic acids (PNA), phosphate-thioester DNA, and other such analogs and derivatives or combinations thereof. Nucleic acids also include DNA and RNA derivatives containing, for example, nucleotide analogs or backbone bonds other than phosphodiester bonds, such as phosphotriester bonds, aminophosphate bonds, phosphate-thioester bonds, thioester bonds, or peptide bonds (peptide nucleic acids). The term also includes equivalents, derivatives, variants, and analogs of RNA or DNA made from nucleotide analogs, single-stranded (sense or antisense), and double-stranded nucleic acids. Deoxyribonucleotides include deoxyadenosine, deoxycytidine, deoxyguanosine, and deoxythymidine. For RNA, the uracil base is uridine.
[0118] As used herein, isolated nucleic acid molecules are nucleic acid molecules separated from other nucleic acid molecules present in natural sources of nucleic acid molecules. Isolated nucleic acid molecules, such as cDNA molecules, may be substantially free of other cellular material or culture medium when produced by recombinant technology, or substantially free of chemical precursors or other chemicals when chemically synthesized. Exemplary isolated nucleic acid molecules provided herein include isolated nucleic acid molecules encoding RNAi or therapeutic proteins.
[0119] As used herein, operatively linked nucleic acid sequences, regions, elements, or domains refer to nucleic acid regions that are functionally related to each other. For example, a nucleic acid encoding a leader peptide can be operatively linked to a nucleic acid encoding a polypeptide, thereby allowing the nucleic acids to be transcribed and translated to express a functional fusion protein, where the leader peptide influences the secretion of the fusion polypeptide. In some cases, a nucleic acid encoding a first polypeptide (e.g., a leader peptide) is operatively linked to a nucleic acid encoding a second polypeptide, and the nucleic acids are transcribed into a single mRNA transcript, but translation of the mRNA transcript can result in the expression of one of the two polypeptides. For example, an amber stop codon can be located between the nucleic acids encoding the first polypeptide and the second polypeptide, such that when introduced into partially amber-repressed cells, the resulting single mRNA transcript can be translated to produce a fusion protein containing both the first and second polypeptides, or can be translated to produce only the first polypeptide. In another instance, a promoter can be operatively linked to a nucleic acid encoding a polypeptide, thereby regulating or mediating the transcription of the nucleic acid.
[0120] As used herein, a eukaryotic virus is a virus containing and expressed by one or more genes in and by a transcriptional / translational regulatory component of a eukaryotic host cell. Exemplary eukaryotic viruses include, for example, adenoviruses, adeno-associated viruses, herpesviruses, vaccinia viruses, and other such viruses known to those skilled in the art.
[0121] As used herein, references to promoters and / or other regulatory sequences as part of a transgene refer to such sequences that control or participate in the production of the product encoded by the transgene. The ITR plasmids provided herein contain at least one ITR3' or 5' transgene, typically two flanking the transgene, rather than other genes encoded by the virus, unless that gene or other such sequences are part of the transgene.
[0122] As used herein, the synthesis of, for example, synthetic nucleic acid molecules, synthetic genes, or synthetic peptides refers to nucleic acid molecules or polypeptide molecules produced by recombination methods and / or by chemical synthesis methods.
[0123] As used in this article, naturally occurring α-amino acid residues are the 20 α-amino acid residues found in nature that are incorporated into proteins by specifically recognizing charged tRNA molecules and their homologous mRNA codons in humans.
[0124] As used herein, a polypeptide refers to two or more amino acids covalently linked together. The terms polypeptide and protein are used interchangeably in this document.
[0125] As used in this article, a peptide refers to a polypeptide with a length of 2 to approximately 40 amino acids.
[0126] As used herein, unless otherwise stated, references to proteins include all forms of peptides, polypeptides, small peptides, and proteins.
[0127] As used herein, an amino acid is an organic compound containing an amino and a carboxylic acid group. A polypeptide contains two or more amino acids. For the purposes of this document, the amino acids contained in the antibodies provided include twenty naturally occurring amino acids (see the table below), non-natural amino acids, and amino acid analogs (e.g., amino acids in which the α-carbon has a side chain). As used herein, amino acids present in the various amino acid sequences of the polypeptides mentioned herein are identified according to their well-known three-letter or one-letter abbreviations (see the table below). Nucleotides appearing in various nucleic acid molecules and fragments are designated with standard one-letter names conventionally used in the art.
[0128] As used herein, amino acid residues refer to amino acids formed during the chemical digestion (hydrolysis) of peptide bonds in a polypeptide. The amino acid residues described herein are typically in their L-isomer form. D-isomer residues may substitute for any L-amino acid residue, provided the polypeptide retains the desired functional properties. NH2 refers to the free amino group at the amino terminus of the polypeptide. COOH refers to the free carboxyl group at the carboxyl terminus of the polypeptide. Consistent with the standard polypeptide nomenclature described in J. Biol. Chem., 243:3557-59 (1968) and adopted in 37C.FR§§1.821-1.822, the abbreviations for amino acid residues are shown in the table below: Correspondence table
[0129] All sequences of amino acid residues represented by the formula in this article have a left-to-right orientation in the conventional direction from the amino terminus to the carboxyl terminus. Phrasal amino acid residues are defined as those included in the corresponding table above, including modified, non-natural, and rare amino acids. A dash at the beginning or end of an amino acid residue sequence indicates a peptide bond with another sequence of one or more amino acid residues, or with an amino-terminal group (such as NH2) or a carboxyl-terminal group (such as COOH).
[0130] In peptides or proteins, suitable conserved substitutions of amino acids are known to those skilled in the art and can generally be performed without altering the biological activity of the resulting molecule. Those skilled in the art will recognize that, generally, substitution of a single amino acid in a non-essential region of a polypeptide does not substantially alter its biological activity (see, for example, Watson et al., Molecular Biology of the Gene, 4th ed., 1987, Benjamin / Cummings Pub. Co., p. 224).
[0131] Such substitutions can be made according to the exemplary substitutions listed in the table below: Exemplary Conserved Amino Acid Substitution
[0132] Other substitutions are also permitted and can be determined based on experience or based on other known conservative or non-conservative substitutions.
[0133] As used in this article, naturally occurring amino acids refer to the 20 L-amino acids present in polypeptides.
[0134] As used herein, the term non-natural amino acid refers to an organic compound having a structure similar to that of a natural amino acid but which has been structurally modified to mimic the structure and reactivity of a natural amino acid. Therefore, non-natural amino acids include, for example, amino acids or amino acid analogs other than the 20 naturally occurring amino acids, and include, but are not limited to, D-stereoisomers of amino acids. Exemplary non-natural amino acids are known to those skilled in the art and include, but are not limited to, 2-aminohexanoic acid (Aad), 3-aminohexanoic acid (bAad), β-alanine / β-aminopropionic acid (Bala), 2-aminobutyric acid (Abu), 4-aminobutyric acid / piperidinic acid (4Abu), 6-aminohexanoic acid (Acp), 2-aminoheptanoic acid (Ahe), 2-aminoisobutyric acid (Aib), 3-aminoisobutyric acid (Baib), 2-aminoheptanoic acid (Apm), 2,4-diaminobutyric acid (Dbu), desmosin (Des), 2,2′-diaminopeptanoic acid (Dpm), 2,3- Diaminopropionic acid (Dpr), N-ethylglycine (EtGly), N-ethylasparagine (EtAsn), hydroxylysine (Hyl), allohydroxylysine (Ahyl), 3-hydroxyproline (3Hyp), 4-hydroxyproline (4Hyp), isodesin (Ide), allo-isoleucine (Aile), N-methylglycine, sarcosine (MeGly), N-methylisoleucine (Melle), 6-N-methyllysine (MeLys), N-methylvaline (MeVal), novovaline (Nva), novoleucine (Nle), and ornithine (Orn).
[0135] As used herein, a DNA construct is a single-stranded or double-stranded, linear or circular DNA molecule containing DNA segments combined and juxtaposed in ways not found in nature. DNA constructs exist as a result of human manipulation and include clones and other copies of the manipulated molecule.
[0136] As used herein, a DNA segment is a portion of a larger DNA molecule that has specified properties. For example, a DNA segment encoding a specific polypeptide is a portion of a longer DNA molecule (such as a plasmid or plasmid fragment) that, when read from the 5′ to 3′ direction, encodes the amino acid sequence of the specified polypeptide.
[0137] As used herein, the term polynucleotide refers to a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to 3' ends. Polynucleotides include RNA and DNA and can be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. The length of a polynucleotide molecule is given herein in the form of nucleotides (abbreviated as nt) or base pairs (abbreviated as bp). The term nucleotide is used for both single-stranded and double-stranded molecules where the context permits. When the term is applied to a double-stranded molecule, it is used to indicate the total length and will be understood to be equivalent to the term base pair. Those skilled in the art will recognize that the two strands of a double-stranded polynucleotide may differ slightly in length and their ends may be staggered; therefore, all nucleotides within a double-stranded polynucleotide molecule may not pair. The length of such unpaired ends will typically not exceed 20 nucleotides.
[0138] As used in this article, production via recombinant methods refers to the use of well-known molecular biology methods to express proteins encoded by cloned DNA.
[0139] As used herein, heteronucleotides are nucleic acids that encode products (i.e., RNA and / or proteins) produced in vivo by cells that are not normally expressed by them, or nucleic acids located at loci in which they are not normally present, or nucleic acids that mediate or encode mediators that alter the expression of endogenous nucleic acids (such as DNA) by influencing transcription, translation, or other regulated biochemical processes. Heteronucleotides, such as DNA, are also referred to as exogenous nucleic acids. Any nucleic acid, such as DNA, that is heterologous or exogenous to the cell in which it is expressed, as will be recognized or considered by those skilled in the art, is covered herein as heteronucleotides; heteronucleotides include exogenously added nucleic acids that are also endogenously expressed. Heteronucleotides are generally not endogenous to the cell in which they are introduced, but are obtained from another cell or synthesized, or are introduced into genomic loci in which they are not naturally present, or whose expression is controlled by regulatory sequences or sequences different from natural regulatory sequences.
[0140] Examples of heterologous nucleic acids in this article include, but are not limited to, DNA molecules, RNA molecules, plasmids, and antisense oligonucleotides. In MEVs, heterologous nucleic acids may be encoded on plasmids. Heterologous nucleic acids, such as DNA, include nucleic acids that can mediate the expression of DNA encoding a therapeutic product in some way, or that can encode products, such as peptides or RNA, that can mediate the expression of a therapeutic product directly or indirectly in some way.
[0141] As used herein, cell therapy involves delivering MEVs to a subject to treat a disease or condition. MEVs are exogenously loaded with cargo, such that they deliver or express the product upon introduction into the subject. MEVs can also be endogenously loaded with cargo (see, for example, co-pending U.S. Provisional Application No. 63 / 349,006, filed June 3, 2022, which details the preparation of endogenously loaded MEVs and their production cell lines) and used as described herein. The transport of MEVs is generally independent of how they are loaded with cargo. Microalgae can be modified to alter the properties of the resulting MEVs. Endogenously loaded MEVs can be used in the methods and compositions described herein.
[0142] As used herein, genetic therapy involves transferring a heterologous nucleic acid (such as DNA) into certain cells (such as target cells) of a mammal (particularly a human) that has a symptom or condition for which such therapy is sought. The nucleic acid (e.g., DNA) is introduced into the selected target cells in a manner that expresses the heterologous nucleic acid (e.g., DNA) and produces a therapeutic product encoded therefrom. Gene therapy can also be used to deliver nucleic acids encoding gene products that replace a defective gene or supplement a gene product produced by the mammal or cell to which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth factor or an inhibitor thereof, or a tumor necrosis factor or an inhibitor thereof, such as its receptor, which is typically not produced in the mammalian host or not produced in a therapeutically effective amount or at a therapeutically useful time. The heterologous nucleic acid, such as DNA, encoding the therapeutic product may be modified prior to introduction into the cells of the afflicted host to enhance or otherwise alter the product or its expression. Gene therapy may also involve delivering inhibitors or repressors or other regulators of gene expression.
[0143] As used herein, expression refers to the process by which polypeptides are produced through the transcription and translation of polynucleotides. The expression level of a polypeptide can be assessed using any method known in the art, including, for example, methods for determining the amount of polypeptide produced from a host cell. Such methods may include, but are not limited to, quantification of polypeptides in cell lysates by ELISA, Coomassie blue staining after gel electrophoresis, Lowry protein assays, and Bradford protein assays.
[0144] As used herein, a host cell is a cell used to receive, maintain, replicate, and / or amplify a vector. Host cells can also be used to express polypeptides encoded by the vector. When a host cell divides, the nucleic acids contained in the vector are replicated, thereby amplifying the nucleic acids.
[0145] As used herein, a vector is a reproducible nucleic acid from which one or more heterologous proteins can be expressed when the vector is transformed into a suitable host cell. References to vectors include those to which nucleic acids encoding polypeptides or fragments thereof can be typically introduced via restriction digestion and ligation. References to vectors also include those to vectors containing nucleic acids encoding polypeptides or RNA. Vectors are used to introduce nucleic acids encoding polypeptides into host cells for the amplification of nucleic acids or for the expression / display of polypeptides encoded by nucleic acids. Vectors typically remain episomes but can be engineered to achieve the integration of genes or portions thereof into chromosomes of the genome. Vectors as artificial chromosomes, such as yeast artificial chromosomes and mammalian artificial chromosomes, are also considered. The selection and use of such vectors are well known to those skilled in the art. Vectors also include viral vectors or viral vectors. A viral vector is an engineered virus operatively linked to a foreign gene to transfer the foreign gene (as a vector or shuttle) into cells.
[0146] As used herein, expression vectors include vectors capable of expressing DNA operatively linked to regulatory sequences (such as promoter regions) capable of enabling the expression of such DNA fragments. Such additional regions may include promoter and terminator sequences and optionally include one or more origins of replication, one or more selection markers, enhancers, polyadenylation signals, etc. Expression vectors are typically derived from plasmid or viral DNA, or may contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, bacteriophage, recombinant virus, or other vector, which, upon introduction into a suitable host cell, results in the expression of cloned DNA. Suitable expression vectors are well known to those skilled in the art and include those that are reproducible in eukaryotic and / or prokaryotic cells, those that remain free, or those that integrate into the host cell genome.
[0147] As used in this article, primary sequence refers to the sequence of amino acid residues in a polypeptide or the sequence of nucleotides in a nucleic acid molecule.
[0148] As used herein, sequence identity refers to the number of identical or similar amino acids or nucleotide bases in a comparison between a test and a reference polypeptide or polynucleotide. Sequence identity can be determined by sequence alignment of nucleic acid or protein sequences to identify regions of similarity or identity. For the purposes of this document, sequence identity is typically determined by alignment to identify identical residues. Alignment can be local or global. Matches, mismatches, and gaps can be identified between the compared sequences. A gap is an empty amino acid or nucleotide inserted between residues in the aligned sequence to align identical or similar characters. Typically, internal gaps and terminal gaps can be present. Sequence identity can be determined without penalty for terminal vacancies when using vacancy penalties (e.g., terminal vacancies are not penalized). Alternatively, sequence identity can be determined as the number of identical positions / lengths in the total aligned sequences x 100, regardless of gaps.
[0149] For the purposes of this article, sequence identity is determined by comparing a test peptide or nucleic acid molecule to a reference molecule and counting the number of differences (including gaps and insertions). The number of differences is divided by the length of the reference molecule (typically the molecule whose sequence is claimed to be protected) and a percentage is determined. For example, if the claimed peptide is 100 amino acids long and variants include those with 90% sequence identity, then a variant could have 10 amino acid differences, including gaps and insertions.
[0150] As used herein, global alignment is an alignment of two sequences from start to finish, with each letter in each sequence being aligned only once. Alignment is produced regardless of whether there is similarity or identity between the sequences. For example, 50% sequence identity based on global alignment means that 50% of the residues are identical in the alignment of the complete sequences of two comparison sequences, each 100 nucleotides in length. It should be understood that global alignment can be used to determine sequence identity even if the aligned sequences are not the same length. Differences at the ends of sequences are considered when determining sequence identity unless no penalty for end gaps is selected. Global alignment is typically used on sequences that share significant similarity over most of their length. Exemplary algorithms for performing global alignment include the Needleman-Wunsch algorithm (Needleman et al., (1970) J. Mol. Biol. 48:443). Exemplary procedures for performing global alignments are publicly available and include a global sequence alignment tool available at the National Center for Biotechnology Information (NCBI) website (ncbi.nlm.nih.gov / ) and a procedure available at deep2.psis.isates.edu / aat / align / align.html.
[0151] As used herein, local alignment compares two sequences, but only those portions that share similarity or identity. Therefore, local alignment determines whether a sub-fragment of one sequence exists in another. If no similarity exists, no alignment is returned. Local alignment algorithms include BLAST or the Smith-Waltman algorithm (Adv. Appl. Mat. 2: 482 (1981)). For example, 50% sequence identity based on local alignment means that in the alignment of the complete sequences of two compared sequences of any length, a 100-nucleotide similarity or identity region has 50% of the same residues in that similarity or identity region.
[0152] For the purposes of this paper, sequence identity can be determined by a standard alignment algorithm procedure used with a default gap penalty established by each vendor. The default parameters of the GAP procedure may include: (1) a univariate comparison matrix (containing a value of 1 for the identity and a value of 0 for the non-identity) and a weighted comparison matrix as described by Gribskov et al. (1986) Nucl. Acids Res. 14: 6745, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and a penalty of 0.10 for each symbol in each gap; and (3) no penalty for the final gap. Known computer algorithms based on local or global alignment (see, for example, wikipedia.org / wiki / Sequence_alignment_software, which provides links to dozens of known and publicly available alignment databases and programs) can be used to determine whether any two nucleic acid molecules have a nucleotide sequence or whether any two polypeptides have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical amino acid sequences, or other similar variants that describe percentage similarity. Typically, for the purposes of this paper, computer algorithms based on global alignment are used to determine sequence identity, such as the Needleman-Wunsch global sequence alignment tool available from NCBI / BLAST (blast.ncbi.nlm.nih.gov / Blast.cgi?CMD=Web Page_TYPE=BlastHome); LAlign (William Pearson's implementation of the Huang and Miller algorithm (Adv. Appl. Math. (1991) 12: 337-357)); and Xiaoqui Huang's program available at deepc2.psis.iastates.edu / aat / align / align.html. Generally, the full-length sequence of each compared polypeptide or nucleotide is aligned across the entire sequence in a global alignment. Local alignment can also be used when the compared sequences are substantially the same length.
[0153] Therefore, as used herein, the term "identity" refers to a comparison or alignment between a test peptide or polynucleotide and a reference peptide or polynucleotide. In a non-limiting example, at least 90% identity means a percentage of identity from 90% to 100% relative to the reference peptide or polynucleotide. Identity at 90% or higher indicates that, for illustrative purposes, assuming a comparison of the lengths of the test peptide and reference peptide or polynucleotides of 100 amino acids or nucleotides, no more than 10% (i.e., 10 out of 100) of the amino acids or nucleotides in the test peptide or polynucleotide differ from those in the reference peptide. Similar comparisons can be made between the test polynucleotide and the reference polynucleotide. Such differences can be represented as point mutations randomly distributed throughout the length of the amino acid sequence, or they can cluster at one or more positions of different lengths up to the maximum permissible, such as 10 / 100 amino acid differences (approximately 90% identity). Differences can also be due to the deletion, insertion, or truncation of amino acid residues. Differences are defined as nucleic acid or amino acid substitutions, insertions, or deletions. Depending on the length of the sequences being compared, results can be independent of the procedure and gap parameter set at levels of homology or identity above approximately 85-90%; such high levels of identity can be easily assessed and are generally independent of software.
[0154] Typically, sequence identity is determined by aligning peptides to maximize the number of matching peptides and counting the number of differences between the two sequences. For example, in determining the sequence identity between two peptides, one sequence is a reference sequence, and the other is the sequence whose identity is determined. If a claim describes a sequence of 100 amino acids and the claimed peptide shares 95% sequence identity with it, then a difference of up to 5 amino acids is permissible between the two sequences. Differences include insertions or deletions (deleted amino acids).
[0155] As used herein, pharmaceutically effective agents include any therapeutic or bioactive agents, including but not limited to, anesthetics, vasoconstrictors, dispersants, and conventional therapeutic agents, including small molecule drugs and therapeutic proteins.
[0156] As used in this article, therapeutic effect refers to the change, usually improved or ameliorated, or cured effect of treatment of a subject.
[0157] As used herein, a therapeutically effective amount or therapeutically effective dose refers to an amount of agent, compound, material, or composition containing a compound that, when administered to a subject, is at least sufficient to produce a therapeutic effect. Therefore, it is the amount necessary to prevent, cure, improve, stop, or partially stop the symptoms of a disease or condition.
[0158] As used herein, therapeutic efficacy refers to the ability of a reagent, compound, material, or composition containing a compound to produce a therapeutic effect in a subject to whom the reagent, compound, material, or composition containing the compound has been administered.
[0159] As used herein, a preventive effective amount or preventive effective dose refers to the amount of a pharmaceutical agent, compound, material, or composition containing a compound that, when administered to a subject, will have the intended preventive effect, such as preventing or delaying the onset or recurrence of a disease or symptom, reducing the likelihood of the onset or recurrence of a disease or symptom, or reducing the incidence of viral infection. Complete preventive effect does not necessarily occur with the administration of a single dose and may occur only after a series of doses. Therefore, a preventive effective amount may be administered in one or more administrations.
[0160] As used herein, improvement of symptoms of a particular disease or condition by treatment (such as by application of a pharmaceutical composition or other therapeutic agent) means any relief of symptoms attributable to or associated with the application of the composition or therapeutic agent, whether permanent or temporary, lasting or transient.
[0161] As used herein, an anticancer agent is any agent that is destructive or toxic to malignant cells and tissues. For example, anticancer agents include agents that kill cancer cells or otherwise inhibit or damage the growth of tumors or cancer cells. An exemplary anticancer agent is a chemotherapeutic agent.
[0162] As used in this article, therapeutic activity refers to the in vivo activity of a therapeutic peptide. Generally, therapeutic activity is activity associated with the treatment of a disease or condition.
[0163] As used herein, a composition refers to any mixture. It can be a solution, suspension, liquid, powder, paste, aqueous, non-aqueous, or any combination thereof.
[0164] As used herein, a combination refers to any association between two or more items. A combination can be two or more individual items, such as two compositions or two collections, mixtures thereof, such as a single mixture of two or more items, or any variation thereof. The elements of a combination are typically functionally related or interdependent.
[0165] As used herein, combination therapy refers to the administration of two or more different therapeutic agents. The different therapeutic agents may be provided and administered individually, sequentially, intermittently, or in a single composition.
[0166] As used herein, a kit is a packaged combination that optionally includes other elements, such as additional reagents and instructions for use of the combination or its elements, for purposes including but not limited to activation, administration, diagnosis and evaluation of biological activity or properties.
[0167] As used herein, unit dosage form refers to a physically discrete unit that is individually packaged and suitable for human and animal subjects, as is known in the art.
[0168] As used in this article, a single-dose formulation refers to a formulation intended for direct administration.
[0169] As used herein, a multi-dose formulation refers to a formulation containing multiple doses of a therapeutic agent and capable of being directly applied to provide several single doses of the therapeutic agent. The doses may be administered over a period of minutes, hours, weeks, days, or months. Multi-dose formulations allow for dose adjustment, dose pooling, and / or dose splitting. Because multi-dose formulations are used over time, they typically contain one or more preservatives to prevent microbial growth.
[0170] As used herein, an emulsion is a system consisting of two closely mixed and dispersed immiscible liquid phases, one entering the other. An emulsion is a colloidal dispersion of two immiscible liquids, such as oil and water (or other aqueous liquids, such as polar solvents), where one is part of a continuous phase and the other is part of a dispersed emulsion phase, typically stabilized by one or more surfactants and / or auxiliary surfactants and / or emulsion stabilizers. Surfactants form an interfacial film between the oil and aqueous phases of the emulsion, thus providing stability. Microemulsions and nanoemulsions are two different types of emulsions. An emulsion is a fine dispersion of tiny droplets of one liquid in another liquid, where the liquid is either insoluble or immiscible. Microemulsions are thermodynamically stable, while nanoemulsions are thermodynamically unstable.
[0171] As used herein, microemulsions are two-phase systems composed of finely dispersed lipid and aqueous phases. Microemulsions are transparent, isotropic, and stable liquid mixtures of lipid and aqueous phases, held together by a surfactant (usually in combination with a co-surfactant). Microemulsions are transparent, thermodynamically stable, isotropic liquid mixtures of oil, water, and surfactants, and optionally co-surfactants. Microemulsions spontaneously form after the aqueous and lipid phases are mixed. Therefore, microemulsions are thermodynamically stable systems in which particles are dispersed in a continuous phase. The droplet size of the dispersed phase in a microemulsion is less than 100 nm, typically in the range of 5 nm to 50 nm, including the extreme values. In contrast, nanoemulsions require an energy input to form an emulsion; nanoemulsions are thermodynamically unstable but kinetically stable. The ophthalmic drop formulations presented herein include both nanoemulsions and microemulsions.
[0172] As used herein, a "surfactant" refers to a synthetic or naturally occurring amphiphilic molecule having both a hydrophobic and a hydrophilic portion. Surfactants contain both hydrophilic and hydrophobic domains, hence the term amphiphilic molecules. Due to their properties, surfactants promote the formation of oil-in-water emulsions, in which micelles require interaction with both the aqueous and oil phases to exist. Because of their amphiphilic (amphiphilic) nature, surfactants and co-surfactants can reduce the surface tension between two immiscible liquids (e.g., the oil and aqueous phases in an emulsion, such as a microemulsion), thereby stabilizing the emulsion. Surfactants can be characterized based on their relative hydrophobicity and / or hydrophilicity. For example, relatively lipophilic surfactants are more soluble in fats, oils, and waxes and typically have a hydrophobic-lipophilic balance (HLB) value of less than 10 or about 10, while relatively hydrophilic surfactants are more soluble in aqueous compositions, such as water, and typically have an HLB value greater than 10 or about 10. Relatively amphiphilic surfactants are soluble in both oil-based and water-based liquids and typically have an HLB value close to 10 or about 10. The surfactants used in the compositions described herein are biocompatible.
[0173] As used herein, a co-surfactant is a surfactant that, in addition to another surfactant, further reduces the surface tension of a liquid. For example, the statement that a microemulsion contains a surfactant refers to both the surfactant and the co-surfactant included. Co-surfactants are inherently hydrophilic and reduce the surface tension of water. They are commonly used as wetting agents, for example, to increase the spreading ability of water-based fluids by reducing the surface tension of water. Co-surfactants are also used and are often required to increase the solubility of the primary surfactant.
[0174] As used herein, “particle size” and “average particle size” are synonymous and refer to the average diameter of particles in a liquid, such as the diameter of droplets or micelles in an emulsion. As used herein, "oil phase" or "lipid phase" refers to a portion (or phase) of a compositional cap containing one or more lipophilic and / or amphiphilic components (such as oils), and is typically a lipid-soluble phase. In oil-in-water (o / w) microemulsions, the lipid phase is typically the dispersed phase, while water is the dispersed phase.
[0175] As used herein, oil phase components refer to the components of the provided composition contained in an oil. Typical oil phase components include nonpolar compounds, such as nonpolar active ingredients; at least one surfactant; oils, such as nonpolar solvents; preservatives; and microemulsion stabilizers. Other lipophilic and / or amphiphilic components may be included in the oil phase.
[0176] As used herein, "aqueous phase" or "aqueous phase" refers to a portion (phase) of a composition, such as those provided herein, that contains one or more hydrophilic and / or amphiphilic components (aqueous phase components) and is typically a water-soluble phase. Generally, in the microemulsion compositions provided herein, the aqueous phase is the continuous phase. "Aqueous phase" is also used to refer to a liquid containing the aqueous phase components generated during the preparation of the microemulsion.
[0177] As used herein, an aqueous phase component refers to a component of the composition contained in the aqueous phase in the provided method for preparing the composition. Typical aqueous phase components may include, but are not limited to, polar solvents, typically polar protic solvents such as water and alcohols, typically alcohols having more than one hydroxyl group such as dihydroxy and trihydroxy alcohols, such as glycerol and propylene glycol; at least one surfactant; a preservative; and an emulsion stabilizer. Other hydrophilic and / or amphiphilic components may be included in the aqueous phase.
[0178] As used herein, the thermodynamic stability of a microemulsion refers to the stability of the dispersion such that the phases do not separate. The microemulsions presented herein exhibit high thermodynamic stability, as demonstrated by their stability at elevated temperatures.
[0179] As used herein, room temperature and ambient temperature are used to describe temperatures common in one or more enclosed spaces where a person typically resides or lives. Room temperature can vary, but is generally referred to as a temperature between 19°C or about 19°C and 25°C or about 25°C. When the composition is stored at room temperature, it should be understood that it is generally maintained at or about this temperature range.
[0180] As used herein, an article of manufacture is a product manufactured and sold. As used throughout this application, the term is intended to cover any composition provided herein contained in packaged articles of manufacture.
[0181] As used herein, fluid refers to any composition that is flowable. Therefore, fluid encompasses compositions in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams, and other such compositions.
[0182] As used herein, isolated or purified polypeptides or proteins (e.g., isolated antibodies or their antigen-binding fragments) or their biologically active portions (e.g., isolated antigen-binding fragments) are substantially free of cellular material or other contaminating proteins from the cells or tissues from which the protein originated, or are substantially free of chemical precursors or other chemicals during chemical synthesis. If a formulation appears to be free of readily detectable impurities by standard analytical methods (e.g., thin-layer chromatography (TLC), gel electrophoresis, and high-performance liquid chromatography (HPLC), which those skilled in the art use to assess such purity), it can be determined that the formulation is substantially free of, or sufficiently pure, impurities such that further purification will not detectably alter the physical and chemical properties of the substance, such as enzyme activity and biological activity. Methods for purifying compounds to produce substantially chemically pure compounds are known to those skilled in the art. However, substantially chemically pure compounds can be mixtures of stereoisomers. In such cases, further purification may increase the specific activity of the compound.
[0183] As used herein, cell extracts or lysates refer to preparations or fractions made from lysed or destroyed cells.
[0184] As used in this article, a control is a sample that is substantially the same as the test sample, except that it has not been treated with the test parameters, or, if it is a plasma sample, it can be derived from a healthy volunteer unaffected by the condition of interest. A control can also be an internal control.
[0185] As used herein, psilocin is the active form of psilocybin. Psilocin is produced by the oxidation of psilocybin in the liver. For the purposes of this article, in the context of MEV-mediated delivery, psilocybin and psilocin should have the same meaning: reference to 'psilocybin' means 'psilocin', and vice versa.
[0186] As used herein, the tropism of MEVs refers to the accumulation of MEVs in cells, tissues, and / or organs upon administration. Unless otherwise specified, the MEVs described herein are not modified to provide specific tropism or targeting properties.
[0187] As used herein, the transport of a MEV at the time of administration refers to the path the MEV takes to one or more of its final destinations. For example, as shown and described herein, an intranasally administered MEV travels through nerves and neurons to reach a location in the brain that is connected to or adjacent to neurons.
[0188] As used herein, the singular forms “a,” “an,” and “the” include plural indicators unless the context clearly specifies otherwise. Thus, for example, references to polypeptides containing immunoglobulin domains include polypeptides having one or more immunoglobulin domains.
[0189] As used herein, the term “or” is used to mean “and / or” unless it is explicitly stated that it refers only to alternatives or that the alternatives are mutually exclusive.
[0190] As used herein, ranges and quantities can be expressed as approximately a specific value or range. “Approximately” also includes the exact quantity. Thus, approximately 5 amino acids means approximately 5 amino acids plus 5 amino acids. Typically, although depending on the context and the understanding of a person skilled in the art, “approximately” includes a range of ±10%.
[0191] As used herein, "optional" or "optionally" means that the event or situation subsequently described occurs or does not occur, and the description includes both the possibility that the event or situation occurs and the possibility that it does not occur. For example, a part that is optionally varied means that the part is varied or not varied.
[0192] As used herein, unless otherwise stated, any abbreviations for protecting groups, amino acids and other compounds are based on their common usage, recognized abbreviations or the IUPAC-IUB committee on biochemical nomenclature (see Biochem. (1972) 11(9): 1726-1732).
[0193] For the sake of clarity and not as a limitation, detailed descriptions are divided into subsequent sub-sections.
[0194] B. Overview Microalgal extracellular vesicle gene therapy vectors (MEV-GTVs) are provided, which are MEVs containing a plasmid encoding a transgene of interest and at least one, typically two, ITRs flanking the transgene. Circular plasmids containing ITRs and one or more transgenes are also provided. For the production of circular small gene plasmids, bacterial plasmids containing ITRs and transgenes are also provided. The bacterial plasmids multiply in a bacterial host and may include sequences flanking the ITR and the transgene construct, which can be induced to recombine or recombined to release the ITR-transgene construct, which can then be circularized.
[0195] The presence of the ITR in the plasmid confers free-form survival and thus persistent expression of the payload (including the encoded product). The ITR is the sole component of the AAV or other viral vector contained in the MEV-GTV; it contains no viral proteins (cap, rep) and no viral genetic elements, such as AAV, with the sole exception of the ITR. They do not require complex manufacturing procedures, making them easier and cheaper to produce, and they possess better safety characteristics (non-viral, non-mammalian) as shown in the figure (co-pending application International PCT Application No. PCT / EP2024 / 057645, published as International PCT Publication No. WO2024 / 194423), and there is no adverse immune response. MEV-GTV provides delivery and persistent expression of the encoded product.
[0196] The resulting plasmid is introduced into a MEV, which encapsulates the plasmid construct, and upon administration, the MEV delivers the encoded product to tissues and organs. This is detailed herein and in jointly owned publications (see International PCT Publications WO2023001894, WO 2023 / 144127, and WO2024088808, and co-pending International PCT Application: PCT / EP2024 / 057645, published as International PCT Publication WO2024 / 194423, and U.S. Provisional Application Serial No. 63 / 562,941). MEVs can be produced and exogenously loaded with the product of interest and administered to subjects (e.g., humans) via various routes, including oral, intramuscular, intranasal, ocular, and other routes. The route of administration determines the in vivo fate of the administered MEV and allows selection of the route for targeting tissues or organs.
[0197] Therefore, the resulting MEV-GTV provides an encapsulated nucleic acid delivery vector for gene therapy. MEVs are used as capsids containing circularized small gene plasmids (see, for example...). Figure 4 It describes the MEV-GTV compared to the AAV carrier. Figure 4 (Image D), and prior art exosomes containing an AAV vector including a capsid). This article details the advantages of MEV-GTV.
[0198] C. Adeno-associated virus (AAV) vector Adeno-associated virus (AAV) vectors have been developed and are among the approved gene therapy vectors. These small viruses, capable of infecting humans and other primates, belong to the genus *Dependoparvovirus* within the family Parvoviridae. Contaminants initially identified in AAV adenovirus preparations have become a key focus for gene therapy applications. Several AAV serotypes have been described, with variations in their capsid structure that affect their tropism and immunogenicity in host organisms. Among naturally occurring serotypes, AAV2 has been the most extensively characterized and is frequently used in research and clinical applications. AAV viruses and vectors with modified or chimeric capsids have been developed, often for enhancing or altering tropism.
[0199] AAV (in) Figure 1 AAVs (as depicted in the image) are non-enveloped viruses, less than 30 nm in diameter, with a linear single-stranded DNA (ssDNA) genome of approximately 4.7 kilobases. AAVs are known to maintain their genome in episome form within host cells, allowing for sustained and stable gene expression without integration into the host genome. At the heart of AAV functionality are inverted terminal repeats (ITRs), each approximately 145 bases long, flanking the AAV genome. These ITRs play crucial roles in AAV replication, transcriptional regulation, and genome packaging. ITRs are essential for the genetic material delivered by intracellular AAVs to exist as episomes (and thus replicate independently of host cell replication); this property is important for the persistent survival of the vector and the persistent expression of the encoded product. This specific characteristic of AAVs makes them highly attractive for gene therapy applications, as they can ultimately ensure the persistent expression of the desired ('cure') phenotype without the integration of viral material into the host genome; the lack of integration is ideal for safety reasons.
[0200] Figure 1 A schematic diagram of the AAV genome, which is lateral to the ITR and encodes the Cap and Rep AAV genes, is provided [from: Asaad et al. (2023). AAV genome modification for efficient AAV production. Heliyon, 9(4), e15071].
[0201] The simplicity of AAV's genomic and non-pathogenic characteristics makes them a commonly used gene therapy vector. AAV vectors have shown efficacy in treating central nervous system (CNS) diseases, retinal degenerative diseases, various muscular dystrophys, and diseases affecting the heart, lungs, and liver. AAV-based gene therapy vectors face several key challenges, such as the limited packaging capacity of AAV, the complexity and cost of manufacturing, the generation of neutralizing antibodies, the impossibility of repeated administration, and the need for sustained cures, among others. As detailed in this paper, the MEV-GTV presented addresses these challenges.
[0202] 1. AAV-based carriers and ITR roles and functions AAVs have been genetically engineered to produce adeno-associated virus vectors (AAV vectors) with specific properties suitable for delivering therapeutic genes into target cells. Engineered AAVs serve as efficient and safe vectors for targeted DNA delivery into cells and tissues. AAV vectors are particularly advantageous in gene therapy for several reasons: (1) they are replication-defective, ensuring they do not regenerate within host cells; (2) they are non-integrative, minimizing the risk of altering the host genome; and (3) they exhibit low immunogenicity (besides neutralization), reducing the likelihood of triggering an immune response.
[0203] In AAV-derived vectors, approximately 96% of the AAV genome is replaced by the cassette of interest, leaving only inverted terminal repeats (ITRs), essential elements within the AAV vector. ITR sequences, primarily derived from AAV serotype 2, form the basis for multiple processes, including genome rescue, replication, packaging, and vector persistence. Each AAV construct contains two ITR sequences, each spanning 145 bases and located flanking the transgene. These ITRs form palindromic structures, characterized by high GC content and the ability to form hairpin structures that promote self-initiation (see [link to relevant documentation]). Figure 2 This allows for primer-independent synthesis of the second DNA strand. Figure 2The secondary structure of the ITR of AAV serotype 2 is shown. The characteristic T-shape of the ITR is formed by two adjacent inverted repeats (BB' and CC') separated by a single unpaired nucleotide. The third inverted repeat is the central AA', forming a three-way connection. The D sequence does not participate in the T secondary structure. The replicase-binding element (RBE) is formed by specific tetranucleotide repeats. The “flip” and “flop” sequences are present in equal proportions at either end of the AAV genome [from: Wilmott et al. (2019). A User's Guide to the Inverted Terminal Repeats of Adeno-Associated Virus. Human Gene Therapy Methods, 30(6), 206-213].
[0204] ITR sequences possess intrinsic transcriptional activity and can drive the expression of desired transgenes in therapeutic applications [see Earley et al. (2020). Adeno-Associated Virus serotype-specific Inverted Terminal Repeat sequence role in vector transgene expression. Human gene therapy, 31(3-4), 151-162]. Many ITR sequences, including natural ITRs (derived from naturally occurring AAV serotypes) and synthetic ITRs, can be used in plasmids. Figure 3 Examples of ITR sequences and structures derived from AAV serotypes 1, 2, 3, 4, 6, and 7 are shown, where bold letters indicate nucleotides that are not conserved in the ITR sequence. ITRs are present in other eukaryotic viruses and can be used for plasmid-containing ITRs and plasmid-containing delivery vectors, including MEV-GTV provided herein.
[0205] For gene therapy applications, the ITR detailed and shown in this article is the only required sequence in cis adjacent to the therapeutic gene. While structural (cap) and packaging (rep) proteins can be delivered in trans form, the ITR plays a crucial role in efficient vector replication and transgene expression. AAV vectors, as extrachromosomal circular (attachment) DNA molecules, undergo replication, allowing the AAV genome to persist within the host cell without integrating into the host genome. Upon entry into the host cell, the AAV gene vector forms an attachment structure replicated by the host cell's machinery. The extracellular body can remain stably in the host cell for extended periods, which is advantageous for gene therapy applications. Long-term expression of the therapeutic gene is possible, avoiding host integration-related complications, including the risks associated with random vector insertion into the host genome.
[0206] Other ITRs can be used. The table below provides a list of some known ITRs and their sources.
[0207] 2. Applications of AAV-based vectors in gene therapy Adeno-associated virus (AAV) vectors are versatile in gene therapy applications, providing a platform for treating a wide range of genetic diseases. These vectors have been used to target diseases affecting various organ systems, including the central nervous system, musculoskeletal system, and cardiovascular system. Furthermore, AAV vectors have been used in both in vitro and in vivo gene therapy methods, further expanding their utility. With advancements in vector engineering and delivery strategies, AAV vectors continue to evolve to meet the diverse needs of gene therapy applications. To date, several AAV-based gene therapies for various diseases have been developed and approved for clinical use. Indicators include only single-gene heritability indicators, i.e., diseases caused by mutations in a single gene.
[0208] Glybera reached this milestone in 2012 with EU approval as the first AAV-mediated gene therapy. Glybera corrects hereditary lipoprotein lipase deficiency (LPLD), which manifests as pancreatitis, recurrent abdominal pain, and explosive fat-filled spots caused by very high triglyceride levels. The rarity of the disease (1 in a million), patient costs, the company's maintenance treatment readiness expenses, and regulatory challenges in the US led to its withdrawal from the market. This form of gene therapy was no longer available after 2018, with only 31 patients treated globally [Keeler et al. (2019) Recombinant Adeno-Associated Virus gene therapy in light of Luxturna]. ® (and Zolgensma® andGlybera): where are we, and how did we get here? Annu. Rev.Virol. 6:601-621].
[0209] Another gene therapy product is Zolgensma ®Zolgensma® was approved by the FDA in May 2019 for the treatment of spinal muscular atrophy type 1 (SMA). Zolgensma® is a vector based on AAV-serotype-9 (AAV9), which encodes complementary DNA (cDNA) of the surviving motor neuron 1 gene (surviving motor neuron, SMN1). After intravenous administration, AAV9 crosses the blood-brain barrier (BBB) and delivers targeted delivery of the SMN gene to neurons [(2019) Zolgensma® - One-time genetherapy for spinal muscular atrophy]. Med. Lett. Drugs Ther. 61:113-114).
[0210] Several other regulatory approvals for gene therapy using AAV vectors have been followed. Luxturna® is designed to treat retinal dystrophy caused by biallelic mutations in the RPE65 gene (an enzyme in retinal cells involved in the regeneration of photopigment). Drug delivery to retinal cells leads to the restoration of normal RPE65 protein synthesis, which is essential for the regeneration of photopigment [Prado et al. (2020) Gene therapy beyond Luxturna®: A new horizon of the treatment for inherited retinal disease]. Curr. Opin. Ophthalmol. 31:147-154]. Hemgenix was approved by the FDA in 2022. ® In China, one drug is used to treat hemophilia B, caused by a congenital deficiency of factor IX. This drug uses a liver-directed AAV5 vector to deliver a functional copy of the F9 gene [Von Drygalski et al. (2019). Etranacogene dezaparvovec (AMT-061 phase 2b: normal / near normal FIX activity and bleed cessation in hemophilia B. Blood advances, 3(21), 3241–3247]. In 2023, two other AAV-based gene therapies were approved. Elevidys was developed from Sarepta, a therapeutic agent used for Duchenne gene therapy. ®(delandistrogene moxeparvovec-rokl). This treatment was designed to deliver the gene encoding microdystrophy protein (i.e., a shortened form of dystrophy protein expressed in normal muscle cells) to all muscles involved in DMD pathology [Zaidman et al. (2023). Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged ≥4 to <8 years) with Duchenne Muscular Dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Annals of Neurology [94(5), 955-968]. BioMarin's Roctavia, approved for the treatment of hemophilia A (factor VIII deficiency). ® (valoctocogene roxaparvovec) is an AAV5-based gene therapy vector carrying a functional copy of the F8 gene, driven by a liver-selective promoter [Ozelo et al. (2022) Valoctocogene roxaparvovec gene therapy for hemophilia A.]. N. Engl. J. Med. 386:1013-1025].
[0211] Dozens of other therapies involving in vivo gene transfer are under development and in clinical trials. These indications include: - Neuromuscular disorders: spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), X-linked myotube myopathy (XLMTM), and central nervous system disorders, including Alzheimer's disease, Parkinson's disease, Canavan disease, aromatic L-amino acid decarboxylase (AADC) deficiency, and giant axonal neuropathy (GAN).
[0212] - Eye conditions: Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), choroidal agenesis, achromatopsia (ACHM), retinitis pigmentosa, and X-linked retinal degeneration (XLRS).
[0213] -The bleeding disorder described is hemophilia.
[0214] - and lysosomal storage disorder (LSD).
[0215] Despite the successful development of AAV-based gene therapy drugs, many preclinical and clinical studies have been suspended or terminated without resulting in drug registration. Consequently, many diseases, especially rare ones, remain untreated. Some failures in clinical trials are due to the limitations of AAV vectors related to efficacy restrictions and safety concerns.
[0216] 3. Advantages and disadvantages of AAV-based carriers Adeno-associated viruses (AAVs) have been used as the backbone for many gene therapy vectors, exhibiting key properties that contribute to their advantages and limitations. These properties are crucial considerations for effectively using these viral vectors in specific applications while addressing safety concerns.
[0217] a. Advantages of AAV-based carriers 1) Long-term expression capability: The significant strength of AAV vectors lies in their ability to express genes long-term. Once introduced into host cells, the AAV genome can persist in an extrachromosomal state without integrating into the host cell genome. This non-integrating property is advantageous for many clinical applications where genome integration is preferred.
[0218] 2) Low immunogenicity: AAV vectors exhibit low immunogenicity, reducing the likelihood of triggering an immune response. This is advantageous in gene therapy applications, as a robust immune response can hinder the efficacy of the vector and lead to adverse effects, as is the case with other well-documented viral vectors.
[0219] 3) Safety Overview: Safety is a key focus when designing AAV vectors. Although derived from naturally occurring viruses, AAV-based vectors undergo modifications to minimize handling-related risks. Crucially, most of the viral genome essential for replication is typically missing, rendering viral replication defective. This ensures (or increases the chance) that, post-infection, AAV requires a helper virus to supply the missing proteins to produce new virions. Such helper viruses may simply be naturally occurring adenoviruses contaminated with wild-type AAV (wild-type AAV naturally carries the genes for Rep and Cap proteins), which can rescue the AAV vector.
[0220] b. Limitations of AAV-based carriers 1) Generation of neutralizing antibodies: Host immune responses to AAV vectors have hindered their widespread use. This includes the generation of neutralizing antibodies in the host. Albeit wild-type AAV is a predominantly nonpathogenic virus, infection with wild-type AAV is very common, and 30-60% of the population is considered to have AAV-neutralizing antibodies. Furthermore, significant cross-reactivity exists among different AAV serotypes [Weber T. (2021). Anti-AAV antibodies in AAV genetherapy: current challenges and possible solutions. Frontiers in Immunology, 12, 658399]. Pre-existing antibodies against AAV may also hinder the vector's ability to efficiently deliver genes to target cells, thereby reducing its therapeutic impact. In addition, capsid-specific cell-mediated cytotoxic T-cell responses affect transgene expression and lead to the clearance of transduced cells, hindering therapeutic efficacy (Arjomandnejad et al., (2023)). BioDrugs ,37(3),311-329).
[0221] 2) Size limitations of transgenes: AAV vectors have limitations on the size of the transgenes they can carry. Their limited packaging capacity restricts the delivery of larger therapeutic genes or complex payloads, thus affecting the vector's versatility. Therefore, many proteins associated with genetic diseases cannot be expressed using a single AAV vector because the expression cassette size exceeds the AAV's packaging capacity.
[0222] 3) Manufacturing Complexity and Cost: The production of AAV vectors presents manufacturing challenges. Because AAV vectors are replication-deficient, they require auxiliary functions for replication and packaging. This is achieved either by co-infecting production cells with helper viruses or by providing the necessary auxiliary functions on separate packaging plasmids. Packaging itself is inefficient, resulting in up to 90% empty capsids. Therefore, large-scale, high-quality, consistent vector production is challenging (Hebben M. (2018) Downstream bioprocessing of AAV vectors: industrial challenges®, engineery requirements). Cell Gene Ther Insights4,131-146). The complex modifications required for optimal vector design and production also contribute to the complexity of manufacturing. All of this translates into the manufacturing cost intensity of AAV vectors. The complex processes involved, coupled with the need for stringent quality control, contribute to the total cost of adopting AAV vectors in gene therapy.
[0223] 4) Lack of Targeting and Administration Challenges: AAV vectors are typically designed to infect a wide range of cell types, lacking specificity. Different serotypes possess different transduction specificities or trophozoites, allowing transgene delivery to specific subpopulations of cells. Various AAV serotypes also differ in the efficacy and kinetics of transgene expression. While this is advantageous for some applications, the inability to target specific cells directly limits the precision of gene delivery. Due to the sensitivity of AAVs to biological barriers, targeting some cells or tissues may require invasive administration routes. For example, in AAV-based therapies, crossing the blood-brain barrier is primarily achieved via intracranial injection, while retroocular delivery is achieved via subretinal or intravitreal injection.
[0224] 5) Residual toxicity: The safety profile is considered very favorable for long-term AAV gene therapy; however, this has changed with the tragic deaths of three children in a clinical trial (NCT03199469) that aimed to treat X-linked myotubular myopathy with an AAV8 vector that promotes functional MTM1 expression (Wilson & Flotte (2020) Moving forward after two deaths in a gene therapy trial of myotubular myopathy). Hum Gene Ther. 31:695-6). In addition, systemic AAV administration has been associated with neurotoxicity in peripheral nerve ganglia and the spinal cord, with neurological signs also observed after direct AAV injection into the brain (Stone et al. (2023) Adeno-associated virus vectors and neurotoxicity-lessons from preclinical and human studies). Gene therapy (10.1038 / s41434-023-00405-1). AAV vectors have also been shown to activate Toll-like receptors, thereby triggering inflammatory responses.
[0225] D. MEV-based gene therapy vector (MEV-GTV) The MEV-GTV described in this article combines the benefits and advantages of AAV vectors and other gene therapy vectors, while overcoming or avoiding the drawbacks and challenges observed with AAV vectors and other gene therapy vectors. It should be understood that other delivery vectors that provide a capsid for administration to subjects and for ITR-containing plasmids can be used instead of MEVs. As described herein, MEVs confer benefits and advantages not conferred by other EVs (e.g., exosomes).
[0226] MEVs comprise a complex consisting of an envelope made of extracellular vesicles from microalgae and a payload made of a simple plasmid carrying an ITR (e.g., AAVITR) viral sequence, which can be obtained, produced, or synthesized in advance. MEV-GTVs can be taken up by cells, and the cells appropriately express the information encoded by the plasmid, which migrates to the nucleus and can persist as an appendage. MEV-GTVs mimic the concept of AAV viruses or AAV-based vectors, but all components of the viral capsid are replaced by MEVs (or other delivery vectors). Because the MEV acts as the active envelope of genetic material, the resulting MEV-GTV shares key features with the MEV to impart the benefits and advantages of the MEV. In terms of biodistribution, tropism, targeting, delivery, and other such properties, the resulting MEV-GTV behaves like a MEV (rather than an AAV).
[0227] In contrast, AAV vectors already encapsulated in other EVs have been prepared, such as the chimeric nanobodies used by EVOX (evoxatheatics.com), which contain the entire AAV particle loaded into mammalian extracellular vesicles. These have not yet been successfully deployed. These chimeric nanobodies require the entire AAV particle (including the capsid protein). Conversely, plasmids containing plasmids with ITRs encapsulated in MEVs and MEV-GTV have successfully encoded, expressed, and delivered gene products.
[0228] Therefore, the product provided herein is a nanoparticle or nanoscale delivery system made of two components: (1) an outer membrane, which is an extracellular vesicle from microalgae (MEV), which is a nanoscale lipid nanoparticle, and (2) an internal payload, which is an expression plasmid carrying at least three genetic elements: (i) an AAV-ITR sequence to confer stability, persistent survival and episome behavior to the plasmid, (ii) control genetic elements, such as promoters, enhancers, introns, IREs, Kozak sequences, etc., and (iii) a transgene, which is made of simple or multiple coding sequences encoding mRNA, siRNA, miRNA or any other kind of genetically active molecule, whether or not.
[0229] Therefore, MEV-GTV represents the most advanced evolution of gene therapy vectors, where the viral presence is reduced to only the ITR (allowing users to incorporate viral promoters into the transgenic construct), and the envelope portion endows MEVs with superior properties. Such superior properties have been reported to date only for MEVs compared to other known delivery systems such as mammalian EVs, LNPs, AAV vectors, or other delivery systems. These include: the ability to accommodate large payloads, high external loading efficiency, high delivery efficiency, specific biodistribution profiles, non-toxicity, non-immunogenicity, no production of neutralizing antibodies, ability to overcome biological barriers, ability to provide a non-invasive route of administration, a safety profile (absence of mammalian viruses), and a range of favorable features regarding manufacturing, such as convenient / high-yield manufacturing, and clean and sustainable industrial applications.
[0230] 1. MEV-GTV This article provides a MEV-based gene therapy vector (or MEV-GTV), which is an MEV loaded with a plasmid carrying an ITR (e.g., a viral ITR, including AAV and other viral ITRs) and other user-selected components (including eukaryotic regulatory sequences and nucleic acid-coding genes of interest, including genes with introns). MEV-GTV is a non-viral delivery system. Plasmids containing ITR circularization can be produced in bacteria. The plasmid is isolated and then introduced into the MEV.
[0231] This document describes and provides compositions and methods related to the characterization, production, and use of MEV GTVs for delivering plasmids carrying AAV-ITR for the sustained expression of various therapeutic modalities (e.g., proteins, peptides, siRNAs, miRNAs, other non-coding regulatory RNAs, and editing complexes, or combinations thereof) to treat diseases or syndromes. These compositions and methods can be used to improve or deliver gene therapy treatments and overcome bottlenecks in gene therapy approaches, thereby slowing, halting, or reversing genetic diseases or syndromes, metabolic diseases or syndromes, and / or multifactorial diseases or syndromes.
[0232] MEV-GTV provides a novel gene therapy vector that combines the rare and convenient features of MEVs, such as their loading capacity and versatility, targeting, biodistribution, and delivery capabilities, with the use of a plasmid containing an ITR sequence from AAV (as the payload of the MEV), which carries the ability to maintain persistent expression, and the plasmid as a free DNA replication in human cells.
[0233] MEV-GTV combines the convenience of MEVs as a delivery system with the properties of AAV vectors as gene therapy vectors. Therefore, MEVs can accommodate and deliver plasmids far exceeding 5 kb in size (the upper limit imposed by the AAV capsid) to accommodate constructs within AAV-based vectors. This breakthrough in AAV's limitations on payload size allows MEV-GTV to carry longer or multiple coding regions within the same construct.
[0234] MEVs can be administered multiple times. As previously disclosed (see International PCT Application No.: PCT / EP2024 / 057645), MEVs do not generate a neutralizing immune response; therefore, they can be repeatedly administered without the need for neutralization of their biological activity by the host's immune system. In contrast, AAVs are considered to be administered only once, as any subsequent administration of such or related AAVs is neutralized by the neutralizing reaction generated by their capsid after the first exposure. The capsule of MEV-GTV is made directly from MEVs, therefore MEV-GTV is intended to be suitable for repeated treatment of patients.
[0235] In other aspects of this disclosure, MEV-GTV exhibits a typical biodistribution pattern of MEVs, depending on the specific route of administration used. For example, while AAV-based gene therapy for brain diseases requires delivery of the vector via invasive methods (such as intracranial administration), MEV-GTV can be administered via intranasal instillation (naso-brain delivery via intranasal administration). As described herein, when administered intranasally as drops or in other forms for nasal administration, MEVs are directed toward brain regions. In the nose, MEVs are internalized by sensory neurons in the olfactory epithelium. From there, they travel through the olfactory bulb to internal structures in both hemispheres of the brain.
[0236] AAV-based gene therapies for retroocular diseases require delivery methods involving intraocular injection, which are invasive and have low patient compliance. However, MEV-GTV can be administered topically to the ocular surface.
[0237] 2. Production of MEV-GTV Like any other type of "loaded MEV" (e.g., an MEV already loaded with a specific payload), the MEV-GTV is a composite element. They have two components: the MEV portion (or other delivery carrier) and the payload portion.
[0238] MEV-GTV is a MEV already loaded with a specific expression plasmid. The plasmid carries the following three genetic elements in a suitable functional array combination: (1) an ITR derived from AAV. The ITR ensures the survival of the plasmid within the recipient cell, which is a replicative and non-integrative episome; (2) a genetic element that ensures the proper expression, processing, and ultimately other activities of the transgene; and (3) the transgene. The plasmid may carry one or two ITRs (see, for example...). Figure 2 and Figure 3 Genetic elements include, but are not limited to, promoters, enhancers, Kozak concordant sequences, IRES, polyA, and other such sequences. Transgenic structures encode biologically active principles intended to convey desired modifications to the recipient cell. Transgenic structures can encode a wide variety of genetic elements, such as mRNA, genes, exons, proteins, peptides, as well as siRNA, miRNA, and other such RNA products, RNA components of gene editing complexes, and a large number of genetic and / or biologically active elements.
[0239] MEV-GTV is produced as follows. The MEV portion is produced, for example, as described in International PCT Publications WO2023001894, WO2023144127, WO2024088808, WO2024194423 and Priority Applications, U.S. Provisional Application Serial No. 63 / 562,941 and any of these herein. The MEV is produced by growing microalgae in a photobioreactor and then purifying the MEV produced from the supernatant of these cultures. The product of this production, clarification and purification process consists of purified MEV, which is ready for use, characterization, storage and ultimately loading with a custom payload. The plasmid (payload) portion, small gene ITR plasmids or ITR plasmids, as described herein, are produced using standard and established plasmid production methods, including transfecting the plasmid construct (carrying the three genetic elements mentioned above) into suitable bacteria, cloning or amplifying the plasmid by growing transformed bacteria, and purifying the plasmid from bacterial cultures according to standard, well-known and established plasmid production and purification methods.
[0240] After obtaining the two parts (purified MEV and purified plasmid payload), the plasmid was loaded into the MEV using the external loading scheme illustrated in this paper (see also International PCT Publication No.: WO2023001894).
[0241] Therefore, the production or manufacture of MEV GTVs is simple and straightforward, highly productive, safe, and inexpensive. In contrast to the complex, low-yield, not necessarily safe, and notoriously expensive production or manufacture of AAV carriers, the manufacture of MEV-GTVs is far more advantageous than that of AAV carriers. This advantage and superiority of MEV-GTVs over AAVs in terms of manufacturing adds to the numerous advantages of MEV-GTVs over AAVs described throughout this disclosure.
[0242] 3. Plasmid structure and loading methods The payload carried by MEV-GTV is a plasmid. This plasmid is double-stranded. The plasmid contains an ITR (a viral element carried solely by MEV-GTV), such as an AAV ITR, along with the target transgene and necessary expression elements to ensure proper expression and processing of the transgene. It should be understood that the ITR plasmids described herein, containing only ITRs from viral vectors, can be loaded into any suitable delivery vector, such as exosomes, lipid nanoparticles, and extracellular vesicles. The delivery vector serves as a capsid for delivering the plasmid nucleic acid. MEV-GTV is exemplary and, as detailed herein, provides advantages and benefits not offered by other such delivery vectors. However, users may choose alternative delivery vectors to achieve the benefits conferred by the plasmid-containing ITRs provided herein.
[0243] Plasmids carrying ITR (e.g., AAV-ITR) sequences can be grown in bacteria using standard protocols for plasmid growth, cloning, and preparation. ITR plasmids, or small gene ITR plasmids, are circular and double-stranded; they contain (1) the sequence necessary for their propagation in bacteria, plus (2) the small gene: the ITR, such as AAV-ITR (in such a configuration that the ITR surrounds the transgene + expression element), plus (3) specific sequences that allow and / or induce internal recombination within the plasmid. The product of such recombination is: (1) a plasmid carrying the transgene expression element flanked by the ITR, such as AAV-ITR, and (2) a plasmid carrying all other plasmid sequences. If desired, the two plasmids can be physically separated to produce a purified plasmid containing only the ITR (e.g., AAV-ITR) + transgene + expression element.
[0244] Regarding the promoter, it is selected based on the specific purpose or application of the ITR plasmid. The promoter is operatively linked to the nucleic acid to be expressed. Promoters include any suitable strength and specificity, including inducible, tissue-specific, heterologous, or homologous to the nucleic acid to be expressed. The promoter is user-selected. Some ITRs, such as the AAV2 serotype ITR, can drive transcriptional activity (see Earley et al. (2020) Adeno-Associated Virus serotype-specific Inverted Terminal Repeat sequence role in vector transgene expression. Humangene therapy, 31(3-4), 151-162); generally, other promoters are included and operatively linked (for transcription) to the nucleic acid to be transcribed in the ITR plasmid.
[0245] Bacterial plasmids containing ITR plasmids multiply in bacteria; recombination events can be induced in a controlled manner; the two plasmid products produced by recombination events can be purified from each other.
[0246] MEV-GTV has at least two alternative plasmids or payloads: (1) microcircular plasmids obtained after induced recombination to eliminate bacterial plasmid sequences but not ITR and transgenes, resulting in well-defined and simplified products for advanced research and human use; or (2) plasmids that still contain sequences that can be used to reproduce in bacteria.
[0247] Bacterial plasmid vectors contain a standard bacterial plasmid backbone, such as the pUC vector; and convenient cloning sites for inserting small genes into the plasmid. Plasmids can be isolated and used as is; or they can include recombination sites, allowing the small gene portion to be excised via recombination to produce microloops containing the small gene with an ITR. If further homogeneity is required, microloops can be selected by size to choose microloops with the copy number of the small gene, such as 1, 2, 3, 4, 5, ..., 10 or more. Large plasmids can be loaded into MEVs.
[0248] As shown and described herein, MEVs can readily accommodate plasmids up to 10 kb in size; they are easily loaded into MEVs. It has also been shown that when approximately 10 kb of plasmid is loaded into an MEV, the average copy number of the plasmid in the payload (= number of plasmid molecules / MEV) is approximately 2. Therefore, MEVs can accommodate approximately 20 kb of plasmid (copy number of 1 plasmid molecule / MEV).
[0249] The constructs provided herein are referred to as small genes. A small gene contains a transgene with a user-selected coding region and regulatory sequences flanked by 5' and 3' ITRs, such as AAV ITRs. Typically, a small gene construct contains two complementary ITRs to circularize the construct. Therefore, a small gene consists at least of a transgene plus 5' and 3' ITRs, such as AAV-ITRs. For propagation, the small gene is cloned into a suitable cloning plasmid, such as a pUC backbone or other convenient bacterial plasmid, for propagation in bacteria. Thus, the bacterial plasmid carries the small gene; the small gene carries two ITRs flanking the transgene; the transgene carries the selected target coding region plus suitable regulatory sequences as detailed herein (promoters, enhancers, Kozaks, IRES, and other sequences known to those skilled in the art for regulating gene expression in eukaryotic hosts). These sequences are introduced into the bacterial plasmid for replication / propagation in the bacterial host.
[0250] This document describes and illustrates exemplary genetic structures and sequences of plasmid constructs used as genetic material within MEV-GTVs. Such constructs include internal terminal repeat (ITR) sequences, such as ITR regions from viral vectors, such as any ITR sequences shown in SEQ ID NO:1-47 and other such ITRs, such as vaccinia virus ITRs; enhancers, such as SEQ ID NO:75-77; promoters, such as any promoters shown in SEQ ID NO:78-80; intron regions, see, for example, SEQ ID NO:81-83; IRES (internal ribosome entry site) sequences, such as those shown in SEQ ID NO:84-86; Kozak sequences, see, for example, SEQ ID NO:90-93; specific transgenes as described below; and / or poly A signaling regions (e.g., AATAAA). Specific transgenes may be single or multiple nucleic acids encoding peptides, proteins, and / or mRNA, and / or for non-coding RNA, such as siRNA, miRNA, or other non-coding RNA, and / or gRNA editing signals, or others. Plasmids may contain sequences encoding structural or functional proteins, endogenous or exogenous proteins, and / or sequences designed to improve loss of protein function in molecular or cellular processes, such as intracellular lipid transport or permeation peptides, or signal peptides that release extracellular proteins. For example, sequences encoding Cas9 proteins (e.g., the amino acid sequence described herein, SEQ ID NO: 95) or Cas9-like proteins (e.g., one of the amino acid sequences described herein, see SEQ ID NO: 96-97).
[0251] Exemplary ITRs include any vector selected from any eukaryotic viral vector, such as AAV. These include ITRs from any AAV serotype, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, other serotypes, or synthetic serotypes (SEQ ID NO: 1-47). Other ITR sequences can be obtained by synthesis or other suitable means by referring to published sequences, such as those available in the literature or in databases (e.g., GenBank, PubMed, etc.). For the examples herein, an ITR from AAV serotype 2 or an ITR from other suitable serotypes or synthetic sequences can be selected or designed.
[0252] MEV-GTV is made from plasmids loaded into isolated MEVs. We provide a method for loading plasmids carrying small genes into isolated MEVs. Thus, the MEV-part provides a means of delivering payloads (plasmids carrying small genes) to selected host cells, tissues, or organs.
[0253] A transgene is a nucleic acid heterologous to a vector sequence flanking the transgene, encoding a polypeptide, protein, or other product of interest (non-coding RNA (siRNA, miRNA, saRNA, lncRNA, others) or (editing complex). The transgene is operatively linked to regulatory components in a manner that allows for appropriate transgene transcription, translation, and / or expression in the host cell. As used herein, regulatory element sequences include expression control sequences adjacent to the gene of interest and expression control sequences that act trans- or at a distance to control the expression of the gene of interest.
[0254] The composition of the transgenic sequence is user-selective and is functionally applicable. For example, one type of transgenic sequence includes a reporter sequence that produces a detectable signal upon expression. Such reporter sequences include, but are not limited to, sequences encoding β-lactamases, β-galactosidase (LacZ), alkaline phosphatases, thymidine kinases, fluorescent proteins (EBFP, ECFP, GFP, EGFP, YFP, mOrange, mcherry, DsRed, RFP, etc.), chloramphenicol acetyltransferase (CAT), luciferases, membrane-bound proteins including, for example, CD2, CD4, CD8, influenza hemagglutinin, and other proteins well known in the art, against which high-affinity antibodies are present or can be generated by conventional means, and fusion proteins comprising a membrane-bound protein appropriately fused to an antigen tag domain derived from hemagglutinin or Myc, etc.
[0255] Transgenic sequences can also be unlabeled sequences encoding products that can be used in biology and medicine, such as proteins, peptides, RNA, enzymes or catalytic RNA, regulatory ncRNAs, editing complexes, or combinations of different sequences that can be used to treat or mitigate, stop, or reverse genetic diseases or syndromes, metabolic diseases or syndromes, and / or multifactorial diseases or syndromes. Ideal RNA molecules include tRNA, dsRNA, ribosomal RNA, catalytic RNA and antisense RNA, miRNA, etc. An example of a useful RNA sequence is a sequence that inhibits the expression of a target nucleic acid sequence in treated animals.
[0256] Transgenics can be used to correct or improve gene deficiencies, including, for example, deficiencies in which normal genes are expressed at below-normal levels or deficiencies in which functional gene products are not expressed. Preferred types of transgenic sequences encode therapeutic proteins or peptides expressed in host cells. Vectors can contain multiple transgenics, for example, to correct or improve gene defects caused by multi-subunit proteins. In some cases, different transgenics can be used to encode each subunit of a protein, or to encode different peptides or proteins. This is advantageous when the DNA encoding a protein subunit is large, for example, for immunoglobulins, platelet-derived growth factors, or dystrophin. Different subunits of a protein can be encoded by the same transgenic. In this case, a single transgenic includes DNA encoding each subunit, with each subunit's DNA separated by an internal ribozyme entry site (IRES). Unlike AAV vectors, which have smaller DNA encoding each subunit (e.g., the total size of the DNA encoding the subunits and the IRES are less than 5 kb of an AAV recombinant vector), the plasmids provided herein do not have such size limitations. For example, polycistronic nucleic acids, such as alternatives to IRES, can be separated from DNA by sequences encoding 2A peptides that self-cleave during post-translational events. The selected transgene can encode any biologically active product or other product, such as those desired for research purposes.
[0257] Expression control sequences include appropriate transcription initiation, termination, promoter, and enhancer sequences; effective RNA processing signals, such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak concordant sequences); sequences that enhance protein stability; and sequences that enhance the secretion of the encoded product when needed. A large number of expression control sequences, including native, constitutive, inducible, and / or tissue-specific promoters, are known in the art and can be used. Examples of constitutive promoters include, but are not limited to, the retroviral Rouss sarcoma virus (RSV) LTR promoter (optionally having an RSV enhancer), the cytomegalovirus (CMV) promoter (optionally having a CMV enhancer) (see, for example, Boshart et al., Cell, 41:521-530 (1985)), the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the fluorophore-glycerol kinase (PGK) promoter, and the EF1α promoter. Inducible promoters allow for the regulation of gene expression and can be regulated by the presence of exogenously provided compounds, environmental factors (e.g., temperature), or specific physiological states (e.g., acute phase, specific differentiation state of the cell), or only in replicating cells. Many other systems have been described, and those skilled in the art can readily select from these systems. Examples of inducible promoters regulated by exogenously provided compounds include, for example, the zinc-inducible sheep metallothioneine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, and the like. Other types of inducible promoters include, for example, promoters regulated by specific physiological states, such as, but not limited to, temperature, acute phase, specific differentiation state of the cell, or only replicating cells.
[0258] In another implementation, a natural promoter of the transgene can be used. For example, a natural promoter can be used when it is desired that the expression of the transgene mimic natural expression. A natural promoter can be used when the expression of the transgene must be regulated temporally or developmentally, or in a tissue-specific manner, or in response to specific transcriptional stimuli. In another implementation, other natural expression control elements, such as enhancer elements, polyadenylation sites, or Kozak concordant sequences, can also be used to mimic natural expression.
[0259] Another implementation of transgenic technology involves transgenes operatively linked to tissue-specific promoters (e.g., if expression in skeletal muscle is desired, promoters active in muscle should be used, including promoters from genes encoding skeletal β-actin, myosin light chain 2A, dystrophin, muscle creatine kinase, and synthetic muscle promoters with higher activity than naturally occurring promoters). Examples of tissue-specific promoters are known for use in the liver (albumin, hepatitis B virus core promoter, alpha-fetoprotein (AFP)), for bone expression in lymphocytes (CD2, immunoglobulin heavy chain; T cell receptor α chain) (osteocalcin, osteosialic acid protein), and for neuronal expression such as neuron-specific enolase (NSE) promoters, neurofilament light chain genes, and neuron-specific VGF genes, for this specific expression and also for other cell types, tissues, or organs.
[0260] Optionally, plasmids carrying an ITR (e.g., AAV-ITR) and encoding a therapeutically useful transgene or sequence also include, for example, selective markers and reporter genes, such as, but not limited to, nucleic acids having sequences encoding resistance to hygromycin, or puromycin. Such selective reporter molecules or marker genes, typically located outside the ITR, can be used to indicate the presence of plasmids in bacterial cells, such as ampicillin resistance. Other components of the plasmid include, but are not limited to, the origin of replication. The selection of these and other promoter and vector elements is conventional, and many such sequences are available for constructs of plasmids carrying ITRs, such as AAV-ITR.
[0261] Small gene constructs can be isolated from bacterial plasmids in which they proliferate, or bacterial plasmids can be isolated. As described above, small gene constructs can be excised from bacterial plasmids by including recombinant sequences and inducing recombination to produce circular small gene constructs. Because ITRs can be multiplied, the resulting microgene constructs can include one or more copies of the microgene. If desired, the resulting constructs can be separated by size to produce a more uniform product. Small gene constructs or bacterial plasmids can be exogenously introduced into MEVs to produce MEV-GTVs.
[0262] MEV-GTV is a virus-free, nonviral gene transfer and gene therapy system that provides the ability to deliver gene editing systems and perform gene editing. MEV-GTV allows for (1) efficient delivery in vitro to a wide range of cell types, (2) efficient delivery in vivo to specific organ / tissue / cell types determined by the natural tropism of the MEV portion, (3) efficient delivery of plasmids carrying AAV-ITRs that allow and support additional replication and non-integration of the genetic material delivered by MEV-GTV into the host genome, and (4) efficient delivery, expression, and bioactivity of multiple types of RNAs, such as those required for gene correction, gene replacement, or gene editing. MEV-GTV provides a system for gene editing therapies for both in vitro and in vivo approaches, including for hemoglobinopathies, immuno-oncology, autoimmune diseases, and involving the brain, muscle, lung, etc. MEV-GTV can be produced by simply loading a plasmid carrying an AAV-ITR into purified MEVs. Multiple modalities can be simultaneously loaded into a MEV to generate MEV-GTVs with highly specific functional activity and therapeutic purposes, such as editing complexes (CAS9 coding region (or other such functions, see, for example, SEQ ID NO: 96-97 of sequences Cas9, Cas11, and Cas12) plus gRNA plus the RNA form required for gene editing). Such specific MEV GTVs are designed to edit specific genes through precise cutting (using any kind of molecular scissors), subsequent DNA repair, or through other specific processes (such as disrupting or deleting sequences, correcting sequences, or inserting new sequences).
[0263] Because they contain only the ITR and transgene, along with the structure of microcircular plasmids for expression and their preparation within the bacterial plasmid backbone, they can reproduce in bacteria. Proliferation in host cells, packaging cells, helper cells, or eukaryotic cells is not required. Therefore, unlike AAV vectors, no expression of any AAV capsid protein (AAV CAP region) in a small gene or cross-complementary serotype is required, nor is expression of the AAV replication protein (AAVREP region) of the same serotype expressing the AAV-ITR. Furthermore, no helper function of another AAV helper virus is required to package the recombinant adeno-associated virus vector (rAAV-vector), if needed.
[0264] The plasmid is propagated in bacteria, and the portion flanked by the ITR is recovered; the ITR leads to circularization (or in some cases, to some cascades to produce a larger circular vector). Microloops are exogenously loaded into MEVs, as described herein and in co-pending applications (see International PCT Publications WO2023001894, WO2023 / 144127, and WO2024088808, and co-pending applications International PCT Application No. PCT / EP2024 / 057645 and U.S. Provisional Application Serial No. 63 / 562,941, which describe and exemplify the preparation of MEVs) to produce MEV-GTV. MEV-GTV offers a significantly better safety profile than any rAAV vector. MEV-GTV can be used as a gene therapy vector for in vitro, ex vivo, and in vivo treatment.
[0265] Therefore, MEV-based vectors offer the best of two technologies: numerous sources of MEVs, including the possibility of repeated administration, the ability to accommodate large payloads (including large transgenes), the ability to overcome strict biological barriers, the ability to efficiently deliver their payloads to recipient cells based on currently known transport and administration routes, and their non-viral nature; and sources of AAVs and other such vectors, including the presence of ITRs, which ensures persistent expression of transgenes.
[0266] 4. MEV-GTV enhances overall efficiency and improves delivery. AAV vectors have become an integral part of gene therapy, providing stable, long-term transgene expression. Due to these limitations, alternative strategies are needed. MEV-GTV offers an alternative strategy that leverages the advantages of AAV vectors and addresses the challenges of gene therapy. Below are examples of the advantages of MEV-GTV, and for some properties, other delivery vectors containing ITR plasmids. It should be understood that ITR plasmids can be delivered and used in other delivery vectors. Some will not provide all the advantages of MEV, but any advantage of being able to carry a payload the size of an ITR plasmid can be utilized with it. Using other delivery vectors will realize the advantages specific to the plasmid component.
[0267] ITR ensures no duplication, no genome integration, and genetic stability. For AAV-ITR, AAV vectors are composed only in cis configuration. ITR endows AAV vectors with the ability to be replicated by cellular machinery as free genetic material. Therefore, the ability of AAV vectors to mitigate the risks of uncontrolled viral replication, host genome integration, and unintended genetic alterations is associated with AAV-ITR. Because MEV-GTVs carry AAV-ITR within a minimal genetic structure, they also maintain a non-integration profile, thereby ensuring genomic stability and minimizing the possibility of off-target effects.
[0268] Neutralizing immune response A neutralizing immune response is triggered upon initial exposure of the host / patient to the AAV vector. This neutralization response is a major obstacle to repeated dosing, as it renders subsequent administration ineffective. MEV-GTV offers a significant advantage over AAV. Unlike AAV, MEV-GTV does not generate neutralizing antibodies, thus providing a covert method for genetic cargo delivery (see International PCT Publication No. WO2024 / 194423).
[0269] Limitations on payload size and properties MEV-GTV significantly outperforms AAV vectors in cargo capacity, thus accommodating significantly larger genetic payloads, particularly larger plasmids. MEV-GTV can accommodate, carry, and deliver biologically active payloads such as DNA, RNA, peptides, and proteins; see published international PCT applications WO2023001894, WO2023001894, WO2023232976, and WO2023144127.
[0270] Many pathways for delivery and the ability to cross biological barriers While AAV vectors face limitations in crossing biological barriers, MEV-GTV possesses a remarkable and rare ability to navigate complex biological environments, such as traveling unimpeded through the gastrointestinal tract while ensuring payload protection, targeting the dorsum of the eye after local administration via ocular drops, or entering the brain and traveling throughout the olfactory canal (to reach relevant areas of the limbic and cortical brain after simple nasal administration). This feature enhances the targeting of cargo delivery to specific tissues or cells (see International PCT Publications: WO2023144127 and WO2024088808). Intranasal administration provides a direct route to the brain. Administration as ocular drops provides a route to the retina and other tissues in the posterior part of the eye, thus avoiding intravitreal injection (see U.S. Provisional Application Serial No. 63 / 562,941).
[0271] Reduced manufacturing complexity and improved cost efficiency Furthermore, compared to AAV vectors, MEV-GTV exhibits significant manufacturing advantages, with lower complexity and reduced safety risks. In addition to the significant burden and complexity associated with generating stable production cell lines suitable for triple transfection, AAV vectors typically involve high production and purification costs. On the other hand, MEV-GTV offers a cost-effective alternative: MEVs themselves are produced by simply growing single-celled suspended green microalgae in freshwater, light, and minerals; the payload is a plasmid grown in bacteria using standard molecular biology techniques; and the loading of MEVs to generate MEV-GTV is based on a simple physicochemical scheme. Manufacturing MEV-GTV is a very economically viable option for large-scale gene therapy applications. See International PCT Publication No. WO2023001894.
[0272] ITR plasmids and MEV-GTV offer the advantages and strengths of AAV vectors, such as stable transgene expression, while mitigating their disadvantages. Increased cargo capacity, reduced immunogenicity, and enhanced ability to navigate biological barriers position MEV-GTV as a significant advancement in the gene therapy landscape, opening pathways to more complex and effective therapeutic interventions. A direct comparison of the features discussed is summarized in the table below.
[0273] MEV-GTV is the final step in the evolution of gene delivery vectors. Figure 4 This paper presents a comparison of the composition of MRV-GTV with that of other (ITR)AAV-based delivery or gene therapy systems: (A) linear ssDNA molecules flanked by ITRs, (B) recombinant AAV vectors (rAAV) carrying native or engineered linear ssDNA molecules flanked by ITRs within a capsid, (C) 200-250 nm exosomes loaded with rAAV vectors with a diameter of 20 nm, and (D) MEV-GTVs loaded into MEVs containing AAV-ITR flanking dsDNA expression plasmids (up to 10 kb). MEV-GTVs offer the advantages of ITR-driven gene expression and the superior in vivo properties of MEVs.
[0274] E. Extracellular vesicles Extracellular vesicles (EVs) are biomolecular structures released from plant and animal cells that play a role in cell-to-cell communication. Structurally, EVs are negatively charged lipid bilayer vesicles with a density of 1.13 to 1.19 g / mL. EVs are capable of crossing barriers such as plasma (or cytoplasmic) membranes and the blood / brain barrier, and provide for the horizontal transfer of their functional contents (i.e., proteins, lipids, RNA molecules, and circulating DNA) from donor to recipient cells (Kuruvinashetti et al. (2020) IEEE 20th International Conference on Nanotechnology 354-357). EVs are also naturally stable and immune-inert in various biofluids and can exhibit organ-specific targeting capabilities (Picciotto et al., (2021) Biomater. Sci., 9(8): 2917-2930, doi: 10.1039 / d0bm01696a). EVs can be loaded with ITR-containing plasmids as presented herein, with MEVs as an example. It should be understood that other EVs and other nanoparticle delivery vectors can be loaded with plasmids. However, MEVs offer advantages and benefits that other delivery vectors do not. Considering any delivery vector, ITR-containing plasmids can be loaded into the delivery vector, and the delivery vector acts as a capsid for delivering the plasmid and for generating the encoded product.
[0275] EVs contain endogenous lipids, nucleic acids, and proteins. Although results vary due to variations in the separation techniques and methods used to analyze the data, EVs generally contain proteins associated with the plasma membrane, cytosol, and those involved in lipid metabolism (see, for example, Doyle and Wang (2019) Cells 8(7):727). Biogenesis of EVs (e.g., components of ESCRT), EV formation and release (e.g., RAB27A, RAB11B, and ARF6), signal transduction and antigen presentation proteins, and tetraspan proteins occur in EVs (Abel and Breakefield (2016) Mol. Neurobiol. 36(3):301-312, doi: 10.1007 / s10571-016-0366-z). EVs are rich in cholesterol, sphingomyelin, glycosphingolipids, and phosphatidylserine (Kuruvinashetti et al., (2020) IEEE 20 th(International Conference on Nanotechnology 354-357). Although a few studies have identified some genomic and mitochondrial DNA in EVs, EVs are primarily rich in endogenous small RNAs. Studies have identified mRNA, miRNA, rRNA, long and short noncoding RNA, tRNA fragments, piwi-interacting RNA, reservoir RNA, and yRNA in EVs. Most RNAs naturally present in EVs are ~200 nucleotides long (a small fraction up to 4 kb), and are therefore fragmented, although circular RNAs have also been shown to be enriched and stable in EVs. RNA in EVs is protected from RNase digestion in the extracellular environment by a lipid bilayer (Abel and Breakefield (2016) Mol. Neurobiol. 36(3):301-312, doi: 10.1007 / s10571-016-0366-z). The Exocarta, Vesiclepedia, and EVpedia databases are publicly available and provide data on the protein, nucleic acid, and lipid content of EVs (typically derived from mammalian sources such as human EVs) and the isolation and purification procedures used in EV studies (Abel and Breakefield (2016) Mol. Neurobiol. 36(3): 301-312).
[0276] Extracellular vesicles are used by cells to mediate several physiological processes or influence various pathological conditions associated with the activation of immune responses or the spread of diseases or infections, and also constitute cross-species communication and are present in all life. Sources of EVs include mammalian cells, bacteria, milk, and plants (Adamo et al., (2021) J. Extracell.Vesicles 10:e12081). Although plants and algae have cell walls outside their plasma membranes, this may be a physical barrier to the release of EVs (Picciotto et al., (2021) Biomater. Sci., 9(8):2917-2930, doi:10.1039 / d0bm01696a).
[0277] As detailed in this article, MEVs offer advantages that other delivery vectors do not. ITR plasmids, and the bacterial plasmids containing them, can be delivered in other delivery vectors to obtain the advantages conferred by ITR plasmids. Loading them into MEVs to produce MEV GTVs provides additional benefits and advantages.
[0278] MEVs encompass any extracellular vesicles of microalgae, particularly those produced by the Chlorella family, such as *Chlorella EV* and *Parachlorella EV*. MEVs are produced in microalgae, for example, species belonging to the family Chlorellaceae. These microalgae include members of the genera *Chlorella* or *Parachlorella*. Examples include: *Chlorella ellipsoidea*, *Chlorella pyrenoidosa*, *Chlorella sorokiniana*, *Chlorella vulgaris*, and *Chlorella variabilis*, as well as species of *Parachlorella*, such as *Parachlorella kessleri*, *Parachlorella beijerinckii*, and *Parachlorella hussii*. MEVs are produced, isolated, and purified from microalgal cultures as described in this article and co-owned publications, and are illustrated by microalgae species from the Chlorella family, such as Chlorella and Parachlorella.
[0279] Types of extracellular vesicles (EVs) a.Exosomes There are three main subtypes of EVs; they are classified based on their biogenesis, release pattern, size, abundance, and function: microvesicles (MVs), exosomes, and apoptotic bodies (Doyle and Wang (2019) Cells 8(7): 727). Exovesicles, or intraluminal vesicles (ILVs), are typically 30–150 nm in diameter and are released via multivesicle bodies (MVBs) in the endosome pathway. In the endosome pathway, early endosomes are formed by inward budding of the plasma membrane and can be converted into late endosomes, which accumulate ILVs by inward budding of the endosome membrane. Late endosomes containing numerous small vesicles are called MVBs. MVBs either fuse with lysosomes and are degraded, or fuse with the plasma membrane, which releases ILVs as exosomes into the extracellular space. The endosomal sorting complex (ESCRT) pathway regulates MVB transport and exosome formation and has been reported as a major driver of exosome biogenesis, although other mechanisms of exosome biogenesis exist, including those mediated by sphingolipid ceramides, which can promote invagination or proteins in the tetraspan protein family. ESCRT accessory proteins Alix, TSG101, HSC70, and HSP90β are often referred to as exosome marker proteins (Doyle and Wang (2019) Cells 8(7):727).
[0280] Exosomes are released into the extracellular space via the fusion of the MVB-restricted membrane and plasma membrane. Many proteins are involved in exosome release, including Rab GTPase, diacylglycerol kinase α, and SNARE protein (Abel and Breakefield (2016) CellMol. Neurobiol. 36(3):301-312).
[0281] Exosomes are already candidates for drug delivery systems: they have long circulating half-lives; exosomes are tolerated by humans and can penetrate cell membranes and target-specific cell types; and they can be loaded with genetic material, proteins or small molecules (Doyle and Wang (2019) Cells 8(7):727).
[0282] b. Microvesicles Microvesicles (MVs or exosomes) form by budding or contraction of the cytoplasmic membrane and have a diameter ranging from 100 nm to 1 μm. MV formation involves cytoskeletal components such as actin and microtubules, molecular motors such as kinins and myosin, and fusion mechanisms such as SNARE and ligand factors. The physiological state and microenvironment of the donor cell influence the number of MVs produced, and the physiological state and microenvironment of the recipient cell influence the number of MVs consumed. MVs also possess a number of marker proteins, including cytoplasmic and plasma membrane-associated proteins, as well as cytoskeletal proteins, heat shock proteins, integrins, and proteins containing post-translational modifications, although no specific markers are known to distinguish MVs from exosomes. Like exosomes, MVs can load cargo (e.g., proteins, nucleic acids, and lipids) for delivery to another cell, thereby altering the function of the recipient cell (Doyle and Wang (2019) Cell 8(7): 727).
[0283] c. Apoptotic bodies Apoptotic bodies are released from dead cells into the extracellular space and have a diameter of 50 nm to 5000 nm. Apoptotic bodies are formed when the cell membrane separates from the cytoskeleton due to the increased hydrostatic pressure after cell contraction. Unlike exosomes and MVs, apoptotic bodies contain intact organelles, chromatin, and a small amount of glycosylated proteins (Doyle and Wang (2019) Cells 8(7): 727).
[0284] d. MEV Although other EVs can be loaded with the ITR plasmids provided herein, as detailed herein, MEVs are the preferred delivery vectors for the ITR plasmids provided and described herein due to their properties, including ease of production and mode of transport at the time of application. Their properties and production are detailed herein.
[0285] 2. EV intake Cells internalize extracellular vesicles by fusing with the plasma membrane, or more commonly by endocytosis (Abel and Breakefield (2016) Cell Mol. Neurobiol. 36(3):301-312). Uptake via endocytosis can occur through several types of endocytic processes, and different processes have been described in different cell types: inclusion-dependent endocytosis and phagocytosis have been described in neurons; macrocytosis has been described in microglia; phagocytosis and receptor-mediated endocytosis have been described in dendritic cells; vesicle protein-mediated endocytosis has been described in epithelial cells; and cholesterol and lipid raft-dependent endocytosis has been described in tumor cells. Blocking heparan sulfate proteoglycans (HSPGs) on the plasma membrane with heparin reduced EV uptake in cell cultures, as did blocking scavenger receptor type B-1 (SR-B1) with synthetic nanoparticle mimics of HDL, suggesting the role of HSPGs and SR-B1 in EV uptake (Abel and Breakefield (2016) Cell Mol. Neurobiol. 36(3):301-312). EV fusion with the plasma membrane is also an uptake method and requires low pH conditions; treatment of EVs with a combination of pH-sensitive fusion propeptides and cationic lipids resulted in increased cellular uptake of exosomes and cytoplasmic release of cargo from exosomes (Nakase and Futaki (2015) Sci. Rep. 5:10112). Low pH conditions occur in tumors (Abel and Breakefield (2016) Cell Mol. Neurobiol. 36(3): 301-312), which allows EVs used to deliver therapeutic payloads to tumor cells to enter the cells by fusing with the plasma membrane.
[0286] Like cells, extracellular vesicles (EVs) have extracellular receptors and ligands on the outside and cytoplasmic proteins and nucleic acids on the inside, thus communicating with cells in different ways. Extracellular vesicles bind to the cell surface, undergo endocytosis, and / or fuse with the plasma membrane, releasing their load into the extracellular space. If they enter via endocytosis, the EV cargo must escape degradation pathways; late endosomes can fuse with lysosomes or the plasma membrane, so the cargo must leave before being degraded in lysosomes or re-released via fusion of MVBs with the plasma membrane. EVs containing cargo (including mRNA and non-coding RNA) can be transferred to recipient cells in culture and in vivo (Abel and Breakefield (2016) Cell Mol. Neurobiol. 36(3):301-312; Maas et al. (2017) Trends Cell Biol. 27(3):172-188).
[0287] 3. General methods for separating EVs a. Ultracentrifugation Ultracentrifugation is used to separate exosomes; alternative methods have also been developed. Separation methods can result in complex mixtures of EVs and other components of the extracellular space due to the complex nature of the biofluid from which exosomes are separated, the overlap of physicochemical and biochemical properties between exosomes and other types of EVs, and the heterogeneity among exosomes. Differential ultracentrifugation relies on the initial sedimentation of larger and denser particles from the extracellular matrix and results in the enrichment of exosomes, but not complete separation of exosomes from other components of the extracellular space. Density gradient centrifugation is another ultracentrifugation method and is based on separation by size and density in the presence of a density gradient (usually made of sucrose or iodixanol) in the centrifuge tube. Density gradient centrifugation effectively separates EVs from protein aggregates and non-membrane particles, but has low exosome recovery rates, although purity can be improved by coupling differential ultracentrifugation with types of density gradient centrifugation such as rate-zone centrifugation or isodense centrifugation (Doyle and Wang (2019) Cell 8(7):727).
[0288] b. Size-based technology Many size-based techniques exist for the separation of exosomes (Doyle and Wang (2019) Cell 8(7): 727). Ultrafiltration separates particles based on membrane size and molecular weight cutoff, thereby retaining particles larger than the membrane's molecular weight cutoff and allowing particles smaller than the membrane's molecular weight cutoff to pass through into the filtrate; however, low separation efficiency can occur if the filter becomes clogged and vesicles are trapped. ExoMir TM The kit (Bioo Scientific; Austin, TX) is a commercially available kit in which two membranes (200 nm and 20 nm) are placed in a syringe and the sample (usually pretreated with centrifugation and proteinase K) is passed through the syringe; larger vesicles are retained above the first 200 nm filter, the smallest vesicles pass through the syringe and are discarded, and vesicles between 20 and 200 nm are retained between the two filters in the syringe. Sequential filtration also relies on a series of filtration steps to separate exosomes (Doyle and Wang (2019) Cell 8(7):727).
[0289] Size exclusion chromatography (SEC) of exosomes, typically used in parallel with ultracentrifugation (where the exosome precipitate obtained from ultracentrifugation is resuspended and further purified using SEC), is similar to protein separation using SEC. In SEC, the column is packed with a porous stationary phase in which small particles can permeate and thus elute after larger particles. Typically, the SEC method requires several hours of run time; however, the qEV Exosome Separation Kit (iZON Science, New Zealand) allows for rapid and accurate exosome separation via SEC in as little as 15 minutes (Doyle and Wang (2019) Cell 8(7): 727).
[0290] In flow field-flow fractionation (FFFF), in addition to the flow perpendicular to the parabolic flow (crossflow), the sample injected into the chamber is also subjected to a parabolic flow as it is pushed down the chamber to separate particles from the sample. Larger particles are more affected by the crossflow and are pushed toward the chamber walls, which have a slower parabolic flow, while smaller particles remain in the center. In FFFF (Doyle and Wang (2019) Cell 8(7): 727), smaller particles are eluted earlier, while larger particles are eluted later.
[0291] In hydrostatic filtration dialysis (HFD), hydrostatic pressure forces the sample through a dialysis tube with a membrane having a molecular weight cutoff of 1000 kDa. As a result, small solutes are able to pass through the tube, but larger particles (including exosomes and EVs) remain in the tube and can then be further separated using, for example, ultracentrifugation (Doyle and Wang (2019) Cell 8(7): 727).
[0292] c. Immunoaffinity capture-based technologies Immunoaffinity-based capture techniques can isolate exosomes based on the expression of antigens on the surface of exosomes and allow for the isolation of exosomes derived from specific sources. In these methods, antibodies specific to the target antigen can be attached to plates (e.g., in enzyme-linked immunosorbent assays, ELISA), magnetic beads (e.g., in magnetic immunoprecipitation), resins, and microfluidic devices; these surfaces are then exposed to the exosome sample, resulting in the immobilization of exosomes expressing the antigen. This assay requires the protein / antigen used for exosome isolation to be expressed on the exosome surface, and its specificity is limited by the specificity of the antibody used, generally resulting in lower yields but higher purity of isolated exosomes. These methods can also be used to isolate exosomes within mixed EV populations. Immunoaffinity-based capture techniques are typically used after ultracentrifugation or ultrafiltration (Doyle and Wang (2019) Cell 8(7):727).
[0293] d. Exosome precipitation Methods for precipitating exomes include precipitation with polyethylene glycol (PEG) and lectin. In PEG precipitation, the PEG polymer titrates water molecules, causing other particles, including exosomes, to precipitate from the solution. PEG precipitation is rapid and not limited by the initial volume of solution, but it lacks selectivity because other EVs, extracellular proteins, and protein aggregates are precipitated with EVs. Sample pretreatment using filtration and / or ultracentrifugation can improve exosome yield. Commercially available kits for separating exosomes using precipitation include, for example, ExoQuick. ® (System Biosciences, Palo Alto, CA) and Invitrogen TMTMTMTM Total Exosome Isolation Kit (Thermo Fisher Scientific, Waltham, MA). Alternatively, lectin precipitation can be used, typically after ultracentrifugation, whereby the lectin binds to carbohydrates on the surface of the exosomes, altering their solubility and causing them to precipitate from the solution (Doyle and Wang (2019) Cells 8(7):727).
[0294] e. Microfluidic-based separation technology Microfluidic-based techniques simultaneously separate exosomes based on their physical and biochemical properties, and are rapid, efficient, and require small starting volumes. In acoustic nanofilters, a matrix containing EVs and other cellular components is injected into a chamber and exposed to ultrasound. Particles respond differently to the radiative forces exerted by the waves, depending on their size and density; larger particles experience stronger forces and migrate toward pressure nodes more quickly. Immunofluidic separation techniques are similar to ELISA, although unlike ELISA, they do not require prior ultrafiltration or ultracentrifugation of exosomes (Doyle and Wang (2019) Cell 8(7): 727). ExoChip (Kanwar et al., (2014) Lab Chip. 14(11): 1891-1900) and ExoSearch chip (Zhao et al., (2016) Lab Chip. 16(3): 489-496) have been developed to separate exosomes using microfluidic techniques.
[0295] 4. Microalgae and extracellular vesicles (MEVs) derived from microalgae The classification and categorization of microalgae can vary. According to some schemes, there are seven (7) microalgal classifications: Euglena (golden algae), Chrysophyta (golden brown algae and diatoms), Dinophyta (fire algae), Chlorophyta (green algae), Rhodophyta (red algae), Phaeophyta (brown algae), and Xanthophyta (yellow-green algae). This paper is of interest to photosynthetic microalgae, such as Chlorella and Chlamydomonas species. The methods and uses described herein generally utilize MEVs from green algae. Examples of such algae are the genera *Chlamydia* and *Chlorella*, which belong to the genera *Chlorella* and *Rhodophyta*, respectively.
[0296] Microalgae are biological resources for the production of extracellular vesicles (EVs) used in nanomedicine and other fields. The mechanisms by which microalgae secrete EVs relative to primary and motile cilia / flagellates are known (Picciotto et al. (2021) Biomater.Sci., 9(8):2917-2930, doi:10.1039 / d0bm01696a). Chlamydomonas flagella lack MVBs, therefore, the ciliated extracellular vesicles detached from Chlamydomonas are classified as ectosomes. Studies have shown that exosomes detach from the flagella and ciliate tips of Chlamydomonas reinhardtii. EVs have also been observed along the length of cilia in Chlamydia. Membrane budding and ciliated EV formation are mediated by components of the endosome sorting complex required for transport (ESCRT), which is present in the separated ciliate transition zone, ciliary membrane, and ciliated EVs in Chlamydia and can act as a sensor of membrane curvature. Ciliary vesicle formation can also occur when ciliary membrane transport is disrupted or during ciliary reabsorption (Wang and Barr (2018) Esays Biochem. 62(2):205-213). Ciliate ectoplasts from Chlamydomonas contain lysinase that digests the mother cell wall and is required for the release of daughter cells. The Ift88-null mutant, which lacks flagella, cannot be derived from maternal cells. Release from the cilia and addition of ciliated exosomes from wild-type cells rescued the phenotype, indicating flagellation and intraflagellate transport (IFT). The role of mechanisms in EV production (Wang and Barr (2016) Cell Mol. Neurobiol. 36(3):449-457).
[0297] EVs were extracted from algal cells using ultracentrifugation (Kuruvinashetti et al., (2020) IEEE 20 thAccording to the method described in the International Conference on Nanotechnology 354-357, algal cells were cultured; the cultured algal cells were collected and centrifuged; the supernatant was collected (and centrifuged further); a sucrose solution was added to the supernatant; and the algal supernatant with the sucrose solution was ultracentrifuged; due to the sucrose solution, high-density EVs settled at the bottom of the ultracentrifuge tube and could be collected using a pipette. The extracted algal EVs could be characterized in size and concentration using nanoparticle tracking analysis (NTA). Studies using this method have isolated green algal EVs with a size range of 25-200 nm and a concentration of 0.89 E8 to 0.94 E8 particles / mL (Kuruvinashetti et al., (2020) IEEE 20 th International Conference onNanotechnology 354-357) Ultracentrifugation protocols have also been used to isolate extracellular vesicles (EVs) from marine microalgae grown under various conditions; NTA revealed that the size distribution of nanoparticles ranged between 100 nm and 200 nm, and Western blot analysis of proteins confirmed the presence of EV markers (VES4US, extracellular vesicles from a natural source of custom-made nanomaterials, 2020). Subsequent studies have identified microalgal extracellular vesicles (sEVs) isolated from the marine photosynthetic microalga *Aesthetica tetraphylla* (sEV), termed nanoparticles. The generation of nanoparticles is an evolutionarily conserved trait in the microalgal strain, as similar results were obtained using sEVs isolated from batch cultures of two other microalgal species, *Dunaliella chlorophylla* and *Ampoules difluoroglycate* sp. Nanoparticles were isolated using differential centrifugation (dUC) and tangential flow filtration (TFF), as well as gradient ultracentrifugation, which was used to further purify the samples enriched with small extracellular vesicles via TFF or dUC. The isolated nanoparticles showed that they shared characteristics with EVs from other sources. The EV yields from dUC and TFF (measured by sEV protein content and sEV number) were consistent with the reporter number of isolated EVs, at approximately 10. 9EV particles / μg EV protein. Biophysical analysis of particle size using multi-angle dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), fluorescence nanoparticle tracking analysis (F-NTA), and fluorescence correlation spectroscopy (FCS) yielded a consistent size distribution, with the most frequently occurring size from DLS (DLS mode) being approximately 70 nm. The nanoparticles exhibit a slightly lower density of 1.13 g / mol compared to exosomes derived from mammalian cells, which have densities of 1.15–1.19 g / mol. Electron microscopy revealed that the nanoparticles were spherical, non-uniform in size and shape, and possessed a lipid bilayer structure. Compared to microvesicles (or large EVs, lEVs) and lysates, sEVs were enriched in three of the four target protein biomarkers (Alix, enolase, HSP70, and β-actin). DLS measurements indicated that the nanoparticles were resistant to pH changes and stable in human plasma. No cytotoxic or genotoxic effects were observed in the tumorigenic MDA-MB-231 breast cancer cell line, the non-tumorigenic 1-7 HB2 cell line, and the human hepatocellular carcinoma Hep G2 cell line after nanosphere treatment. Furthermore, the nanooligosaccharides were absorbed by the MDA-MB-231 and 1-7 HB2 cell lines (Adamo et al. (2021) J. Extracell. Vesicles 10:e12081).
[0298] At least eighteen microalgae strains from major microalgae lineages have been identified (Ankistrodemus sp., Brachiomonas sp., Chlamydomonas reinhardtii, Dunaliella tertiolecta, Tetratrasemis chuii, Clomonassus sp., Rhodella violacea, Kirchneriella sp., Pediastrum sp., Nannochloropsis sp., Cyanophora paradoxa, Cryptomonas pyredifera, Phaeodactyluum tricortum, Phaeothnion sp., Diacronecma). EVs have been isolated from and studied in the genera *Isochrysis gallana*, *Stauroneis*, and *Amphidinium*. The studied strains include those with diverse characteristics, such as saline and freshwater inhabitants, small and large cells, colonies and single cells, and species with sequenced genomes.
[0299] MEVs were isolated using differential ultracentrifugation and characterized according to the International Society for Extracellular Vesicles (ISEV) guidelines. All tested algal strains showed the presence of MEVs in the culture medium. EV-producing microalgae were established based on EV protein content, expression of EV protein markers (e.g., Alix, Hsp70, enolase, and β-actin), total scattering signal (measured by dynamic light scattering DLS) or total particle number (measured by NTA), and mean sEV size and size range. These EV-producing algal strains include *Cyanophora paradoxa*, *Tetraselmis chuii*, *Amphidinium* sp., *Rhodella violacea*, *Diacronema* sp., *Dunaliella tertiolecta*, *Phaeodactylum tricornutum*, *Pediastrum* sp., and *Phaeothamnion* sp. (Picciotto et al., (2021) Biomater. Sci., 9(8): 2917-2930, doi: 10.1039 / d0bm01696a). Consistent with data from plant-derived vesicles, *Cyanophora paradoxa* data showed ~2 x 10⁻⁶ vesicles per mL of microalgae conditioned medium. 9 sEV particles, EV markers, showed strong positive signals and a size distribution with a mode of 130±5 nm. Cytotoxicity and genotoxicity studies showed that sEVs isolated from a freshwater Glaucophyte, a cyanobacterium, did not show toxicity to the tumorigenic MDA-MB-231 breast cancer or C2C12 myoblast cell lines, neither over time nor at different concentrations. MDA-MB-231 cells treated with sEVs also did not show morphological nuclear changes associated with apoptotic events (Picciotto et al., (2021) Biomater. Sci., 9(8): 2917-2930, doi: 10.1039 / d0bm01696a).
[0300] EVs have also been isolated from *Synechocystis* sp. In the work of Zhao et al., PCC6803 (cyanobacteria), *reinhardtii* (green microalgae), *Euglena* (Euglena), and *Thermococcus listeri* (chlorophyll) were also subjected to RNomic and proteomic analyses in EVs isolated from *Chlamydomonas reinhardtii* under different cell growth stages and different types of abiotic stress (Zhao et al., (2020) doi: 10.21203 / rs.3.rs-38027 / v1). EVs were separated using differential ultracentrifugation and filtration, and the resuspension showed membrane structures with small particle clumps with diameters of 110–120 nm, consistent with reported diameters of exosomes and small MVs, although diameters varied among microalgal species. Specifically, EVs from *reinhardtii* ranged in diameter from 37–710 nm, with an average particle size of 120.1 nm. Synechycystis-derived EVs ranged in diameter from 24 to 450 nm, with an average particle size of 94.68 nm. Despite the presence of a cell wall, Chlamydia cells were able to take up extracellular vesicles, as evidenced by the presence of extracellular vesicles labeled with fluorescent lipophilic dyes within microalgal cells. Thus, microalgal EVs can be taken up by recipient cells. Non-coding RNAs were detected in microalgal EVs at different growth stages and under various treatments (biological stress, nitrogen depletion, and nitrogen recovery), and proteomic analysis identified many flagellin-associated membrane proteins in microalgal EVs (Zhao et al., (2020) doi: 10.21203 / r.3.rs-38027 / v1).
[0301] These studies show that microalgae produce EVs that can be isolated using conventional or standard methods; EVs derived from microorganisms are similar in size and concentration and exhibit similar markers compared to EVs isolated from other species; EVs isolated from microalgae do not show cytotoxic or genotoxic effects in vitro; and EVs derived from microorganisms can be absorbed by cells.
[0302] It has been demonstrated that mammalian EVs can deliver cargo to target cells and therefore have therapeutic uses for delivering a variety of cargoes to treat a variety of diseases or conditions; this is generally not shown for MEVs. However, mammalian EVs, apart from bovine milk EVs, cannot be administered orally because they cannot survive the harsh conditions of the stomach. For example, small molecules such as hydrophobic and hydrophilic drugs can be injected into exosomes, or large protein and nucleic acid molecules can be embedded in exosomes. Nucleic acids may include those encoding genes of interest. Specific targeting ligands, imaging probes, and covalent bonds can be attached to the exosome surface and tracked using NTA, fluorescence, or bioluminescence.
[0303] In addition to mentioning in publications that microalgae EVs may be used to deliver drugs of interest to target cells, tissues, or organs (Kuruvinashetti et al. (2020) IEEE 20 th At the International Nanotechnology Conferences 354-357, there was no publicly available evidence, nor any technical description of the use of MEVs for the treatment of mammalian diseases, conditions, or illnesses. There are no publications or technical descriptions describing how to understand the application of EV technology to microalgal-derived extracellular vesicles, nor whether it is possible to do so, nor how to do so. Previous studies have not considered Chlorella species, nor have they comprehensively assessed the biodistribution and associated properties of MEVs. Therefore, the methods illustrated in this paper using Chlorella, such as oral delivery, could utilize MEVs from other microalgae.
[0304] However, as described and shown in this paper, microalgal EVs have many advantages over existing drug delivery systems, such as exosomes derived from mesenchymal stem cells (MSCs), gold nanoparticles, liposomes, and other plant and animal-derived EVs. MSCs are a common source of exosomes, and MSC-derived exosomes are used for drug delivery, such as anticancer vaccines, because they possess enhanced passive targeting (methods for preparing drug delivery systems to maintain circulation in the bloodstream). MSC-derived EVs also possess passive targeting capabilities due to their small size, inherent properties, and ability to cross biological barriers. However, MSCs have limited exosome secretion, and scaling up exosome production is challenging due to the need for optimized purification, increased exosome homogeneity, and the development of efficient transfection strategies. Nanoparticles can cause toxicity, and current technologies used to synthesize nanoparticles limit their ability to scale up for manufacturing purposes. Nanoparticle- and liposome-based drug delivery methods can also lead to teratoma formation (tumors composed of several different tissue types). Liposome-based drug delivery methods have further demonstrated lower efficiency for internalization into specific cells, tissues, or organs compared to exosomes. Plant-derived EVs, such as those from curcumin, ginger, grapefruit, and lemon, have been used for drug delivery, but their extraction processes and therapeutic uses have not been optimized. Producing EVs from agricultural products (e.g., fruits and milk) is economically impractical compared to algal EVs, which can grow anywhere and within days, and requires 3–4 months to grow. Algal EVs avoid phagocytosis or degradation by macrophages, circulate in the body for extended periods, and exhibit low immunogenicity. Algal EVs also have a lower risk of teratoma formation. Therefore, algae provide a source from which high-quality, pure, and well-characterized EVs can be obtained (Kuruvinashetti et al. (2020) IEEE 20 th(International Conference on Nanotechnology 354-357). Kuruvinashetti et al. did not describe the use of Chlorella species as a source of EVs, nor did they describe the advantages of using them as a source. The prior art does not describe the biodistribution of MEVs themselves, nor does it describe the implications of administering MEVs in conjunction with drugs targeting specific organs, tissues, or systems.
[0305] 5. Green algae – Chlorella species Chlorella species and other members of the Chlorellaceae family (such as Parachorphyra) are favorable sources of EVs. Chlorella and the resulting EVs have advantages in the growth, manipulation, and application of drugs not provided by other species and EVs. Green algae belong to the phylum Chloroplast and include different groups of photosynthetic eukaryotes. Green algae include both unicellular and multicellular organisms. The algae originally included in the genus Chlorella are among the most widely distributed and frequently encountered algae in freshwater. These algae exist in aquatic environments and on land. They are typically small (about 2 to 10 μm in diameter), unicellular, spherical, nonmotile, and contain a single chloroplast, and some have rigid cell walls (Blanc et al., (2010) Plant Cell 22(9): 2943-2955).
[0306] Molecular analysis has separated Chlorella species into two chlorophyll classes: Trebouxiophyceae, which includes true Chlorella; and Chlorophyceae. As used herein, Chlorella species include any species that can be used as or can be used as food complement, or that can be consumed by humans or other animals, such as livestock. Exemplary species include, but are not limited to, the following: Chlorella ellipsoides, Chlorella proteoglycinae, Chlorella sorokinense, Chlorella commonis, and Chlorella variantis.
[0307] True Chlorella species are characterized by glucosamine as a major component of their rigid cell walls. Although most Chlorella species are naturally free-living, true algae include most known endosymbiotic organisms of green algae, living in lichens, single-celled eukaryotes, plants, and animals (e.g., mussels and aquatic organisms). For example, Chlorella NC64A is a genetically photosynthetic endophyte (or photosynthetic endophyte) of Siberian paracalcium, a single-celled protozoan, and NC64A is also a host of a family of large double-stranded DNA viruses that appear in freshwater (Blanc et al., (2010) Plant Cell 22(9): 2943-2955).
[0308] a. Lifecycle In unicellular organisms such as microalgae, the life cycle is identical to the cell cycle. Chlorella is a haploid organism that regenerates asexually through autosporosis. The cell cycle and proliferation of Chlorella have been investigated by flow cytometry analysis of algal cells stained with 5(6)-carboxyfluorescein diacetate N-succinimide (CFSE) using Rioboo et al. (2009), Aquatic Toxicology, 94(3): 229-237, doi: 10.1016 / j.aquatox.2009.07.009. Their results indicate that, as is generally described for microalgae, the growth of Clostridium vulgare mother cells occurs during the photoperiod, while the cytoplasmic division and release of daughter cells occur during the dark period. Clostridium vulgare also exhibits a distinct light / dark cycle, characterized by an increase in cell size, cell complexity, and autofluorescence during the photoperiod measured over a 96-hour period. A single-parameter histogram of CFSE-stained Clostridium vulgare cells showing only one daughter cell peak indicates that each mother cell undergoes only one division cycle within 96 hours; further, cytoplasmic division occurs during the dark period. Therefore, the Chlorella vulgaris strain used exhibits three life cycle phases: 1) mother cell growth, 2) cell division, and 3) daughter cell release. Clostridium vulgare cells grow during two light periods and begin division during the subsequent dark period; cell division occurs once the mother cell is twice the size of the daughter cells. Furthermore, Clostridium vulgare cells exposed to the herbicide terbutaline require a longer growth period to reach a sufficiently large cell size for division. This suggests the existence of a critical threshold size required for Clostridium vulgare to complete its growth phase and begin the division phase, and that this critical threshold controls the progression of the G1 phase of the Clostridium vulgare cell cycle. Finally, this study shows that the intensity of the CFSE-fluorescence peak of the mother cell is four times that of the daughter cell, indicating that each mother cell produces four daughter cells. Therefore, Clostridium vulgare cells undergo a first mitosis, followed by cytoplasmic division, and then two more simultaneous mitosis, which results in the release of four daughter cells (see, for example, Rioboo et al. (2009) Aquatic Toxicology, 94(3): 229-237, doi: 10.1016 / j.aquatox.2009.07.009).
[0309] b. Genome analysis of Chlorella species Although Chlorella species have been reported to be nonmotile and lack sexual cycles, genomic analysis of Chlorella NC64A (NC64A) and Chlorella vulgaris 211 / 11P (211 / 11P) revealed the presence of genes involved in sexual reproduction and motility (Blanc et al. (2010) Plant Cell 22(9): 2943-2955; Cecchin et al. (2019) Plant J.100(6): 1289-1305). The nuclear genome of NC64A (GenBank accession number ADIC00000000.1) is 46.2 Mb and consists of 12 chromosomes. Meiosis-specific protein dose inhibitors of MCk1 DMC1, homologous pairing proteins HOP1 and HOP2, meiotic recombinant protein MER3, meiotic nucleoprotein MND1, and mutS homolog MSH4 are encoded in NC64A; these genes are also present in most other sequenced chlorophyll algae species. Nineteen homologs of the Chlamydia gametolysin protein, which promotes cell wall breakdown and allows gamete fusion, were also identified in NC64A. Additionally, orthologs of the Chlamydia GCS1 protein, essential for cell fusion, were found in NC64A (Blanc et al., (2010) Plant Cell 22(9): 2943-2955). Besides genes encoding gametolysin (g3347) and genes encoding proteins containing domains with the putative GCS1 / HAP2 function, primary genes involved in meiosis were also found in the Chlorella 211 / 11P 40Mb genome (GenBank accession number SIDB00000000) (Cecchin et al., (2019) Plant J.100(6): 1289-1305). Therefore, although Chlorella species were observed only in the haploid stage, the presence of meiotic genes suggests that the life cycle of Chlorella may include a diploid stage.
[0310] Similarly, although flagella were not observed in NC64A, orthologs of flagellomonas proteins were identified in the NC64A genome, including orthologs of intraflagellate transport (IFT) proteins IFT52, IFT57 and IFT88, actin-2 motor protein FLA8, actin-associated protein KAP and proteins involved in the axonal condyle (Blanc et al., (2010) Plant Cell 22(9): 2943-2955).
[0311] Sequencing of three Chlorella strains (strain 1228, UTEX 1230, and DOE1412) revealed the presence of serum and flagella-related genes (Hovde et al., (2018) Algal Research 35: 449-461). The genomes of several other Chlorella species have been sequenced: Chlorella sp. 0710 (Gao et al. (2014) BMC Genomics 15(1):582; GenBank accession number APJO00000000); Chlorella UTEX 1602 (GenBank accession number LHPG00000000) and Chlorella strain SAG 241.80 (Micractinium Conductrx; GenBank accession number LHPF00000000) (Arriola et al. (2018) Plant J.93(3):566-586); as well as Chlorella strain UTEX 395 (Guarnieri et al. (2018) Front. Bioeng. Biotechnol.6:37; GenBank Accession No. LDKB00000000), UMT-M1 (Teh et al. (2019) Data Brief 27:104680; GenBank Accession No. VJNP00000000), UTEX259 (GenBank Accession No. VATW00000000) and NJ-7 (Wang et al. (2020) Mol. Biol. Evol. 37(3):849-863; GenBank Accession No. VATV00000000).
[0312] c. Commercial and biotechnological uses of Chlorella Commercial cultivation of microalgae for food purposes began in Japan and Taiwan in the 1960s with the production of Chlorella. Due to reports of high protein content, nutritional value, and health benefits, dried biomass products from Arthrospira and Chlorella are included in dietary supplements. For example, Chlorella extract has been shown to lower cholesterol and possess antioxidant, antibacterial, and antitumor activities. High-yield production of Chlorella is routine, and as detailed herein, MEVs can be isolated from cell culture media. Regarding its use as a pharmaceutical agent, ingestion of Chlorella is known to be non-toxic and non-immunogenic in humans.
[0313] Chlorella has been used in a variety of biotechnological applications, including biofuels, CO2 chelation, the production of high-value molecules, and the removal of heavy metals from wastewater (Blanc et al., (2010) Plant Cell 22(9): 2943-2955). Chlorella species exhibit metabolic flexibility in response to environmental disturbances and are able to directly utilize nutrients, such as organic carbon and minerals, from wastewater for growth. Among microalgae, Chlorella species have higher photosynthetic efficiency than other photosynthetic organisms. In addition, Chlorella can grow under autotrophic, heterotrophic, or fasciotrophic conditions (Blanc et al., (2016) Plant Physiol. 172(1): 589-602).
[0314] Chlorella species can also be genetically modified through Agrobacterium-mediated transformation. Cha et al. developed a method for genetic transformation of common Chlorella using Agrobacterium tumefaciens strain LBA4404, and the presence of gene fragments in 30% of the transgenic lines compared with wild-type uninfected Chlorella indicated that T-DNA was integrated into the Chlorella genome (Cha et al. (2012) World J. Microbiol. Biotechnol. 28:1771-1779).
[0315] d. Chlorella MEV As described herein, Chlorella species (e.g., Clostridium vulgare) are advantageous species for producing EVs (referred to herein as MEVs) for delivering ITR plasmids and bacterial ITR plasmids. Of particular interest herein are MEVs produced by members of the Chlorella family, including Chlorella species. Chlorella and related species offer numerous advantages as sources of EVs. Chlorella is a haploid organism, meaning that specific and targeted variants can be produced through genetic engineering; it can be readily genetically modified or loaded to produce or contain bioactive molecules and small molecules, including ITR plasmids and bacterial ITR plasmids. Stable cell lines can be generated, including stable producers encoding the products. These are defined products, and when exogenously loaded, the resulting compositions contain EVs containing the same cargo.
[0316] Detailed genetic maps are available, and correlations between genotypes and phenotypes can be established. The Chlorella genome has been fully sequenced, so the structure and function of various genes are known. In plant genetics, Chlorella occupies a very crossover position between higher plants and microalgae. Therefore, Chlorella shares a large number (and useful) molecular biological and metabolic features with higher plants, but remains a single-celled haploid microalga. An example of a molecular biological feature common to eukaryotes is the intracellular mechanism involving a cleavage enzyme system for processing exogenous RNA into siRNA. Chlorella is autotrophic: unlike mammalian and other animal cells, it can therefore be cultured and replicated without the need for animal-derived nutrients or factors.
[0317] Regarding the use of its EVs as therapeutic agents, Chlorella and related species are non-toxic. For example, tablets made from common Chlorella biomass (i.e., compressed whole Chlorella cells) have been regularly consumed by the public worldwide for many years as a dietary supplement without any restrictions related to toxicity or immunogenicity. Japan is a world leader in the consumption of Chlorella biomass. It is also used in medical treatments, for example in Japan, because it has shown immunomodulatory properties and claimed anticancer activity; for anti-aging applications, such as for cardiovascular disease, hypertension, and cataracts; it reduces the risk of atherosclerosis and stimulates collagen synthesis in the skin.
[0318] Chlorella cells naturally produce extracellular vesicles (EVs) that respond to the standard specifications of better-known EVs (e.g., mammalian EVs). Plant-derived EVs possess several characteristics that make them more promising / convenient than synthetic nanoparticles or semi-synthetic EVs for use as drug delivery systems in humans. These include, for example, higher stability, lower toxicity, and lower immunogenicity. As closely related to plants, Chlorella provides a source of EVs with similar characteristics to plant EVs. Furthermore, large-scale production of Chlorella is easier and cheaper than that of higher plants. The glycosylation patterns of membrane proteins in Chlorella are similar to / identical to those present in higher plants.
[0319] Chlorella microcystis metamorphic endogenous vesicles (MEVs) range in size from approximately 50 nm to 200 nm, with an average size of approximately 130 nm. This morphology is similar to plant and mammalian exosomes. For application purposes, the size distribution can be made more uniform by separating MEVs by size and selecting those of the size of interest, which can vary depending on the intended use and route of application.
[0320] F. Exemplary loaded microalgal extracellular vesicles (MEVs), coded as transgenic cargo and targets Targets and goods (see discussion below) include any targets and goods known to those skilled in the art as suitable for gene therapy. Details and examples of the biodistribution of MEVs after administration via various routes, as well as the meaning, uses, and methods for targeting or treating specific diseases, conditions, and statuses, and for formulating and administering MEVs, are described herein and illustrated in examples.
[0321] 1. Isolation of MEV The methods used for separation are discussed in the above sections and detailed in the embodiments.
[0322] 2. MEV loading and cargo MEVs can carry any desired cargo (also known as payloads). For the purposes of this document, the cargo contains plasmids containing transgenes that can encode proteins and other products of interest, including but not limited to nucleic acid coding, RNAi, antisense nucleic acids, detectable marker proteins and tags, small molecule drugs, gene editing systems, and combinations thereof, and can be used to deliver gene editing systems, such as gene / Cas, and to achieve gene editing.
[0323] Treatable diseases and conditions include any diseases and conditions known to those skilled in the art that can be treated by gene therapy or by the delivery and expression of DNA. Diseases, disorders, and conditions include, for example, genetic disorders, neurological disorders, infections, and other conditions treated by administration of viral vectors that require the delivery of gene products and / or gene editing systems. Delivered transgenes include transgenes encoding protein products (e.g., antibodies and their antigen-binding forms), RNA products (e.g., but not limited to siRNA, miRNA (microRNA), lncRNA (long non-coding RNA), saRNA (small activating RNA), shRNA, and mRNA), and other such products. Plasmids may encode reporter genes and other detectable products, such as fluorescent proteins, such as, but not limited to, enhanced green fluorescent protein (EGFP; SEQ ID NO:99), luciferase gene (SEQ ID NO:100), LUX operon (SEQ ID NO:98), and related products.
[0324] Disease-related genes, such as oncogenes and checkpoints, can be regulated by cargoes encoding products that repress or activate gene expression or repress or activate gene products. Examples of such regulators are RNAi-type regulators, such as siRNA, miRNA, shRNA, antisense oligonucleotides (ASO), peptides, and / or tetrapeptides.
[0325] Gene silencing using RNA interference (including siRNA and microRNA) can be used to silence developmental genes, such as adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged spiral family members, Hox family members, cytokines / lymphokines and their receptors, growth / differentiation factors and their receptors, and neurotransmitters and their receptors; oncogenes; tumor suppressor genes; enzymes; genes associated with pathological conditions; genes associated with autoimmune diseases; anti-angiogenic genes; angiogenic genes; immunomodulatory genes; genes associated with alcohol metabolism and liver function; genes associated with neurological diseases; genes associated with tumorigenesis or cell transformation; and genes associated with metabolic diseases and conditions (see, for example, WO 2009 / 082606, JP 2014-240428A, WO 2011 / 072292 A2, WO 2010 / 141724, and WO 2020 / 097540). These types of products can be delivered or encoded in the MEV to activate genes or pathways or provide therapeutic effects. Some cytokines can be used to treat diseases / conditions, such as certain cancers, in which immunosuppression plays a role.
[0326] MEV-GTV can be used to transfer nucleic acids encoding therapeutic agents, such as microRNA, mRNA, tRNA, rRNA, siRNA, regulatory RNA, non-coding and coding RNA, DNA fragments and DNA plasmids (see, for example, CN105821081A and CN110699382A; non-limiting examples of proteins that can be encoded by nucleic acid loading molecules include, but are not limited to: antibodies, in vivo antibodies, single-stranded variable fragments, affinity molecules, enzymes, transport proteins, tumor inhibitors, viral or bacterial inhibitors, cellular component proteins, DNA and / or RNA-binding proteins, DNA repair inhibitors, nucleases, proteases, integrases, transcription factors, growth factors, apoptosis inhibitors and inducers, toxins, structural proteins, neurotrophic factors, membrane transport proteins, nucleotide-binding proteins, heat shock proteins, CRISPR-related proteins, cytokine receptors, caspases and any combination and / or derivatives thereof (see, for example, AU2018365299).
[0327] For example, as summarized in the table below, a mixture of three siRNA oligonucleotides targeting human MYCN with two thymidine residues (dTdT) at the 3' end of the sequence can be used (purchased from B-Bridge International Inc. (Sunnyvale, CA)). Anti-MYCN siRNA (siMYCN) and negative control siRNA (non-target control library) (siNeg) (ON-TAREGETplus siRNA, Dharmacon, Cambridge, UK) can also be used (see Reference 1). Exemplary target oncogenes and exemplary siRNA sequences (also see SEQ ID NO: 101-123) are provided in the table below.
[0328] Nara et al. (2007) Int. J. Oncol. 30(5): 1189-1196; Silencing MYCN via RNA interference induces growth inhibition, apoptosis, and cell differentiation in neuroblastoma cell lines with MYCN amplification. 2 Maeshima et al., (2020) Nucleic Acid Ther. 30(4): 237-248; MYCN silencing via RNAi induces neurogenesis and inhibits proliferation in a retinoic acid-resistant neuroblastoma model. 3 Veas-Perez de Tudela et al. (2010) J. Neurochem. 113(4): 819-825; By upregulating glutamate-cysteine ligase through transcription, human neuroblastoma cells with MYCN amplification exhibit selective resistance to oxidative stress. 4 Watson et al. (1991) Cancer Res. 51(15): 3996-4000; The inhibition of c-myc expression by phosphate thioester antisense oligonucleotides identified the key role of c-myc in the growth of human breast cancer. 5 Yoshikawa et al. (2019) Mol. Ther. Ther. Methods Clin. Dev. 13: 290-302; Anticancer effects of chemically modified miR-143 on bladder cancer via systemic or intravesical therapy. 6 Tsujino et al., (2019) Cancer Sci. 110(7): 2189-2199; MicroRNA-143 / Musashi-2 / KRAS cascade makes a positive contribution to the carcinogenic effect in human bladder cancer. 7 Tirella et al., (2019) Int. J. Pharm. 561: 114-123; CD44 KRAS silencing targeted delivery of siRNA in cancer therapy using HA-modified nanotechnology. 8 Nakada et al. (2001) Pancreatology 1(4): 314-319; Mutant K-ras gene-specific antisense oligonucleotides inhibit the invasiveness of human pancreatic cancer cell lines 9 Adams et al. (2015) Expert Opin. Ther. Targets 20(6): 737-753; Tumor suppression and potential therapeutic function of miR-34a in epithelial carcinoma 10 Poeck et al. (2008) Nat. Med. 14(11): 1256-1263; 5'-triphosphate-siRNA: silencing of translocation genes and activation of Rig-I in melanoma 11 Szegedi et al., (2008) Pathol. Oncol. Res. 14(3): 275-279; Bcl-2 antisense oligonucleotides inhibit the proliferation of B-cell lineage childhood leukemia / lymphoma cells. 12 Ripoll et al. (2018) RSC Adv. 8: 20758-20763; Synergistic cell killing induced by co-delivery of anti-PLK-1 siRNA and camptothecin via nanopolyacetylene micelles 13 Liu et al. (2012) BMC Cancer 12(1): 519-529; MicroRNA-100 is a potential molecular marker for non-small cell lung cancer and acts as a tumor inhibitor by targeting Poloo-like kinase 1. 14 Spnkuch et al. (2008) Tumor formation 10(3): 223-234; Plk1 expression is downregulated by receptor-mediated uptake of antisense nanoparticles loaded with oligonucleotides.
[0329] 3. It can encode reporter genes, reporter proteins, and / or their regulators in plasmids, and can deliver other products in MEV GTV. Reporter protein Target sequences, in the form of siRNA, miRNA, antisense oligonucleotides (ASO), peptides, and / or tetrapeptides, are used to regulate (inhibit or stimulate) each marker gene, such as GFP protein, eukaryotic luciferase, or prokaryotic luciferase, for example: Lux operon (luxCDABE) and lux operon (luxABCDE), and plasmids encoding reporter genes / reporter proteins, for example, for diagnostic and gene expression assessment (SEQ ID NO: 124-130, respectively):
[0330] Other exemplary coding products Chemotherapy agents, especially encoded prodrugs, can be encoded in vectors. Anti-angiogenic agents, such as antibodies, Fc fusions, and cytokines, bind to growth factors or growth factor receptors involved in promoting angiogenesis. Examples of anti-angiogenic agents include, but are not limited to, antibodies that bind to vascular endothelial growth factor (VEGF) or VEGF-R, RNA-based therapeutics that reduce VEGF or VEGF-R expression levels, VEGF-toxin fusions, Regeneron's VEGF traps, angiostatins (plasminogen fragments), antithrombin III, angiotensin, ABT-627, Bay 12-9566, Beenfin, bevacizumab, bisphosphonates, BMS-275291, chondroitin derivatives (CDI), CAI, CD59 complement fragments, CEP-7055, Col 3, Combiretastatin A-4, endothelial statins (collagen XVIII fragments), farnesyltransferase inhibitors, fibronectin fragments, GRO-β, halofopontoxin, heparinase, heparin hexasaccharide fragments, and HMV. 833, Human chorionic gonadotropin (hCG), IMD-862, alpha interferon, interferon beta, interferon gamma, interferon inducible protein 10 (IP-10), interleukin-12, kring5 (plasminogen fragment), hippocampal protease inhibitor, metalloproteinase inhibitor (e.g., TIMPs), 2-methoxyestradiol, MMI 270 (CGS27023 A), plasminogen activator inhibitor (PAI), platelet prothrombin 222594-745G.
[0331] Other goods include tyrosine kinase inhibitors, including but not limited to quinazolines such as PD 153035, 4-(3-chloroaniline)quinazoline; pyridopyrimidines; pyrimidopyrimidines such as CGP 59326, CGP 60261 and CGP 62706; pyrazolopyrimidine, 4-(phenylamino)-7H-pyrrolo(2,3-d)pyrimidine; curcumin (diphenylmethane, 4,5-bis(4-fluoroaniline)phthalimide); tyrphostins containing a nitrothiophene moiety; PD-0183805 (Warner-L ambert); antisense molecules (e.g., those binding to ErbB-encoded nucleic acids); quinoxaline (US Patent No. 5,804,396); tyrphostins (US Patent No. 5,804,396); PTK-787 (Novartis / Schering). AG); pan-ErbB inhibitors, such as C1-1033 (Pfizer); Affinitac (ISIS 3521; Isis / Lilly); imatinib mesylate (STI571, Gleevec®; Novartis); PKI 166 (Novartis); GW20PCT (GlaxthKline); C1-1033 (Pfizer); US 569 (Wyigen).
[0332] Other coded goods include immunomodulators that increase or decrease the production of one or more cytokines, upregulate or downregulate self-antigen presentation, mask MHC antigens, or promote the proliferation, differentiation, migration, or activation of one or more types of immune cells.
[0333] Other coded cargoes include cytokines, including but not limited to lymphokines, monokines, and conventional polypeptide hormones. Cytokines include growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; relaxin; glycoprotein hormones such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); liver growth factor; fibroblast growth factor; prolactin; placental milk; tumor necrosis factor-α and-β; Mürian inhibitory substance; mouse gonadotropin-related peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF-β; platelet-derived growth factor; transforming growth factor (TGF), such as TGF-α and TGF-β. β; insulin-like growth factor-I and-II; erythropoietin (EPO); bone-inducing factor; interferons, such as interferon-a, β and -γ; colony-stimulating factors (CSFs), such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs), such as IL-1, IL-1a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15; tumor necrosis factors such as TNF-α or TNF-β; and other polypeptide factors, including LIF and kit ligand (KL).
[0334] Other exemplary coded goods include cytokines and other agents that stimulate immune system cells and enhance desired effector functions. For example, agents stimulating NK cells include IL-2; agents stimulating macrophages include, but are not limited to, C5a, formyl peptides such as N-formyl-methionyl-leucyl-phenylalanine. In another embodiment, the compositions of the present invention comprise agents that stimulate neutrophils, such as G-CSF and GM-CSF. Additional agents include, but are not limited to, interferon-γ, IL-3, and IL-7. Other goods include nucleic acids encoding complement peptide inhibitors, such as complement proteins C3 or C5, including proteases that inhibit C3 modification.
[0335] Nucleic acids can be operatively linked to regulatory elements recognized in a specific subject (e.g., a mammal) in which they will be delivered.
[0336] 4. Generation of MEV for Payload (Cargo) - Load As illustrated herein, isolated MEVs, such as Chlorella MEVs, can be loaded with plasmid cargo for delivery to humans via any suitable route, including but not limited to intravenous, oral, topical, mucosal, inhalation, and any other routes known to those skilled in the art for delivering vectors (e.g., lipid nanoparticles, carriers, therapeutic bacteria, and therapeutic viruses). Upon administration, MEV-GTV is absorbed by cells. The transgene can be engineered to cause transcription and / or only occur in target cells, for example, in the case where the cargo is a plasmid encoding a therapeutic product. Transcriptional regulatory signals can be selected to cause the encoded product to be expressed in target cells. For example, for expression in the liver, the encoded product can be expressed under the control of a liver-specific promoter, or the product can target a receptor or target expressed in target cells, such as in a tumor or in the tumor microenvironment. The loading methods described in the examples above and below include, but are not limited to: a. Electroporation b. Ultrasonic treatment c. Extrusion d. Surfactants e. Other methods known to those skilled in the art for introducing exosomes into cells.
[0337] F. Pharmaceutical compositions, formulations, kits, articles, and combinations 1. Pharmaceutical compositions and formulations Compositions containing the MEVs and loaded MEVs described herein can be formulated as pharmaceutical compositions intended for administration via a desired route, such as oral and intramuscular (IM) delivery to the immune system, or formulated for administration to the eye. Pharmaceutically acceptable compositions are prepared in view of approval by a regulatory agency or other agency prepared according to a recognized pharmacopoeia for use in animals and humans, and also for agricultural applications, for use in plants. Typically, compounds are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see, for example, Ansel Introduction to Pharmaceutical Dosage Forms, 4th Edition, 1985, 126).
[0338] The pharmaceutical compositions described herein are intended for therapeutic and preventative applications. The MEVs and cargo-carrying MEVs described herein may be formulated with pharmaceutically acceptable carriers or diluents. Typically, such pharmaceutical compositions comprise components that do not significantly impair the biological or other properties of the cargo. Each component is pharmaceutically and physiologically acceptable, making it compatible with other ingredients and harmless to the subject to whom it will be administered. Formulations may be provided in unit dosage forms and may be prepared by methods known in the pharmaceutical field, including but not limited to tablets, pills, powders, liquid solutions or suspensions (e.g., including injectable, ingestible, and topical formulations such as eye drops, gels, pastes, creams, or ointments), aerosols (e.g., nasal sprays and inhalers), liposomes, suppositories, vaginal suppositories, injectable and infusionable solutions, and sustained-release forms. See, for example, Gilman et al. (p. 1990), Goodman and Gilman: Pharmacological Base of Therapeutics, 8. th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17 th ed. (1990), Mack Publishing Co., Easton, PA; Avis, et al. (eds. 1993) Pharmaceutical Dosage Forms: Parenteral Medications Dekker, NY; Lieberman, et al. (p. 1990) Pharmaceutical Dosage Forms: Tablets Dekker, NY; and Lieberman, et al. (p. 1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY. When administered systemically, the therapeutic composition is sterile, pyrogen-free, and generally free of particulate matter, and is in a parenteral acceptable solution with appropriate consideration of pH, isotonicity, and stability. These conditions are known to those skilled in the art. Methods for preparing parenteral-applied compositions are well known or will be apparent to those skilled in the art, and are described, for example, in "Remington: The Science and Practice of Pharmacy (Forly Remington's Pharmaceutical Sciences)," 19 th It is described in more detail in ed., Mack Publishing Company, Easton, PA. (1995).
[0339] The pharmaceutical compositions described herein can be in various forms, such as solid, semi-solid, liquid, powder, aqueous, and lyophilized forms. Examples of suitable drug carriers are known in the art and include, but are not limited to, water, buffers, saline solutions, phosphate-buffered saline solutions, various types of wetting agents, sterile solutions, alcohols, gum arabic, vegetable oils, benzyl alcohol, gelatin, glycerol, carbohydrates such as lactose, sucrose, amylose or starch, magnesium stearate, talc, silica, viscous paraffin, fragrance oils, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethyl cellulose, and powders, etc. The pharmaceutical compositions described herein may contain other additives, including, for example, antioxidants, preservatives, antimicrobial agents, analgesics, binders, disintegrants, colorants, diluents, excipients, bulking agents, flow aids, solubilizers, stabilizers, tension agents, mediators, viscosity agents, flavoring agents, emulsions (e.g., oil / water emulsions), emulsifiers and suspending agents (e.g., gum arabic, agar, alginic acid, sodium alginate, bentonite, carbomer, carrageenan, carboxymethyl cellulose, cellulose, cholesterol, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, octylphenyl ether-9, oleyl alcohol, povidone, propylene glycol monostearate, sodium lauryl sulfate, sorbitol ester, stearyl alcohol, tragacanth gum, xanthan gum and its derivatives), solvents and various components (e.g., crystalline cellulose, microcrystalline cellulose, citric acid, dextrin, dextran, liquid glucose, lactic acid, lactose, magnesium chloride, potassium metaphosphate and starch, etc.) (see Alfonso for more details). R.Gennaro (2000) Remington: The Science and Practice ofPharmacy, 20 th Edition. Baltimore, MD: Lippincott (Williams & Wilkins). Such carriers and / or additives can be formulated using conventional methods and administered to subjects at appropriate doses. Stabilizers such as lipids, nuclease inhibitors, polymers, and chelating agents can protect the composition from degradation in vivo.
[0340] The route of administration conforms to known methods, such as intravenous, intraperitoneal, intracerebral, intramuscular, subcutaneous, intraocular, intraarterial, intrathecal, inhalation or intralesional routes, local, rectal, mucosal, and via injection or infusion through a sustained-release system. MEVs or cargo-loaded MEVs can be administered continuously by infusion or bolus injection. MEVs or cargo-loaded MEVs can be administered locally or systemically.
[0341] MEVs, or cargo-carrying MEVs, can be prepared in a mixture having a pharmaceutically acceptable carrier. Techniques for formulating and administering the compound are known to those skilled in the art (see, for example, "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA). The therapeutic composition can be administered intravenously or via the nose or lung, for example, as a liquid or powder aerosol (lyophilized). The composition can also be administered parenterally or subcutaneously as needed. When administered systemically, the therapeutic composition should be sterile, pyrogen-free, and in a parenterally acceptable solution taking into account pH, isotonicity, and stability. These conditions are known to those skilled in the art.
[0342] Suitable pharmaceutical compositions include those contained in an amount appropriate to effectively achieve their intended purpose in a MEV or a cargo-loaded MEV. The determination of therapeutically effective amounts is entirely within the capabilities of those skilled in the art. Therapeuticly effective doses can be determined by using in vitro and in vivo methods and / or by a technician.
[0343] Therapeutic formulations can be administered in many conventional dosage forms. The dosage forms of MEVs and cargo-loaded MEVs provided herein are prepared for storage or administration by mixing compounds of desired purity with physiologically acceptable carriers, excipients, or stabilizers. Such materials are non-toxic to recipients at the doses and concentrations used and may include buffers such as Tris HCl, phosphates, citrates, acetates, and other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) peptides such as polyarginine; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates, including cellulose or derivatives thereof, glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and / or nonionic surfactants such as polysorbate (TWEEN), Pluronic acid, polyethylene glycol, etc.
[0344] In specific examples herein, pharmaceutical compositions containing stabilizers are provided. Stabilizers may be amino acids, amino acid derivatives, amines, sugars, polyols, salts, or surfactants. In some examples, the stabilizing co-formulation contains a single stabilizer. In other embodiments, the stabilizing co-formulation contains 2, 3, 4, 5, or 6 different stabilizers. For example, stabilizers may be sugars or polyols such as glycerol, sorbitol, mannitol, inositol, sucrose, or trehalose. In a particular example, the stabilizer is sucrose. In other examples, the stabilizer is trehalose. The concentrations of sugars or polyols are approximately 100 mM to 500 mM, 100 mM to 400 mM, 100 mM to 300 mM, 100 mM to 200 mM, 200 mM to 500 mM, 200 mM to 400 mM, 200 mM to 300 mM, 250 mM to 500 mM, 250 mM to 400 mM, 250 mM to 300 mM, 300 mM to 500 mM, 300 mM to 400 mM, or 400 mM to 500 mM, each including the end values.
[0345] In the example, the stabilizer can be a surfactant, such as polypropylene glycol, polyethylene glycol, glycerin, sorbitol, poloxamer, and polysorbate. For example, the surfactant can be polypropylene glycol, polyethylene glycol, glycerin, sorbitol, poloxamer, and polysorbate, such as poloxamer 188, polysorbate 20, and polysorbate 80. In a specific example, the stabilizer is polysorbate 80. The concentration of the surfactant, as a percentage of the mass concentration (w / v) in the formulation, is between 0.005% and 1.0%, 0.01% and 0.5%, 0.01% and 0.1%, 0.01% and 0.05%, or 0.01% and 0.02%, or approximately between 0.005% and 1.0%, 0.01% and 0.5%, 0.01% and 0.1%, 0.01% and 0.05%, or 0.01% and 0.02%, each including the end values.
[0346] When intended for in vivo administration, the formulation should be sterile and formulated according to standard pharmaceutical practice. This can be readily achieved by filtration through a sterile filter membrane before or after lyophilization and reconstitution. MEVs, or cargo-loaded MEVs, can be stored in lyophilized form or in solution; they can be frozen or refrigerated. Other carriers may be included, such as naturally occurring vegetable oils like sesame oil, peanut oil, or cottonseed oil, or synthetic fatty acid carriers like ethyl oleate. Buffers, preservatives, and antioxidants may be incorporated according to accepted pharmaceutical practice.
[0347] Depending on the application and the subject, the MEV or plasmid-loaded MEV provided herein may be provided in concentrations of about 0.1 to 10 mg / mL or higher or lower, for example at least or at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10 mg / mL or higher. The volume of the solution can be or approximately 1 to 100 mL, for example, at least or approximately 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 mL or more. In some examples, the MEV or the MEV carrying the cargo is supplied in phosphate-buffered saline.
[0348] The MEVs or cargo-loaded MEVs described herein can be provided as controlled-release or sustained-release compositions. Polymer materials for formulating pills and capsules are known in the art that can achieve controlled or sustained release of the MEVs and cargo-loaded MEVs described herein (see, for example...). Medical Applications of Controlled Release , Langer andWise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance , Smolen and Ball (eds.), Wiley, New York (1984); Langer and Peppas (1983) J. Macromol. Sci. 23:61; see also ... Levy et al. (1985) Science 228:190; Fin et al. (1989) Ann.Neurol. 25:351; Howard et al. (1989) J. Neurosurg. 71:105; US Patents 5,679,377, 5,916,597, 5,912,015, 5,989,463, 5,128,326; and PCT Publications WO99 / 15154 and WO99 / 20253. Examples of polymers for use in sustained-release formulations include, but are not limited to, poly(2-hydroxyethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolic acid (PLG), polyanhydride, poly(N-vinylpyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactide (PLA), poly(lactide-co-glycolic acid) (PLGA), and polyorthoesters. Typically, the polymers used in sustained-release formulations are inert, free of leaching impurities, stable during storage, sterile, and biodegradable. Any technique known in the art for producing sustained-release formulations can be used to produce sustained-release formulations comprising the MEVs provided herein or MEVs loaded onto cargo.
[0349] In some instances, the pharmaceutical composition contains the MEV or plasmid-loaded MEV provided herein and one or more additional agents, such as antibodies or other therapeutic agents, for combination therapy.
[0350] 2. Products / Reagent Kits and Combinations Pharmaceutical compositions of MEVs or MEVs loaded with cargo may be packaged as articles containing packaging materials, pharmaceutical compositions that are effective in treating diseases or conditions (e.g., those described herein or known in the art) by administration of a specific MEV or MEV loaded with cargo, and labels indicating that the cargo (e.g., antibodies or nucleic acid molecules) will be used to treat an infection, disease, or condition. The pharmaceutical compositions may be packaged in unit dosage forms containing a single or multiple doses of the pharmaceutical composition. Packaged compositions may contain lyophilized powders of the pharmaceutical composition, the pharmaceutical compositions containing MEVs loaded with cargo, the MEVs loaded with cargo, which may be reconstituted prior to administration (e.g., with water or saline).
[0351] The articles described herein include packaging materials. Packaging materials used for packaging pharmaceutical products are well known to those skilled in the art (see, for example, U.S. Patents 5,323,907, 5,052,558, and 5,033,252). Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubing, inhalers (e.g., pressurized metered-dose inhalers (MDI), dry powder inhalers (DPI), nebulizers (e.g., jet or ultrasonic nebulizers) and other single-dose air-liquid systems), pumps, bags, vials, containers, syringes, bottles, and any packaging materials suitable for selected formulations and intended administration and treatment modes.
[0352] MEVs or cargo-loaded MEVs may be provided in combination and as kits. Kits may optionally include one or more components, such as instructions for use, devices, and additional reagents (e.g., sterile water or saline solutions for diluting the composition and / or reconstituted lyophilized proteins), and components such as tubes, containers, and syringes for practicing the method. Exemplary kits may include the MEVs or cargo-loaded MEVs provided herein and may optionally include instructions for use, devices for administering the MEVs or cargo-loaded MEVs to a subject, devices for detecting the MEVs or cargo-loaded MEVs in samples obtained from the subject, and devices for administering additional therapeutic agents to the subject.
[0353] The kit may optionally include instructions for use. Instructions for use typically include a tangible description of the MEV or the cargo-loaded MEV, as well as other components optionally included in the kit, and methods for administration, including methods for determining the appropriate status of the subject, appropriate dosage, dosing regimen, and appropriate administration methods for administering the MEV or the cargo-loaded MEV. Instructions for use may also include instructions for monitoring the subject throughout the duration of treatment.
[0354] The kit may also include the pharmaceutical compositions described herein and articles for diagnostic purposes. For example, such a kit may include articles for measuring the concentration, amount, or activity of MEVs in subjects and in cargo.
[0355] In some examples, MEVs or cargo-loaded MEVs are provided in diagnostic kits for the detection of MEVs or cargo-loaded MEVs or cargoes in isolated biological samples (e.g., tumor cells, such as circulating tumor cells obtained from a subject or tumor cells removed from a subject).
[0356] The kits provided herein may also include a device for administering the MEV to a subject. Any of a variety of devices known in the art for administering a drug to a subject may be included in the kits provided herein. Exemplary devices include, but are not limited to, subcutaneous needles, intravenous needles, catheters, nebulizers, and inhalers. Generally, the device for administering the composition is compatible with the desired method of administration of the composition.
[0357] 3. Administration and route of administration of plasmid-loaded MEVs The plasmid-loaded MEVs described herein can be administered to subjects by any method known in the art for administering peptides, including, for example, systemic or local administration. Typically, plasmid-loaded MEVs can be administered via routes such as parenteral (e.g., intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intracavitary routes), local, epidural, or mucosal (e.g., local, intranasal, oral, vaginal, vulvovaginal, esophageal, bronchial, rectal, and pulmonary routes). Cargo-loaded MEVs can be administered to subjects externally to the disease site to exert local or transdermal effects. Compositions containing cargo-loaded MEVs can be administered, for example, by infusion, inhalation, bolus injection, or absorption through epithelial or mucosal skin linings (e.g., local, oral, vaginal, rectal, and intestinal mucosa). Compositions containing cargo-loaded MEVs can be administered together with or sequentially with other bioactive agents. For example, cargo-loaded MEVs can be administered via infusion delivery (e.g., via an infusion pump or syringe pump) and can be administered in combination with another therapeutic agent or as a monotherapy.
[0358] The method and / or route of administration may be modified to mitigate adverse side effects associated with the administration described herein. For example, if a patient experiences a mild or moderate (i.e., Grade 1 or 2) infusion reaction, the infusion rate may be reduced (e.g., by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more). If a patient experiences a severe (i.e., Grade 3 or 4) infusion reaction, the infusion may be temporarily or permanently discontinued.
[0359] In some instances, treatment adjustments may be made if a subject experiences adverse side effects, such as severe skin toxicity, like severe acneiform eruptions. For example, administration may be delayed, for example, for 1 to 2 weeks or until the adverse side effects improve, following the occurrence of an adverse side effect. In some cases, the dose may be reduced after another adverse side effect occurs. Specific protocols and treatment regimens can be established by a skilled physician or other practitioner.
[0360] Those skilled in the art can select an appropriate delivery method based on the properties of the MEV loaded with the cargo or the dosage of the pharmaceutical composition containing the MEV loaded with the cargo. These properties include, but are not limited to, solubility, hygroscopicity, crystallinity, melting point, density, viscosity, flowability, stability, and degradation profile.
[0361] 4. Combination therapy The cargo-loaded MEV described herein may be administered before, after, or concurrently with one or more other treatment regimens or agents. A skilled medical practitioner may determine this based on experience or by considering the pharmacokinetics and mode of action of the agent, one or more appropriate doses of each treatment regimen or agent, and appropriate timing and method of administration. Additional treatment regimens or agents may improve the efficacy, safety, or other properties of the cargo-loaded MEV. In some examples, additional treatment regimens or agents may treat the same disease or comorbidity. In some instances, additional treatment regimens or agents may improve, reduce, or eliminate one or more side effects known in the art or described herein that are associated with the administration of the cargo-loaded MEV or cargo.
[0362] For example, the cargo-loaded MEV described herein can be administered in combination with other immunomodulators or treatments. The cargo-loaded MEV can be administered in combination with other antipathogenic therapeutics and treatments. The cargo-loaded MEV can be administered in combination with one or more other prophylactic or therapeutic agents, including but not limited to antibodies, cytotoxic agents, chemotherapeutic agents, cytokines, growth inhibitors, antihormonal agents, kinase inhibitors, antiangiogenic agents, cardioprotective agents, immunostimulants, immunosuppressants, agents that promote the proliferation of hematologic cells, angiogenesis inhibitors, protein tyrosine kinase (PTK) inhibitors, FcγRIIb or other Fc receptor inhibitors, or other therapeutic agents.
[0363] One or more additional agents may be administered simultaneously, sequentially, or intermittently with the cargo-loaded MEV. These agents may be administered co-administered, for example, as part of the same pharmaceutical composition or the same delivery method. In some instances, the agents may be administered simultaneously with the cargo-loaded MEV, but via different delivery methods. These agents may also be administered at different times from the administration of the cargo-loaded MEV, but close enough in time to have a combined preventative or therapeutic effect. In some instances, one or more additional agents are administered after or before the administration of the cargo-loaded MEV, separated by selected time periods. In some examples, this time period is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or 3 months. In some instances, one or more additional agents are administered multiple times in conjunction with / or multiple administrations of the cargo-loaded MEV provided herein.
[0364] G. A flowchart of methods for generating advertisements via various routes. 1. Biodistribution of mammalian EVs The pharmacokinetics and biodistribution of mammalian extracellular vesicles (EVs) in organs and tissues have been extensively studied (Vader et al. (2016) Advanced Drug Delivery Review 106(Pt A): 148-156, doi.org / 10.1016 / j.addr.2016.02.006; Morishita et al. (2017) Journal of Pharmaceutical Sciences 106(9): 2265-2269, hdoi.org / 10.1016 / j.xphs.2017.02.030). Treatment with mammalian cell-derived EVs is typically based on intravenous or intraperitoneal administration. The main target organs after systemic administration of mammalian EVs are the liver, spleen, and lung. Comprehensive studies of the tissue distribution of fluorescently labeled mammalian EVs from various cell sources are available (see Wiklander et al. (2015) J). Extracellular Vesicles 4 :26316) showed that 24 hours after intravenous (iv) injection in mice, the highest fluorescence signal was observed in the liver, followed by the spleen, gastrointestinal tract, and lungs. Furthermore, cell source, EV dose, and route of administration showed effects on EV distribution; for example, higher EV doses resulted in relatively lower liver accumulation compared to lower doses, which may be due to saturation of the mononuclear phagocyte system (MPS). Comparisons between intraperitoneal (ip), subcutaneous (sc), and iv administration showed that intraperitoneal and subcutaneous doses resulted in reduced EV accumulation in the liver and spleen, and enhanced accumulation in the pancreas and gastrointestinal tract, compared to iv injection. Systemic administration of EVs has been reported to be rapidly absorbed by the mononuclear phagocyte system (MPS), particularly in the liver and spleen. The clearance mechanism is similar to that described for synthetic nanoparticles such as liposomes (Van der Meel et al. (2014) J. Control). Release 195 (72–85). Most splenic accumulation is caused by EV storage in the spleen, rather than by splenic uptake. (Lai CP et al., (2014) ACS Nano 8: 483-494). The biodistribution of mammalian EVs following other routes of administration was also investigated. Intranasal administration of curcumin-loaded mammalian EVs to target the central nervous system resulted in the localization of EVs in the brain. Drug levels peaked 1 hour after administration and were detected at significant levels after 12 hours, with no toxic effects observed (Zhuang et al., (2011) Mol) Ther. 19: 1769-1779).
[0365] Typically, mammalian extracellular vesicles (EVs) are not used for oral delivery due to their low stability at various pH and temperature levels, rapid degradation of biomolecules in the digestive tract, and limitations in industrial-scale production for oral administration (Cheng et al., (2019) Protein Cell 10: 295-299). The only exception to date is extracellular vesicles derived from bovine milk, which exhibited a distribution pattern upon oral delivery to mice, analyzed using a whole-body in vivo imaging system (IVIS), including rapid accumulation in the intestine, where EVs were detectable at 2 and 6 hours, followed by fluorescent signals observed in the liver, spleen, lung, kidney, heart, and gastrointestinal tract at 24 hours. After 48 hours, the fluorescent signals faded in most organs, indicating clearance of the nanovesicles from the system (Samuel et al., (2021) Nat Commun 12: 3950, doi.org / 10.1038 / s41467-021-24273-8). Therefore, mammalian EVs (derived from sources other than milk) cannot be absorbed by the gut and intestines, thus failing to become bioavailable in target organs (Zhong et al., (2021) Biomaterials.277:121126.Doi:10.1016 / j.biomaterials.2021.121126).
[0366] Treatment using mammalian cell-derived extracellular vesicles (EVs) typically involves intravenous or intraperitoneal administration for systemic delivery, with target organs including the liver, spleen, and lungs. As mentioned above, most mammalian EVs have not been used for oral delivery due to their low stability at various pH and temperature levels, rapid degradation of biomolecules in the digestive tract, and limitations in industrial-scale production of oral administration (Cheng et al., (2019) Protein Cell 10(4): 295-299). The only exception is milk-derived extracellular vesicles, which exhibited a distribution pattern upon oral delivery to mice, analyzed using a whole-body in vivo imaging system (IVIS), including rapid accumulation in the intestine, where the EVs were detectable at 2 and 6 hours, followed by fluorescent signals observed in the liver, spleen, lungs, kidneys, heart, and gastrointestinal tract at the 24-hour time point. After 48 hours, the fluorescent signals faded in most organs, indicating clearance of the nanovesicles from the system.
[0367] As described herein, and in a jointly owned, pending application (see PCT / EP2023 / 051650), MEVs possess properties distinct from mammalian EVs. For example, they are stable in the harsh environment of the gastrointestinal tract compared to mammalian cell-derived EVs. Therefore, microalgal EVs as described herein are particularly well-suited for oral administration and drug delivery, as well as other delivery routes as described herein.
[0368] 2. Biodistribution of microalgae (EVs) MEVs, including those derived from Chlorella as described herein, have properties distinct from mammalian EVs, including bovine EVs (see co-owned PCT / EP2023 / 051650, published as PCT Publication No. WO2023 / 144127, which details the preparation, administration, and biodistribution of MEVs). For example, a significant difference is that MEVs can be administered orally, and the primary target is the spleen, particularly the white pulp of the spleen (white spleen). This makes MEVs suitable for use as vaccines and for delivering immunomodulatory cargo. MEVs can be administered intranasally, by inhalation into the lungs, by intraocular administration, including by topical administration as eye drops, or by injection, intramuscular administration, and by any other suitable route. MEVs can be formulated for administration via each route. Thus, compositions containing MEVs for treating specific diseases and for specific routes of administration are provided. For immunomodulation and vaccination, MEVs are delivered via routes such as oral and intramural, and by mucosal delivery, including by inhalation into the lung, nasal, and intestinal mucosa, resulting in delivery of MEV cargo to the organs and tissues of the immune system.
[0369] The route of administration determines the fate of the MEV, and the final location of the MEV is a function of the route of administration. Targets and endpoints of the MEV include, but are not limited to, the liver, spleen, lungs, intestines, and brain. Routes of administration include, but are not limited to, respiratory (nasal, lung), oral (digestive), intravenous, central nervous system (CNS), and local administration. The choice of route depends on the final target and the payload. This paper demonstrates that intranasal administration reaches the lungs, intratracheal administration reaches the lungs via a spray, intravenous administration accumulates in the spleen and liver, and oral administration (per animal) reaches the digestive tract and spleen. Conversely, mammalian EVs cannot be administered orally. As described herein, routes of delivery to the immune system include oral and intravenous administration.
[0370] MEVs are readily internalized by human cells. For example, when cells in a culture (e.g., A549 cells) are given MEVs in vitro at a ratio of 1000 / 1, 93% of the cells internalize the MEVs, and this occurs within 24 to 48 hours after the cells are exposed to the MEVs.
[0371] DIR-labeled MEVs were administered to mice via four routes: intranasal (IN), intratracheal (IT), intravenous (IV), and oral. The fate of the MEVs was visualized for 3 days using whole-body imaging as a function of time, after which the mice were sacrificed to harvest organs for research. As illustrated in the examples, intravenous administration targeted the liver approximately 4–12 hours after administration and the spleen, which appeared to be in red pulp (red spleen), at 10–30 hours. Oral administration targeted the intestine and spleen. This paper shows that the MEVs were orally administered; they were resistant to passing through the stomach and reached the intestine in 0.5 to 4 hours, and then the spleen in 0.5 to 10 hours. The pathways to the spleen are of interest; there are two possible pathways to the spleen, via the blood (to the red spleen) and via lymphocytes (to the white spleen), which means targeting cargo and delivering it to the immune system, accumulating from 4 to 28 hours. This can be achieved through the internalization of lymphocytes that are activated and terminate in the spleen where they reproduce, and / or through the internalization of lymphocytes that engulf MEVs, which are not activated and enter the white pulp (white spleen) of the spleen from where they are dispersed by the immune system.
[0372] 3. Diseases and conditions treated with MEV Based on the target organ, a variety of diseases and conditions can be treated with MEVs. MEVs can be loaded or manufactured to contain therapeutic agents for treating these diseases and conditions. The appropriate route of administration is selected for the target organ and disease. For example, oral administration is chosen to target the spleen and intestines; and inhalation or nasal administration is chosen to target the lungs. Based on biodistribution and pharmacokinetic data, the following organs can be targeted to treat diseases exemplified below: Eye: Diseases of the eye, including the posterior part of the eye, including the retina and choroid; • Brain: Diseases involving the brain and CNS (see co-owned international PCT publication: WO 2024 / 088808, which details the MEV for intranasal administration to the brain, the transport pathway, and the target loci in the brain and CNS). Liver: Cancer, cancer metastasis, metabolic syndrome, genetic disorders (delivery of gene therapy), alpha-antitrypsin (AAT) deficiency and other congenital errors in metabolism, hemophilia, hypercholesterolemia, liver inflammation, steatohepatitis, and other diseases and conditions that can be treated by delivering therapeutic agents to the liver; Spleen: Diseases treated through immunomodulation, including cancer, immune cell disorders and cancer, as well as other diseases that can be treated by administration to the spleen, particularly by immune cells occurring in or entering the white spleen; Intestinal: diseases and conditions treated or prevented by vaccines, intestinal infections, microbiome modulation, Crohn's disease, cancer, ulcers, diseases treated with oral medications (such as small molecules and proteins), and other such diseases, conditions, and illnesses; and Lungs: Infectious diseases, especially respiratory diseases, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma, other inflammatory lung diseases, cystic fibrosis, ATT deficiency, lung diseases, cancer, cancer metastasis, and other such diseases and conditions.
[0373] H. Exemplary display, monitor, and control for testing WITH MEV-GTV As described above, the MEV GTV can be loaded with any plasmid encoding any desired cargo, including but not limited to nucleic acid molecules encoding therapeutic proteins, detectable marker proteins and tags, small molecule drugs, gene editing systems, and combinations thereof, for delivering therapeutic molecules and gene editing systems, such as gene editing systems for achieving gene editing. Therapeutic products include encoded polypeptides, peptides, and mRNA. Any product administered as a DNA vector can be encoded in an ITR plasmid and administered in the MEV-GTV, and the encoded gene therapy is used to achieve gene therapy, for example, for treating metabolic gene therapy diseases by delivering encoded products, nucleic acids (including CRISPR-CAS), and other such gene editing products that can be encoded in plasmids.
[0374] MEVs can carry cargo. In this document, cargo includes ITR plasmids encoding products. An MEV containing an ITR plasmid is a MEV-GTV. The products include, for example, products for treating diseases characterized by genetic defects leading to the deficiency of functional proteins, or products for treating diseases characterized by peptide overexpression. Non-limiting examples of diseases that can be treated by silencing target genes include, for example, the use of siRNA or microRNA (see, for example, International Publication No. WO). 2013 / 048734) includes cancers (e.g., lung cancer, leukemia and lymphoma, pancreatic cancer, colon cancer, prostate cancer, glioblastoma, ovarian cancer, breast cancer, head and neck cancer, liver cancer, skin cancer and uterine cancer), cardiovascular diseases, eye diseases (e.g., age-related macular degeneration, herpetic stromal keratitis, glaucoma, dry eye syndrome, diabetic retinopathy, and conditions related to ocular angiogenesis and ocular hypertension), neurological diseases (e.g., amyotrophic lateral sclerosis, Alzheimer's disease, myasthenia gravis, Huntington's disease, spinocerebellar ataxia, frontotemporal dementia, Parkinson's disease, prions and Laufua disease, and those caused by ischemic or hypoxic conditions), kidney diseases, inflammation or autoimmune diseases. Diseases (e.g., ischemia or reperfusion injury, restenosis), rheumatoid arthritis, inflammatory bowel disease such as Crohn's disease or ulcerative colitis, lupus, multiple sclerosis, diabetes (e.g., type 2 diabetes) and diabetic conditions, arthritis such as rheumatoid arthritis or psoriasis), respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, acute respiratory distress syndrome (ARDS), emphysema and acute lung injury), hearing impairment, epilepsy, spinal cord injury, stomatitis, male infertility, uterine conditions, endometrial conditions or disorders, and conditions related to metabolism (e.g., obesity), ischemia, stroke, alcohol metabolism, and liver function (see, e.g., International Publication No. WO) 2006 / 029161, WO 2007 / 022470, WO 2007 / 130604, WO 2008 / 021157, WO 2009 / 104051, WO 2009 / 142822, WO 2019 / 217459, WO 2020 / 123083; European Publication No. EP 2504435; and US Patent Publications US2011 / 0223665, US2012 / 0116360, US2012 / 0071540, US2016 / 0257956, US2015 / 0196648, and US2017 / 0304459). RNAi molecules can target genes encoding, for example, oncogenes, transcription factors, receptors, enzymes, structural proteins, cytokines, cytokine receptors, lectins, selectins, immunoglobulins, kinases, and phosphatases, wherein the targeted gene or gene product plays a role in eye diseases, symptoms, or conditions.
[0375] MEV-GTV can be used to deliver DNA-encoding products for therapeutic purposes, such as gene silencing, or for prevention, for example, through vaccination, of infectious diseases of the eye, diseases such as muscular dystrophy, cystic fibrosis, and others. Gene silencing can also be used to target pathogen-associated proteins, such as viral proteins involved in host immunosuppression, pathogen replication, pathogen transmission, or infection maintenance; or host proteins that promote pathogen entry into the host, pathogen or host drug metabolism, replication or integration of the pathogen genome, establishment or spread of infection in the host, or assembly of the next generation of pathogens. Pathogens may include, for example, RNA and DNA viruses, such as arenaviruses, coronaviruses, influenza viruses, paramyxoviruses, flaviviruses (e.g., West Nile virus), piconemaviruses (e.g., Coxsackievirus, poliovirus, and rhinovirus), striaviruses, filamentous viruses, retroviruses (e.g., lentiviruses and Rous sarcoma virus), adenoviruses, poxviruses, herpesviruses, human papillomaviruses, cytomegaloviruses, hepatotropic DNA viruses (e.g., hepatitis B and hepatitis C), rotaviruses, respiratory syncytial virus, polyomaviruses, etc.; bacteria; fungi; worms; micronuclei; trypanosomes; parasites, including Plasmodium (e.g., Plasmodium malariae, etc.); and mammalian transposable elements (see, for example, International Publications WO 2010 / 141724, WO 2011 / 071860, WO 2011 / 072292, WO 2013 / 126803, WO US Patent Publications 2020 / 035620 and WO 202009740; Australian Patent Publications AU 200573A1, AU 20203219 B2 and AU 2016225873; European Patent Publications EP 2395012 and EP 2888240; US Patent Publications US 2011 / 0223665, US 2014 / 0256785 and US 2019 / 0032051; Japanese Patent Publication 2018-197239A; and Taiwan Patent Publication TW 201204351A.
[0376] MEV-GTV can also be used to deliver DNA or mRNA molecules encoding therapeutic or therapeutically useful peptides. For example, in cases where a subject lacks a specific gene product, the gene can be encoded in a nucleic acid molecule (e.g., DNA or RNA). Nucleic acid molecules encoding gene products can be loaded into an MEV and delivered to a subject lacking the gene product. Examples of diseases, conditions, or illnesses resulting from the lack or insufficiency of a gene product include retinitis pigmentosa and other hereditary eye diseases, particularly those leading to vision loss. Other diseases, conditions, and illnesses include ophthalmoplegia, and autosomal dominant and recessive progressive extraocular muscle disorders with mitochondrial DNA deletion; (see, for example, International Publications WO 2011 / 068810, WO 2019 / 243574, WO 2019 / 092287, and WO 2020 / 099682).
[0377] As described, the plasmid, and therefore MEV-GTV, can encode clusters of regularly spaced, short palindromic repeats (CRISPR) / Cas systems to enable gene editing targeting genes with mutations that cause diseases, symptoms, or conditions involving the eyes. CRISPR technology allows modification of the genome in living organisms and is based on a bacterial CRISPR / Cas9 antiviral defense system. This system allows DNA cleavage at the target site. In another embodiment, the invention provides a method for encoding between nucleic acid sequences within a host genome, the method comprising: processing a transcript from a crRNA repeat sequence into crRNA. Each crRNA contains a variable sequence derived from exogenous DNA transcription and a portion of the CRISPR repeat sequence. Each crRNA hybridizes with a second trans-activating CRISPR RNA (tracrRNA); the two RNAs form a complex and guide a Cas9 nuclease to cleave the target DNA sequence. By delivering a Cas nuclease complexed with a synthesis guide RNA (gRNA) comprising a fusion of crRNA and tracrRNA into cells, the cellular genome can be cleaved at desired locations, thereby allowing the removal of existing genes and / or the addition of new genes in vivo (Sander and Joung (2014) Nat. Biotechnol. 32(4):347-355). In some embodiments, the Cas peptide or single RNA-guided endonuclease Cpf1 can be delivered in lipid nanoparticles, extracellular vesicles, and other vesicles (see, for example, International Patent Publications WO 2017 / 161010, WO 2019 / 238626, and WO 2020 / 097540).
[0378] Exemplary gene therapy methods include gene replacement, such as replacing the gene encoding a defective product. Gene therapy has been used to treat eye diseases. RNA editing is an alternative to DNA editing. Because unused RNA molecules degrade rapidly, any errors introduced by the therapeutic agent are not permanent. RNA can be introduced via RNA transsplicing. RNA transsplicing is a technique that hijacks this naturally occurring phenomenon to remove the mutated segment and replace it with a healthy version.
[0379] H. Examples The following examples are for illustrative purposes only and are not intended to limit the scope of the invention.
[0380] Example 1 Chlorella cell production and MEV isolation A. Batch production of inoculum Any strain of *Chlorella vulgaris* can be used to produce MEVs. Exemplary strains include, but are not limited to, UTEX 265, UTEX 395, UTEX 26, UTEX 30, UTEX 259, UTEX 2219, UTEX 2714, UTEX B 1811 (available from the UTEX Culture Collection), a strain named CCAP 211 / 19, GEPEA, the University of Nantes, France, and any other suitable strain (transformed or untransformed) that can be used to produce algal cell material. For illustrative purposes, UTEX 265 is used.
[0381] Chlorella was preserved on nutrient agar slants until inoculation into a flask / photobioreactor (PBR). Different production scales were used for different experiments, ranging from 400 mL (flasks) to 170 L (several PBRs with different total volumes). This specification pertains to the highest volume PBR used for culturing microalgae (170 L, HECTOR PBR "Hector" photobioreactor designed by Laboratory of Process Engineering - Environment - Agri-food (GEPEA) / CNRS. No.: 20160067_0017. Year of manufacture: 2016. Maximum dimensions: 56.43 × 37.66 cm / 170 L / 300 dpi).
[0382] 4 L of sterile BG11 medium was filled into 5 L of PBR (see, for example, the table below (Table 1) describing its preparation, utex.org / products / bg-11-medium and autotrophic growth) and inoculated directly from the stored algae slant on nutrient agar. Chlorella strains were then grown as batch cultures in bubble column using the following culture parameters: temperature 23 °C; medium pH 7.5–8.0; light intensity: 100 μmol·m⁻¹. -2 ·s -1 Photoperiod: Continuous. Estimate the biomass concentration, specific growth rate, and biomass productivity of *Chlorella* daily. Typically, after 6 days of continuous growth, the culture reaches a biomass concentration of approximately 1.2 g / L. Collect 20 L of the total crop volume for subsequent scaling-up to a PBR reactor.
[0383] B. Scale-up production in a semi-industrial photobioreactor (PBR) Chlorella cells were further cultured in a 170 L photobioreactor system (HECTOR). The inoculum was added to sterile BG11 medium (see Table 1) in a total volume of 150 L, and the cells were allowed to autotrophically grow as a semi-batch culture, mixed with bubble column. The following culture parameters were used: temperature 18 ± 4 °C; medium pH 8.0 ± 0.05; light intensity: 150–300 μmol·m⁻¹. -2 ·s -1 ; 150 μmol·m⁻¹ for each batch on the first day -2 ·s -1 Heaven, 250 μmol·m -2 ·s -1 Days four and five and 300 μmol·m -2 ·s -1 Six and seven days, then harvested as a photoperiod: continuously, with the light intensity gradually increasing.
[0384] Estimate the biomass concentration, growth rate, and biomass productivity of Chlorella daily. Harvest on day 6 of culture at a biomass concentration of approximately 1.5 g / L Chlorella.
[0385] Table 1. Composition of BG11 medium
[0386] Stock solutions for BG11 medium:
[0387] C. Production of three consecutive batches of Chlorella Chlorella production was carried out in three half-batch batches of 130 L each, from which approximately 80% of the culture volume was aseptically removed for downstream processing and replenished with sterile BG11 medium. After harvest, the light intensity was reduced to 140 μmol·m⁻¹. -2 ·s -1 To avoid excessive photon intake, the inoculation line was changed from 100 mL to 150 L of culture. Three consecutive batches were run over 6–7 days to extract vesicle concentrates without microalgae.
[0388] Culture parameter monitoring 1. Determination of protein content The protein content of the culture was determined by elemental analysis using Vario el III (Vario EL, Elementar Analyser systeme, GmbH, Hanau, Germany) according to the procedures provided by the manufacturer. The final protein content was calculated by multiplying the percentage of nitrogen given by the elemental analysis by 6.25.
[0389] 2. Estimation of chlorophyll content The culture samples were centrifuged at 2547 g for 15 minutes using a Hermle centrifuge (HERMLE Labortechnik GmbH, Washington, Germany). The pigment was extracted from the resulting precipitate by bead milling in acetone. Genesys chromatographs were then used to extract the pigment. TM The 10SUV-VIS spectrophotometer (Thermo Fisher Scientific, Massachuetts, USA) was used to obtain the full absorption spectrum of the extract, which was repeatedly decomposed into standard pigment spectra to obtain the total chlorophyll content.
[0390] 3. Growth estimation Dry weights of culture samples were obtained by filtering them through a pre-weighed 0.7 μm GF / C 698 filter (VWR, Pennsylvania, USA) and dried at 120 °C until constant weight was obtained using a DBS 60-30 electronic moisture analyzer (KERN&SOHN GmbH, Balingen, Germany). All dry weight samples were washed with softened water to remove salts from the growth medium.
[0391] D. Isolation of microalgal extracellular vesicles: Production of concentrated MEV formulations (Down-Treatment: Clarification and Concentration Steps) The culture harvested from the PBR was centrifuged at 2,700 g for 5 minutes at room temperature to remove cells. The supernatant was transferred to a fresh bottle and centrifuged again at 2,700 g for 5 minutes at room temperature. The clarified MEV-containing solution was then membrane filtered using a 1.2 μm cutoff cartridge filter. The filtrate was concentrated using a 100 kDa MWCO tangential filtration system. Chlorophyll and particulate matter were analyzed spectrophotometrically at each separation step. The final product had a dry weight <0.01 g / L and a concentration factor of approximately 20 relative to the initial volume of the processed culture. The resulting MEV suspension was stored at -50°C in 1–1.2 L bags for further purification.
[0392] E. Detailed protocol for purifying extracellular vesicles of Chlorella microalgae. 1. Thaw overnight in a cold room at 4°C. Prepare MEV by pre-clarification, concentration and storage as described in Part D (1.0-1.2 L).
[0393] 2. When thawing the formulation, harvest the biomass by centrifugation (setting the temperature to 4°C): 2 × 10000 g for 10 minutes at 4°C.
[0394] 3. Collect the supernatant (MEV) and filter it through a vacuum filter onto a 0.65 μm filter to remove any remaining cells.
[0395] 4. Concentrate and purify MEVs using tangential flow filtration (TFF) with the Sartorius VivaFlow® filtration system.
[0396] a. Wash the membrane with running water at approximately 100 ml / min, as described by the manufacturer. Afterward, wash the circuit with cell-free culture medium (BG-11 medium) at approximately 200 ml / min (pressure reading 2 / 2.5 bar).
[0397] b. The MEV formulation (supernatant) is run in the loop at approximately 200 ml / min (pressure reading 2 / 2.5 bar).
[0398] When the residual volume in the circuit plus the reservoir is about 200 mL, TFF is used to percolate the culture medium from BG-11 and change it to PBS using 1 L of PBS.
[0399] c. When the residual volume in the circuit plus the reservoir in PBS is approximately 200 ml, reduce the flow rate to approximately 100 ml / min (20 min, 1 bar).
[0400] d. From a residual volume of 30-60 ml, slow the flow to a rate below 50 ml / min and allow the MEV in PBS to be recirculated for 30 minutes to recover particles trapped on the membrane surface.
[0401] e. The MEV was then filtered using a 0.45 μm filter and purified by ultracentrifugation.
[0402] f. Load the filtered MEV onto ultracentrifuge tubes and centrifuge at 4°C, 100,000g (27,400 rpm) (acceleration and deceleration, maximum 10) for 1 hour, for example, in a SorVall. TM WX Ultra 80TST 28.38. Particles containing MEVs were resuspended in 1–2 ml of PBS buffer, sterilized by filtration through a 0.2 μm filter, and analyzed by nanoparticle tracking analysis (NTA; diluted 1:1000 prior to NTA analysis).
[0403] F. A protocol for purifying extracellular vesicles of Chlorella microalgae using size exclusion chromatography (SEC). When higher purity MEV is required, a final purification step is added. The MEV, previously concentrated by TFF and purified by ultracentrifugation, and prepared in PBS at a concentration of 10 Exp11 to 10 Exp13 / mL, is seeded into a pre-packed column qEV1 from IZON. The MEV is eluted with PBS solution. 0.5 mL of the elution fraction is collected. Figure 5 As shown, MEVs are recovered in the first stage.
[0404] Measured by Bradford, using ZetaView ® The engine (Nanoparticle Tracking Analyzer from Particle Metrix) assessed the MEV concentration in the initial sample and fractions collected throughout the elution process as the amount of protein. The most concentrated fractions (4-5) were combined and stored at 4°C before use.
[0405] Example 2 MEV characterization A. Nanoparticle Tracking Analysis (NTA) The size and dispersion (size distribution) of MEVs were analyzed using a NanoSight NS500 system (Malvern Panalytical Instruments). This instrument is equipped with a 488 nm laser, a high-sensitivity sCMOS camera, and a syringe pump. MEV samples were diluted in particle-free PBS (0.02 μm filtered) to obtain concentrations within the recommended measurement range (1–10 × 10⁻⁶). 8 Particles / mL), corresponding to dilutions of 1 / 1000 to 1 / 10000, depending on the initial sample concentration.
[0406] For each sample, five 60-second duration experimental videos were analyzed using NTA 3.4 Build 3.4.003 (camera grade 15-16) at a syringe pump speed of 30. A total of 1500 frames were examined for each sample. These frames were captured and analyzed using instrument-optimized settings with appropriate detection thresholds, ensuring that observed particles were marked with a red cross and no more than five blue crosses were visible. Further settings were set to "Auto" and viscosity to "Water". To characterize MEVs, MEV samples were prepared and purified as described in Example 1: MEVs were concentrated by tangential flow filtration (TFF), dialysis filtration, and ultracentrifugation, purified by SEC, and sterilized by 0.22 μm filtration. After SEC purification and filtration, the MEVs were diluted 10,000-fold in PBS (1X) and measured in a ZetaView® analyzer (Particle Metrix GmbH, Ammersee, Germany).
[0407] B. Z-potential measurement (NTA) The zeta potential of the MEV was measured three times at 25°C under the following settings: sensitivity of 85, shutter speed of 70, and frame rate of 30 frames per second, with ZetaView software used for data collection and analysis. This protocol (Particle Metrix GmbH, Ammersee, Germany) was employed. Table 2 below shows the results of the three independent measurements.
[0408] Table 2. MEV: Z-potential measurement
[0409] C. Transmission electron microscopy (TEM) To verify the presence of intact MEVs, the formulation was analyzed using transmission electron microscopy (TEM). Fixed (4% formaldehyde, 0.2% glutaraldehyde) MEV samples were attached to a Formvar / carbon-coated grid for 15–20 minutes, washed again with PBS, then with distilled water, and finally stained with 0.4% uranyl acetate / 1.8% methylcellulose before drying. The formulation was observed at 80 kV using a JEOL-JEM1230 TEM (JEOL Ltd., Tokyo, Japan), and images were acquired using a Morada digital camera and iTEM software (Olympus, Münster, Germany).
[0410] Figure 6TEM imaging revealed that the MEVs are spherical vesicles with a diameter of approximately 50–250 nm. The MEVs are encapsulated in a single lipid bilayer membrane, which has a slightly higher electron density in its lumen, and the membrane thickness is estimated to be ~5–10 nm, matching the thickness of the plasma membrane. Figure 6 An exemplary image of the MEV obtained using transmission electron microscopy (TEM) is shown.
[0411] D.DiR fluorescent labeling For uptake and internalization studies, and for further characterization in vivo, MEVs were labeled with DiR, a lipophilic carbocyanine derivative (1,1′-octadecyl-3,3,3',3'-tetramethylindole tricarbocyanine iodide; Thermo Fisher Scientific), which exhibits low fluorescence in water but becomes highly fluorescent upon membrane incorporation and diffuses laterally within the plasma membrane. Fresh samples of MEVs (prepared as above) were resuspended in 1 ml of BG11 medium. 5 μl of 1 mg / ml DiR solution was added to the sample, and the mixture was incubated at 37 °C for 1 h. The sample was then ultracentrifuged at 100,000 g for 30 min at 28,100 rpm using a Kontron TST 55.5 rotor. The supernatant was removed, and the precipitate was washed twice with 1 ml of PBS and centrifuged at 100,000 g for 30 min. Finally, the precipitate was resuspended in 1 ml of PBS. DiR-labeled MEVs were stored at 4 °C and used rapidly to ensure the highest possible fluorescence intensity. The DiR fluorescence of labeled MEVs was measured using a SpectraMax® fluorescence microplate reader (Molecular Devices, USA), which is excited at 750 nm and emitted at 780 nm.
[0412] E.PKH26 fluorescent labeling For uptake and internalization studies, and for further in vivo characterization, MEVs can be alternatively labeled with PKH26 (Merck-Sigma), a fluorescent dye in a red spectrum with peak excitation (551 nm) and emission (567 nm), which can also be excited by a 488 nm laser. Fresh samples of the P40 fraction (prepared as above) are resuspended in 1 ml of diluent C from the PKH26 kit. 6 μl of PKH26 dye is added to the sample, followed by gentle pipetting for 30 seconds. After incubation at room temperature for 5 minutes, the sample is quenched by adding 2 ml of 10% BSA in 1×PBS solution. The volume of medium is brought to 8.5 ml, and 1.5 ml of 0.971 M sucrose solution is added to the bottom of the tube slowly and carefully, ensuring no turbulence is generated. The PKH26-labeled MEVs remain on top of the sucrose pad. Then, samples were ultracentrifuged at 190,000 g for 2 h at 2–8 °C using a Kontron TST 55.5 rotor. The supernatant was removed, and the precipitate was washed with 1×PBS by gentle pipetting and centrifuged again at 100,000 g for 30 min. Alternatively, labeled MEVs were purified from the free dye by size exclusion chromatography using a qVE 1 / 70 nm column (IC1-70-IZON Science) and washed with PBS. MEVs were recovered in the first two fractions. Finally, the precipitate was resuspended in 1 mL of 1×PBS. PKH26-labeled MEVs were stored at 4 °C and filtered through a 0.45 μm filter before being added to cells. Figure 7A The MEV labeled with PKH26 is shown using confocal microscopy.
[0413] F.DiD fluorescent labeling For uptake and internalization studies, MEVs can alternatively be labeled with DiD (ThermoFisher Scientific), a fluorescent dye with peak excitation (650 nm) and emission (670 nm) in the red spectrum. Fresh MEV samples (prepared as described above) are resuspended in 1 ml and incubated with 2 μl of DiD dye added to the sample, followed by gentle pipetting for 30 seconds. After incubation at room temperature for 5 minutes, the sample is quenched by adding 2 ml of 10% BSA in 1×PBS solution. Alternatively, labeled MEVs are purified from the free dye by size exclusion chromatography using a qVE 1 / 70 nm column (IC1-70-IZON Science) and washed with PBS. MEVs are recovered in the first two fractions. PKH26-labeled MEVs are stored at 4 °C and filtered through a 0.45 μm filter before addition to cells. Figure 7B The MEV labeled with DiD is shown using confocal microscopy. Figures 8A-8C This shows the uptake of labeled MEVs by cells.
[0414] G. Flow cytometry experiment Using CellQuest TM Flow cytometry analysis was performed using an LSRII flow cytometer with Pro software (BD Biosciences). Latex beads with diameters of 0.3 and 1.1 μm were prepared and used according to the manufacturer's recommendations to define the MEV gate. Since latex beads typically have a higher refractive index than MEVs and therefore a lower size detection limit by flow cytometry, the forward and side scattering thresholds were adjusted to avoid background noise during acquisition. The predefined MEV gate was applied to all samples during analysis. Figure 9 The cell counting analysis of labeled MEVs with fluorescent payloads or loaded with MEVs is shown. Figures 10A-10B The uptake of MEVs by different types of cells is shown through cell counting.
[0415] Example 3 Exogenous loading of MEVs with plasmids carrying AAV-ITR: Obtaining MEV-GTV A. Freeze-thaw cycle - loading plasmid DNA (pDNA) As described in Example 1, purified MEV was diluted in PBS to specific concentrations (10exp8, 10exp9, 10exp10, 10exp11, and 10exp12). Next, various concentrations of cargo (pDNA 0.2, 1, 2, or 40 μg / ml; mRNA 0, 2, and 2 μg / ml) were added to the MEV suspension (total volume 500 μl). The mixture of MEV and cargo was frozen at -80°C or immersed in liquid nitrogen (-196°C). The samples were then thawed in a water bath at 37°C. This freeze-thaw cycle was repeated 2 or 4 times for each sample.
[0416] Table 3. Protocol optimization for freeze-thaw cycle loading of DNA (plasmids); parameters and values of variables used for sensitivity analysis.
[0417] B. Extrusion-loading of plasmid DNA (pDNA) As described in Example 1, purified MEV was diluted to a specific concentration (10 exp 10) in PBS. Next, different concentrations of cargo (pDNA 2 or 20 μg / ml; mRNA 0.1, 1, 2, and 10 μg / ml; GFP 2 or 20 μg / ml) were added to the MEV suspension (total volume 500-1000 μl). The mixture of MEV and cargo was extruded using a syringe-based handheld microextruder (SKU: 610023-1 EA, Avanti® Polar Lipids). The sample was extruded through a membrane filter with pores of 50 nm-100 nm diameter 10 to 15 times using two facing syringes. In some experiments, the sample was extruded sequentially through membranes with pores of 200 nm, 100 nm, and 50 nm diameter. Extrusion was performed at room temperature or at 65°C.
[0418] Table 4. Scheme optimization for extrusion loading of DNA (plasmids); parameters and values of variables used for sensitivity analysis.
[0419] C. Electroporation-load of plasmid DNA (pDNA) As described in Example 1, purified MEV was diluted in PBS to specific concentrations (10exp8, 10exp9, or 10exp10). Next, different concentrations of cargo (pDNA 1, 2, 5, 10, or 20 μg / ml; mRNA 2 and 20 μg / ml) were added to the MEV suspension (total volume 110-150 μl). The mixture of MEV and cargo was transferred to 100 μl electroporation cuvettes and placed in a NEPA 21 (NEPAGENE) superelectroporator. The following parameters were set for each electroporation: voltage (50V, 100V, or 200V), pulse length (5ms, 10ms, or 15ms), pulse interval (set to 50ms), decay rate (set to 10%), polarity (set to positive), number of pulses (1, 9, or 15), and the presence or absence of a transmission pulse (5 pulses at 20V over 50ms, with a 50ms interval and a 10% decay rate). To assess aggregation, for each condition, 20 mM EDTA or 10 mM citrate was added prior to electroporation.
[0420] Table 5. Protocol optimization for electroporation loading of DNA (plasmids); parameters and values of variables used for sensitivity analysis.
[0421] D. DNA enzyme treatment: After each loading method, a portion of the sample was treated with deoxyribonuclease I (DNase) (10104159001, Roche) to eliminate all free nucleic acids (unloaded). DNase and DNase buffer (Tris-HCl 10 mM, MgCl2 2.5 mM, CaCl2 0.5 mM, pH 7.6) were mixed with the sample and incubated at 37°C for 40 minutes. Finally, ethylenediaminetetraacetic acid (EDTA) (20 mM) was added to inhibit DNase activity. The sample was then stored at 4°C.
[0422] E. Purification of MEV after loading After treatment with a totipotent nuclease (benzonase), the loaded MEVs were purified to remove undigested nucleic acids and the totipotent nuclease used to degrade the nucleic acids. MEVs prepared in PBS at a concentration of 10exp¹¹ to 10exp¹² / mL were seeded into a pre-packed column qEV1 from IZON. The MEVs were eluted with PBS. A 0.7 mL eluent fraction was collected. The MEVs were recovered from the first two fractions.
[0423] Measured by Bradford, using ZetaView ® The engine (NanoparticleTracking Analyzer from Particle Metrix) assesses the MEV concentration in the initial sample and fractions collected throughout the elution process as the amount of protein.
[0424] Example 4 MEV characterization after loading plasmid payload A. DNA extraction: Following the manufacturer's recommendations, the nucleic acids encapsulated in MEVs were extracted using the RQIAprep® Spin Miniature Preparation Kit (available from QIAGEN). At the end of the protocol, the nucleic acids were eluted in 50 μL of nuclease-free water.
[0425] B. qPCR: To quantify the plasmid extracted from MEV, quantitative polymerase chain reaction (qPCR) analysis was performed. NanoDrop was used. TM A 2000 analyzer (obtained from Thermo Scientific) measures the DNA concentration in the sample and, if proper amplification is required during qPCR, dilutes the sample (volumes for each condition are listed in the membrane label). A 0.4 x 10⁻⁶ analyzer was achieved. -6 ng up to 5.1x10 -6 The plasmid range for ng pDNA. Use 5 μL of PowerUp per well. TM SYBR TMGreen (Cat. No. A25776, from Fisher Scientific) TM Applied Biosystems TM The master mixture was prepared by adding 0.5 μL of forward primer (concentration = 10 μM) and 0.5 μL of reverse primer (concentration = 10 μM) per well. Primers complementary to the resistance gene sequence of the pDNA had previously been designed to amplify only the plasmid of interest. MicroAmp was used. TM Optical 384-well reaction plate (Cat. No. 10411785, from Fisher Scientific) TM Applied Biosystems TM Add 6 μL of the master mixture to each well, followed by 4 μL of sample. Prepare two negative controls: one with SYBR... TM Nuclease-free water with green dye, and water with SYBR TM Green dye and nuclease-free water with primers. All conditions were performed in duplicate. The plates were sealed and briefly centrifuged. The thermal cycler was a CFX384Touch. TM Real-time PCR detection system (from Bio-RAD). The three-step cycle is summarized in the table below, followed by the melting curve protocol.
[0426] Table 6. Three-step cycling protocol for qPCR
[0427] Table 7. Melting curve scheme for qPCR
[0428] For plasmid quantification (1000 dilution), real-time qPCR was performed in technical replicates on qPCR plates equipped with a rapid thermal cycling system (LightCycler® 480 II, 384 (well)). The protocol was as follows: 3 μl of cDNA (with a defined dilution factor of X1000) was mixed with one forward primer and one reverse primer (added at an optimized concentration typically between 200 nM and 1.0 μM). Takyon No ROX SYBR 2X MasterMix blue dTTP (Eurogentec, UF-NSMT-B0701) was mixed with dNTPs, MgCl2, Taq DNA polymerase, and buffer to a total volume of 10 μl. This mixture was then placed in a LightCycler® plate.
[0429] The amplification protocol begins with an initial incubation at 95°C for 10 minutes (for Taq DNA polymerase activation), followed by 45 amplification cycles consisting of two steps: Step I) denaturation at 95°C for 10 seconds, and Step II) primer annealing and extension at 60°C for 40 seconds (detection of the fluorescent product is performed in single acquisition mode at the end of this 60°C extension period). The amplification protocol is then followed by a melt profile step, which consists of one cycle of denaturation at 95°C for 5 seconds, annealing at 60°C for 40 seconds, and a final extension at 95°C (achieved by increasing the temperature from 60°C to 95°C at a rate of 0.04°C / s, accompanied by continuous detection of the fluorescent product). The amplification protocol is concluded by cooling at 37°C for 10 seconds.
[0430] The qPCR primers and their concentrations are listed below: Plasmid (pDNA) pcDNA3.1 SEQ ID NO 53+ Primers (SEQ ID NO: 54 and 55): • Left primer PCDNA3.1+1: GACCACCAAGCGAAACATGG • Right primer PCDNA3.1+1: CCATGGGTCACGACGAGATC • PCDNA3.1 LR1 (left primer PCDNA3.1+1, right primer PCDNA3.1+1): 700 nM Control for qPCR assay For the "DNA efficacy and quantification control" sample, a mixture of plasmid (pDNA) and pcDNA3.1+ was prepared. Subsequently, nine different concentrations were prepared using RNase / DNase-free water (1000 ng, 500 ng, 100 ng, 50 ng, 10 ng, 5 ng, 1 ng, 0.5 ng, 0.1 ng), extracted and diluted (same as the sample, dilution factor X1000), and mixed with the corresponding primers used on the qPCR plate.
[0431] C. dPCR is used to quantify the number of plasmid molecules loaded in the MEV.
[0432] For the examples, MEVs carrying plasmids were isolated and purified as described in Example 1, characterized as described in Example 2, and loaded as described in Example 3. Subsequently, the MEVs were purified by SEC as described in Example 3, and then subjected to digital PCR (dPCR) (QIAcuity). ® Quantification using the Qiagen System. The control plasmid contains the mcherry coding sequence.
[0433] Digital PCR (dPCR) is designed to deliver precise and multiplexed quantitative results for mutation detection, copy number variation (CNV), gene expression studies, and gene editing analysis. In this example, it is used to determine the exact number of plasmids loaded in a defined amount of MEV. In this embodiment, QIAcuity is used. ® Digital PCR System (Qiagen), QIAcuityProbe PCR Kit (Qiagen, 250102), and QIAcuity ® Nanoplate 26k 24-well (Qiagen, 250001).
[0434] MEV was loaded with the following plasmid as described in Example 3: 1- Plasmid encoding eGFP protein: pAAV-ssGFP SEQ ID NO: 48 from PlasmidFactory.
[0435] pBCB-23-0041 plasmid with AAV-ITR, SEQ ID NO: 48.
[0436] pEGFP-N1-FLAG is from Addgene, plasmid, without AAV-ITR, SEQ ID NO:52.
[0437] 2- Plasmid encoding the aflibercept (SEQ ID NO: 94) protein trap: pBCB-23-0065, a plasmid with AAV-ITR, SEQ ID NO:49.
[0438] pBCB-23-0070, a plasmid with AAV-ITR, SEQ ID NO:50.
[0439] The plasmid encoding the mcherry protein was used to normalize the reaction and was not loaded into the MEV: pBCB-24-0005, a plasmid without AAV-ITR, SEQ ID NO:51.
[0440] Table 8. Primers and probes used for the reaction: (EGFP plasmid assay) SEQ ID NO: 56, 57 and 58.
[0441] Table 9. Primers and probes used for the reaction: (Aflibercept plasmid assay) SEQ ID NO: 59, 60, 61, 62, 63 and 64.
[0442] Regarding pBCB-23-0070
[0443] Regarding pBCB-23-0065
[0444] Table 10. Primers and probes used for the reaction: (mcherry plasmid assay) SEQ ID NO: 65, 66 and 67.
[0445] dPCR was used to quantify the payload in each batch of plasmid-loaded MEVs from different batches. dPCR reactions were performed using 0.8 mg of each primer and 0.4 mg of the probe, with a final reaction volume of 40 mL. All fluorescent dyes (FAM, HEX, and TAMRA) were measured in each well.
[0446] The copy number of each plasmid was >95% by dPCR compared to Nanodrop quantification of the same plasmid formulation measured in dPCR tests on the same day. The quantification results are summarized in Tables 11-12.
[0447] Table 11: Quantification of payloads from MEVs loaded with plasmids carrying or not carrying AAV-ITR (EGFP primers and probes).
[0448] Table 12: Quantification of payloads from MEVs loaded with plasmids carrying or not carrying AAV-ITR (primers and probes for aflibercept).
[0449] D. Flow cytometer with fluorescent payload Using CellQuest TM Flow cytometry analysis was performed using an LSRII flow cytometer with Pro software (BD Biosciences). Latex beads with diameters of 0.3 and 1.1 μm were prepared and used according to the manufacturer's recommendations to define the MEV gate. Since latex beads typically have a higher refractive index than MEVs and therefore a lower size detection limit by flow cytometry, the forward and side scattering thresholds were adjusted to avoid background noise during acquisition. The predefined MEV gate was applied to all samples during analysis. Figure 11 The percentage of loaded MEVs with fluorescent payloads is shown.
[0450] E. Statistical Analysis: The experimental design for screening and optimization was generated using NemrodW software. Results were analyzed using R Studio (version 1.4.1717) and Prism (version 8.3). The significance of variables compared to controls was assessed using unpaired t-tests. "ns" represents "not significant" (p > 0.05), "*" represents "p < 0.05", "**" represents "p < 0.01", and "***" represents "p < 0.001". Loading efficiency was calculated based on the amount of pDNA obtained via qPCR compared to the initial amount of pDNA for each condition. Linear regression modeling was implemented to evaluate the impact of the test variables on plasmid encapsulation.
[0451] F. External load efficiency The external loading efficiency and internalized payload of the obtained, purified, characterized, and loaded MEVs as determined in Examples 1-3 are shown in Table 13 below. For different payloads, the external loading efficiency using different loading methods was calculated using the following parameters: (i) loading efficiency, and / or (ii) loading capacity, or (iii) the percentage of loaded MEVs.
[0452] Table 13: Summary of the conditions and results obtained by loading plasmids using different loading methods.
[0453] Keywords: Load (0) very low; (+) low; (++) acceptable; (+++) best results; ND undetermined, with parameters as follows: Internalized payload is the total amount of payload molecules measured in the MEV after loading reaction (DNA). After removing residual payload molecules from the loading reaction medium at the end of the reaction by specific enzyme treatment (DNAse), the internalized payload is determined by specific quantitative methods (qPCR).
[0454] • Copy number of payload: The copy number of the payload molecule (DNA or RNA) in the initial or internalized payload quantity. The copy number is calculated using the following method: Copy number = (ng × [6.022exp23]) / (length × [1exp9] × 650) in: ng represents the amount of nucleic acid (plasmid). 6.022 exp23=Avogadro’s number.
[0455] The length is the length of the DNA fragment in the base pair multiplied by 1000 (kb). Multiply by 1exp9 to convert to nanograms.
[0456] Loading efficiency is the percentage of the initial amount of payload molecules in the loading reaction medium that are internalized into the extracellular vesicles from microalgae (MEVs) at the initial time point.
[0457] • Load capacity is the number of copies of payload internalized per MEV. Load capacity is calculated as the ratio between the number of copies of internalized payload and the number of MEVs in the reaction.
[0458] • The percentage of loaded MEVs as determined by flow cytometry, as described in Example 4G and by Figure 11 express.
[0459] Example 5a Biodistribution of MEVs in vivo.
[0460] MEVs can be delivered in vivo via several routes of administration. Experiments are being conducted to determine the pathway and fate of MEVs when administered via various routes.
[0461] A. MEV labeling using DiR fluorescence As described in Example 2, the fluorescent lipophilic carbocyanine DiR (1,1-bis(octadecyl-3,3,3,3-tetramethylindole) tricarbocyanine iodide) exhibits weak fluorescence in water, but when incorporated into the membrane, it is highly fluorescent and photost...
Claims
1. An ITR plasmid comprising an ITR and a transgene, wherein: the ITR is a eukaryotic viral ITR; the ITR is the only element of the plasmid from a eukaryotic virus, except for promoters and regulatory sequences that are part of the transgene or used for expression of the transgene; the transgene comprises a nucleic acid encoding a gene product operably linked to a promoter recognized in a eukaryotic cell; and optionally additional eukaryotic transcriptional and / or translational regulatory sequences.
2. The ITR plasmid of claim 1, consisting of an ITR, one or more transgenes, and optionally regulatory sequences.
3. The plasmid of claim 1 or 2, wherein the size of the plasmid is at most about 20 kB.
4. A bacterial plasmid comprising an ITR and a transgene, wherein: the ITR is a eukaryotic viral ITR; and the bacterial plasmid comprises a bacterial cloning vector for propagation in bacteria.
5. A bacterial plasmid comprising the ITR plasmid of any one of claims 1-3.
6. The bacterial plasmid of claim 4 or 5, wherein the cloning vector is selected from the group consisting of a plasmid, a phage, a cosmid, and a bacterial artificial chromosome (BAC).
7. The bacterial plasmid of claim 3 or 4, comprising a pUC or pBR322 backbone.
8. The plasmid of any one of claims 1-7, wherein the ITR is a eukaryotic viral ITR, for example from a poxvirus, adenovirus, or adeno-associated virus, or a synthetic ITR.
9. The plasmid of claim 8, wherein the ITR is selected from the group consisting of ITRs of AAV.
10. The plasmid of claim 8, wherein the ITR is selected from the group consisting of ITRs having a sequence as set forth in any one of SEQ ID NOS: 1-47.
11. The plasmid of claim 8, wherein the ITR is selected from the group consisting of the following ITRs: 。 12. A delivery vehicle comprising the plasmid of any one of claims 1-11.
13. The delivery vehicle of claim 12, which is an extracellular vesicle, an exosome, or a nanoparticle.
14. The delivery vehicle of claim 12 or claim 13, which is an extracellular vesicle (EV).
15. The delivery vehicle of claim 13 or claim 14, which is a microalgal extracellular vesicle (MEV).
16. A microalgal extracellular vesicle gene therapy vehicle (MEV-GTV) comprising: a) a MEV; and b) an ITR plasmid containing a transgene operably linked to an ITR, wherein: the transgene encodes one or more therapeutic products, and regulatory elements for controlling / directing expression of the encoded products in a eukaryotic cell; the transgene optionally encodes multiple therapeutic products; and the multiple can be separated by a nucleic acid encoding a 2A peptide to create a polycistronic message, or each can comprise a separate promoter, or a combination of such structures.
17. A microalgal extracellular vesicle (MEV) comprising the plasmid of any one of claims 1-11, wherein the MEV is a MEV-GTV.
18. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-17, wherein the transgene encodes one or more therapeutic products for treating or preventing or regulating a disease, symptom, or condition.
19. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-18, wherein the transgene encodes a protein, peptide, or nucleic acid product.
20. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-19, wherein the encoded product comprises a nucleic acid molecule, polypeptide, protein, plasmid, aptamer, or antisense oligonucleotide (ASO).
21. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-20, wherein the encoding product is an RNA product or an oligonucleotide.
22. The plasmid, delivery vector, or MEV-GTV according to claim 21, wherein the encoding product is RNAi or mRNA.
23. The plasmid, delivery vector, or MEV-GTV according to claim 21, wherein the RNAi is a silent RNA (siRNA), or a short hairpin RNA (shRNA), a microRNA (miRNA), a short activating RNA (saRNA), or a long non-coding RNA (lncRNA).
24. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-22, wherein the encoding product is ASO, oligonucleotide, dsRNA, ribozyme, or RNAi.
25. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-24, wherein the encoded product is siRNA, shRNA, or miRNA.
26. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-20, wherein the encoded product is a polypeptide or peptide.
27. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-20, wherein the encoded product is a protein that is a therapeutic product for treating cancer, or an infectious disease, or a neurodegenerative disease or other central nervous system (CNS) condition, or for improving aging, or slowing or reversing aging, or for treating age-related diseases, or an ophthalmic condition, or an immune condition.
28. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-27, wherein the encoded product comprises a gene editing system.
29. The plasmid, delivery vector, or MEV-GTV of claim 28, wherein the gene editing system comprises a CRISPR-CAS system.
30. The plasmid, delivery vector, or MEV-GTV of claim 29, wherein the gene editing system comprises a CRISPR-related or CRISPR-like system.
31. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-30, wherein the encoded product comprises an immunomodulator.
32. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-31, wherein the encoded product comprises an immunomodulator to increase or decrease the production of one or more cytokines; upregulate or downregulate self-antigen presentation; mask MHC antigens; or promote the proliferation, differentiation, migration, or activation of one or more types of immune cells.
33. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-32, wherein the encoded product comprises a hormone, cytokine, or chemokine.
34. The plasmid, delivery vector, or MEV-GTV according to claim 33, wherein the encoded hormone or cytokine or growth factor is selected from human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; relaxin; glycoprotein hormones, such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); liver growth factor; fibroblast growth factor; prolactin; placental prolactin; tumor necrosis factor-α and-β; Müllerian inhibitory factor. Substances; mouse gonadotropin-related peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factor, transforming growth factor (TGF); insulin-like growth factor-I and-II; erythropoietin (EPO); bone-inducing factor; interferons, such as interferon-α,-β and-γ; colony-stimulating factors (CSFs), such as macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF) and granulocyte-CSF (G-CSF); or interleukin (IL).
35. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-34, wherein the encoded product is a drug for treating infection.
36. The plasmid, delivery vector, or MEV-GTV of claim 35, wherein the infection comprises a respiratory tract infection and / or a sinus infection.
37. The plasmid, delivery vector, or MEV-GTV according to claim 35 or claim 36, wherein the encoding reagent is used to treat fungal, parasitic, or viral infections.
38. The plasmid, delivery vector, or MEV-GTV according to any one of claims 35-37, wherein the encoded reagent is an antifungal agent, antibacterial agent, antiviral agent, or antiparasitic agent.
39. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-38, wherein the encoded product comprises an antibody or an antigen-binding fragment thereof.
40. The plasmid, delivery vector, or MEV-GTV of claim 39, wherein the antibody is scFv, a bispecific antibody, or an antigen-binding fragment thereof.
41. The plasmid, delivery vector, or MEV-GTV according to claim 39 or claim 40, wherein the antibody or antigen-binding fragment thereof is a checkpoint inhibitor antibody or antigen-binding fragment thereof, or a tumor antigen-specific antibody or antigen-binding fragment thereof, or an anticancer gene-specific antibody or antigen-binding fragment thereof, or a tumor-specific receptor, or a signaling molecule antibody or antigen-binding fragment thereof.
42. The plasmid, delivery vector, or MEV-GTV according to claim 39 or claim 40, wherein the antibody or its antigen-binding fragment specifically binds to and inhibits one or more of CTLA-4, PD-1, PD-L1, PD-L2, PD-1 / PDL1 pathway, PD-1 / PDL2 pathway, HER2, EGFR, TIM-3, LAG-3, BTLA-4, HHLA-2, CD28, and other checkpoints or immunosuppressants or tumor antigens.
43. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-42, wherein the encoded product comprises a vaccine for treating or preventing a disease, condition, or illness, or for reducing the risk of a disease, condition, or illness.
44. The plasmid, delivery vector, or MEV-GTV according to claim 43, wherein the vaccine is a DNA, RNA, or protein vaccine.
45. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-44, wherein the encoded product is a therapeutic product for treating cancer, or infectious diseases, or neurodegenerative diseases or other central nervous system (CNS) disorders, or for improving aging, or slowing or reversing aging, or treating age-related diseases, or ophthalmic disorders, or immune disorders.
46. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-45, wherein the encoded product is a therapeutic agent for treating eye diseases, conditions, or illnesses.
47. The plasmid, delivery vector, or MEV-GTV of claim 46, wherein the disease, symptom, or condition is a disease, symptom, or condition of the posterior ocular region.
48. The plasmid, delivery vector, or MEV-GTV according to claim 45 or claim 46, wherein the disease, symptom, or condition involves the choroid-retinal region, retinal pigment epithelial (RPE) cells, and / or photoreceptor cells.
49. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-48, wherein the encoded product is a therapeutic agent for treating diseases, conditions, or ailments involving or affecting the posterior eye or the posterior part of the eye.
50. The plasmid, delivery vector, or MEV-GTV according to any one of claims 45-49, wherein the disease, symptom, or condition involves one or more of choroidal cells, RPE cells, retina, and photoreceptor cells.
51. The plasmid, delivery vector, or MEV-GTV according to any one of claims 45-50, wherein the disease, condition, or symptom is one or more of the following: age-related macular degeneration (AMD), retinal degenerative disease, condition, or symptom, or disease, condition, or symptom involving choroidal neovascularization, genetic disease, condition, or symptom involving the retina, and ocular hypertension.
52. The plasmid, delivery vector, or MEV-GTV according to any one of claims 45-51, wherein the disease, condition, or ailment is selected from one or more of age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, diabetic macular edema (DME), retinal vein occlusion (RVO), and optic neuropathy glaucoma.
53. The plasmid, delivery vector, or MEV-GTV according to any one of claims 45-52, wherein the disease, condition, or ailment is wet AMD, geographic atrophy, diabetic retinopathy, macular edema, retinitis pigmentosa, or glaucoma.
54. The plasmid, delivery vector, or MEV-GTV according to any one of claims 45-53, wherein the transgene encodes a product for treating AMD, glaucoma, or ocular hypertension.
55. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-54, wherein the transgene encodes a product that inhibits VEGFR or inhibits VEGF.
56. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-55, wherein the transgene encodes an immunomodulator to increase or decrease the production of one or more cytokines; upregulate or downregulate self-antigen presentation; mask MHC antigens; or promote the proliferation, differentiation, migration, or activation of one or more types of immune cells.
57. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-56, wherein the transgene encodes a prodrug or an enzyme that converts the prodrug into a drug for treating, preventing, or regulating a disease, symptom, or condition.
58. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-57, wherein the transgene encodes a product for treating, preventing, or regulating a disease, symptom, or condition of the brain.
59. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-57, wherein the transgene encodes a prodrug or an enzyme that converts the prodrug into a drug for treating or involving a disease, condition, or illness of the brain.
60. The plasmid, delivery vector, or MEV-GTV according to claim 58 or claim 59, wherein the disease, symptom, or condition includes an infection in or involving the brain.
61. The plasmid, delivery vector, or MEV-GTV according to any one of claims 58-60, wherein the encoded product is used to treat cancer or tumors in the brain, or to treat infectious diseases in the brain, or to treat neurodegenerative diseases or other central nervous system (CNS) disorders, or to treat dementia.
62. The plasmid, delivery vector, or MEV-GTV according to any one of claims 58-61, wherein the transgene encodes a product that has an effect on the cell or organism to which it is delivered, or the product is detectable or used as a detectable marker or biomarker to enable the treatment, detection, diagnosis, or monitoring of diseases, symptoms, or conditions of the brain or involving the brain.
63. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-62, wherein the bioactive molecule is diagnostic, therapeutic, or therapeutic for the treatment, diagnosis, detection, and / or monitoring of diseases, symptoms, or conditions of the brain or for treatments involving the brain.
64. The plasmid, delivery vector, or MEV-GTV according to any one of claims 58-63, wherein the disease, condition, or illness is a neurodegenerative disease (such as Parkinson's disease, Alzheimer's disease, Huntington's disease, Creutzfeldt-Jakob disease, or other neurodegenerative diseases; or cognitive impairment (such as dementia, amnesia, delirium, or other cognitive impairment); or brain disease (such as encephalitis, epilepsy, tumor, or other brain disease); or nervous system disease (such as pain, epilepsy, infection, or other nervous system disease); or genetic disease (such as cystic fibrosis, thalassemia, sickle cell anemia, Huntington's disease, Duchenne muscular dystrophy, Ty Sachs disease, Rett syndrome, or other genetic disease); or brain tumor; or Niemann-Pick disease; or prions; or Parkinson's disease; or multiple sclerosis; or amyotrophic lateral sclerosis (ALS); or muscular dystrophy; or other diseases of the brain or involving the brain.
65. The plasmid, delivery vector, or MEV-GTV according to any one of claims 58-64, wherein the disease, symptom, or condition of the brain, or the disease, symptom, or condition involving the brain, is cancer, or a disease, symptom, or condition that is treated or prevented by a vaccine.
66. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-65, wherein the disease, symptom, or condition is caused by or involves an infectious agent.
67. The plasmid, delivery vector, or MEV-GTV according to claim 66, wherein the infectious agent is one or more of bacteria, viruses, oomycetes, and fungi.
68. The plasmid, delivery vector, or MEV-GTV of any one of claims 58-66, formulated for intranasal administration to deliver an encoded product to one or more of neurons, astrocytes, oligodendrocytes, microglia, ependymal cells, and / or neural stem cells of the brain.
69. The plasmid, delivery vector, or MEV-GTV according to any one of claims 18-68, wherein the disease, condition, or illness is one or more of cognitive, emotional, behavioral, psychotic, neurological, degenerative, genetic, malignant (cancer), and / or traumatic encephalopathy, condition, or illness.
70. The plasmid, delivery vector, or MEV-GTV of claim 69, wherein the disease, symptom, or condition of the brain, or the disease, symptom, or condition involving the brain, is caused by damage to the brain or central nervous system (CNS).
71. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-70, wherein the transgene encodes a product having psychoactive activity or treating mental illness, or an immunomodulatory product, or a detectable product, or treating brain injury or trauma, or treating cancer, or treating neurocerebrovascular diseases, or treating CNS diseases, or treating genetic brain diseases, or treating brain cancer, or having anti-aging activity, or having brain regeneration activity.
72. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-71, wherein the transgene encodes a product comprising one or more of a hormone, growth factor, enzyme, immunomodulatory compound, receptor, receptor agonist, or receptor antagonist.
73. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-72, wherein the transgene encodes a product for treating, preventing, or regulating a disease, symptom, or condition caused by or involving a pathogen, or an inflammatory disease, or involving a signaling pathway activated by a TLR or intracellular receptor or endosome receptor, or an autoimmune disease, or any disease, symptom, or condition treated by immunomodulation.
74. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-72, wherein the transgene encodes a vaccine product for regulating, inducing, or altering an immune response or for treating or preventing a disease, symptom, or condition.
75. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-74, wherein the transgene encodes a product that initiates or contributes to a protective humoral response, the response comprising serum IgG and IgA and / or mucosal IgG and IgA.
76. The plasmid, delivery vector, or MEV-GTV of claim 75, comprising humoral responses of serum IgA and / or mucosal IgA that generate or induce IgA-producing memory B cells to provide systemic and mucosal responses to prevent reinfection.
77. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-76, wherein the transgene encodes one or more of the following: An antigen or its immunogenic portion, or an epitope, or a nucleic acid encoding an antigen or its immunogenic portion, or an epitope; and / or Immunomodulators that reduce or eliminate immune tolerance to previous immunotherapies or vaccines.
78. The plasmid, delivery vector, or MEV-GTV of claim 77, wherein the disease, symptom, or condition is cancer or an autoimmune disease.
79. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-77, wherein the transgene encodes a product as a TLR antagonist or agonist.
80. The plasmid, delivery vector, or MEV-GTV according to claim 79, wherein the TLR and its agonist are one or more of the following: 。 81. The plasmid, delivery vector, or MEV-GTV according to claim 79, wherein the TLR and its antagonist are one or more of the following: 。 82. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-81, wherein the transgene encodes one or more products for treating a disease, symptom, or condition, said disease, symptom, or condition being cancer or an inflammatory disease, symptom, or condition.
83. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-82, wherein the disease, symptom, or condition is an autoimmune disease.
84. The plasmid, delivery vector, or MEV-GTV of claim 82, wherein the disease, symptom, or condition is an inflammatory disease, symptom, or condition, or wherein inflammation plays a role in the etiology of the disease, symptom, or condition.
85. The plasmid, delivery vector, or MEV-GTV according to any one of claims 82-84, wherein the product comprises an immunomodulator that inhibits the inflammatory response.
86. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-71, wherein the transgene encodes one or more products for the treatment, prevention, or regulation of chronic or acute inflammatory diseases, symptoms, and conditions.
87. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-86, wherein the transgene encodes one or more products comprising an immunomodulator that inhibits an inflammatory response but not an anticancer immune response.
88. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-87, wherein the transgene encodes one or more products for treating diseases, conditions, or illnesses involving excessive or persistent inflammation and severe immunopathology.
89. The plasmid, delivery vector, or MEV-GTV of claim 88, wherein the transgene encodes one or more products for treating a disease, symptom, or condition, including septic shock, autoimmune disease, atherosclerosis, metabolic syndrome, and gastric cancer.
90. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-89, wherein the transgene encodes one or more products for treating a disease, symptom, or condition, including inflammatory bowel disease, rheumatoid arthritis, sepsis, allergy, Alzheimer's disease, or Parkinson's disease.
91. The plasmid, delivery vector, or MEV-GTV of claim 90, wherein the disease, symptom, or condition includes ulcerative colitis and Crohn's disease.
92. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-91, wherein the transgene comprises a eukaryotic regulatory sequence to control the expression of one or more encoded products.
93. The plasmid, delivery vector, or MEV-GTV of claim 92, wherein the regulatory sequence comprises a eukaryotic promoter sequence recognized by RNA polymerase II or RNA polymerase III.
94. The plasmid of claim 93, wherein the promoter is recognized by RNA polymerase II and is a eukaryotic virus promoter or a plant or animal promoter.
95. The plasmid according to claim 93 or claim 94, wherein the promoter is selected from cytomegalovirus promoters, simian virus 40 promoters, herpes simplex virus promoters, Epstein-Barr virus promoters, adenovirus promoters, synthetic promoters, actin promoters, and synthetic chimeric promoters.
96. The plasmid, delivery vector, or MEV-GTV according to any one of claims 92-95, wherein the plasmid further comprises other eukaryotic transcription sequences and eukaryotic translation sequences.
97. The plasmid, delivery vector, or MEV-GTV of claim 96, wherein the additional regulatory sequence or element is selected from one or more of enhancers, introns, IRES, 2A peptides, and Kozak sequences.
98. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-97, wherein the MEV is derived from a classification of microalgae selected from Euglenophyta (euglena), Chrysophyta (golden brown algae and diatoms), Dinophyta (fire algae), Chlorophyta (green algae), Rhodophyta (red algae), Phaeophyta (brown algae), and Xanthophyta (yellow-green algae).
99. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-97, wherein the microalgae is a species of the Chlorellaceae family.
100. The plasmid, delivery vector, or MEV-GTV according to claim 99, wherein the microalgae is a species of the genus Chlorella or Chlorophytum.
101. The plasmid, delivery vehicle or MEV of claim 100, wherein the Chlorella is selected from Chlorella ellipsoidea (Chlorella vulgaris var. ellipsoidea) Chlorella ellipsoidea ), Chlorella pyrenoidosa (Chlorella vulgaris var. pyrenoidosa) Chlorella pyrenoidosa ), Chlorella sorokiniana (Chlorella vulgaris var. autotrophica) Chlorella sorokiniana ), Chlorella vulgaris (Chlorella vulgaris var. vulgaris) Chlorella vulgaris ) and Chlorella variabilis (Chlorella vulgaris var. variabilis) Chlorella variabilis ).
102. The plasmid, delivery vector, or MEV-GTV according to claim 101, wherein the Chlorella is common Chlorella.
103. The plasmid, delivery vector, or MEV-GTV according to claim 100, wherein the microalgae is selected from *Chlorella vulgaris* (…). Parachlorella kessleri ), Bejelin's Chlorella Parachlorella beijerinckii ) and *Pseudochophyton floccosum* ( Parachlorella hussii ) species of the genus Chlorella.
104. A composition comprising the plasmid, delivery vector, or MEV-GTV as described in any one of claims 1-103.
105. The composition according to claim 104, which is formulated for intramuscular administration.
106. The composition according to claim 104, formulated for oral or oral administration.
107. The composition according to claim 104, which is formulated for application to the eye.
108. The composition of claim 107, wherein the composition is formulated for application to the eye by instillation as an eye drop onto the surface of the eye, or by intraocular injection, intravitreal injection, choroidal injection, or subretinal injection.
109. The composition of claim 108, wherein the composition is formulated for intraocular injection.
110. The composition of claim 109, wherein the composition is formulated as eye drops.
111. The composition according to any one of claims 104-110, comprising phosphate-buffered saline (PBS).
112. The composition according to any one of claims 104-111, wherein the composition is an emulsion of a microemulsion or nanoemulsion.
113. The composition of claim 104, which is formulated for oral, intramuscular, inhalation into the lungs or nose, mucosal, topical, or subcutaneous administration.
114. The composition according to any one of claims 104-112, wherein the composition is formulated for administration via a route comprising the gut-associated lymphoid tissue (GALT).
115. A composition comprising any plasmid, delivery vector, or MEV-GTV according to any one of claims 1-103, the composition being formulated for oral administration to treat diseases, symptoms, or conditions involving the gastrointestinal tract or immune system or spleen.
116. The composition according to any one of claims 104-112, which is formulated for oral administration.
117. The composition according to any one of claims 104-116, wherein the plasmid, delivery vector or MEV-GTV is MEV-GTV.
118. The composition according to claim 117, wherein the MEV is Chlorella MEV.
119. The composition according to any one of claims 104-118, wherein the composition is formulated for administration by means of transport to the spleen.
120. The composition according to any one of claims 104-118, wherein the composition is formulated for application via a route that includes or targets mucosal tissue.
121. The composition according to any one of claims 104-118, which is formulated for administration by inhalation into the lungs or nose.
122. The composition of claim 121, wherein the composition is formulated for intranasal application to treat a disease, symptom, or condition of the brain or a disease, symptom, or condition involving the brain.
123. The composition according to any one of claims 104-118, which is formulated for intramuscular administration.
124. The composition according to any one of claims 1-123, wherein it is formulated as tablets, pills, powders, liquid solutions or suspensions (e.g., including injectable, ingestible and topical formulations, such as eye drops, gels, pastes, creams or ointments), aerosols (e.g., nasal sprays and inhalers), suppositories, vaginal suppositories, injectable and infusionable solutions, and sustained-release forms.
125. A method or use of a product for treating, preventing or regulating a disease, symptom or condition, wherein the product is MEV-GTV as defined in any one of claims 1-103.
126. A method of treating, preventing, or regulating a disease, symptom, or condition, comprising administering to a subject the plasmid, delivery vector, or MEV-GTV of any one of claims 1-103, or the composition of any one of claims 104-124.
127. The plasmid, delivery vector, MEV-GTV plasmid, or method according to any one of claims 1-126, wherein the disease, condition, or ailment is described, and wherein the plasmid encodes a treatment for retinal disease or neovascularization disease.
128. The plasmid, delivery vector, MEV-GTV plasmid, or method according to claim 126 or claim 127, wherein the disease, symptom, or condition involves retinal pigment epithelial (RPE) cells, neuronal cells, and endothelial cells.
129. The plasmid, delivery vector, MEV-GTV plasmid, or method according to any one of claims 1-128, wherein the therapeutic product encoded on the plasmid is a polypeptide, siRNA, or mRNA.
130. The plasmid, delivery vector, MEV-GTV plasmid, or method according to any one of claims 1-129, wherein the encoded product inhibits VEGF or VEGFR1, inhibits CD44, or inhibits the HIF-1a pathway.
131. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-103, or the composition according to any one of claims 104-124, for the treatment, prevention, or regulation of a disease, symptom, or condition.
132. The plasmid, delivery vector, MEV-GTV, or composition according to any one of claims 1-104, administered or formulated for administration via a route to target organs and tissues, such as the choroid, retina, endothelial cells, intestinal cells, GALT cells, spleen cells, neurons, brain cells other than neurons, lung cells, skin cells, immune cells, blood cells, and / or mucosal cells.
133. The plasmid, delivery vector, or MEV-GTV or composition or method according to any one of claims 1-132, wherein the transgene encodes a therapeutic product for treating eye or brain or CNS diseases, symptoms or conditions.
134. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-103, or the composition according to any one of claims 104-124, wherein the disease, symptom, or condition is selected from metabolic diseases, genetic diseases, lung diseases, intestinal diseases, and eye diseases.
135. The plasmid, delivery vector, or MEV-GTV according to any one of claims 1-102, the composition according to any one of claims 104-124, or the method according to any one of claims 125-134, wherein the plasmid, delivery vector, or MEV-GTV is a MEV-GTV for gene therapy.
Citation Information
Patent Citations
Methods of delivering oligonucleotides to immune cells
AU2016225873A1
Exosomes comprising RNA therapeutics
AU2018365299A1
Exosome transfer of nucleic acids to cells
CN105821081A
Preparation method of exosome for delivering siRNA
CN110699382A
Modified siRNA molecules and uses thereof
EP2395012A2
